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Probiotic bacteria and synbiotics are used as therapeutic and prophylactic agents.
The majority of probiotic and synbiotic applications contain bacterial strains that are
allochthonous to the human gastrointestinal (GI) tract. Accordingly, many bacterial strains
do not survive digestion, or are not capable of persisting and competing the resident gut
microbiota, and are therefore washed out of the GI tract shortly after the treatment is
discontinued. This might reduce the health effects of these treatments. Therefore, research
is needed to address the ecological challenges that probiotic strains encounter in the GI
tract in order to develop probiotic regimens. Determining which ecological factors are
limiting the colonization of bacteria remains a challenge. To gain insight into the complex
interplay between host and microbe, we chose Lactobacillus reuteri and its rodent host as
a model to investigate which genes of L. reuteri contribute to tolerance towards host gastric
acid secretion. We established the urease cluster as the predominant factor in mediating
resistance to gastric acid, and a mutation of this cluster resulted in substantially decreased
population levels of L. reuteri in mice.
Secondly, we established a method to select for synergistic synbiotic
combinations. Based on in vivo selection (IVS), autochthonous putative probiotic strains
are enriched in the GI tract of subjects by the continued consumption of a prebiotic. We

used IVS to select a strain of Bifidobacterium adolescentis that became enriched in a
human feeding trail with galactooligosaccharides (GOS). Here we have shown that the
synbiotic combination of Bifidobacterium adolescentis IVS-1 and GOS significantly
enriched for the putative probiotic component in rats. IVS-1 became the most dominant
operational taxonomic unit in the GI tract, outcompeting the resident Bifidobacterium
species. Similarly, we tested this synbiotic in a human trial with obese adults. In this
random, placebo-controlled parallel arm study, the synbiotic combination of IVS-1 and
GOS led to establishment of IVS-1 in significantly higher numbers in the GI tract than a
commercial synbiotic.
Together, the studies presented in this dissertation allowed new insights into the
colonization factors of a true GI symbiont, which could contribute to the development of
improved probiotics, and provided novel insight into a rational selection of probiotics and
synbiotics.
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PREFACE

This dissertation is comprised of five chapters. Chapter 1 focuses on the current literature
on synbiotic applications, with an emphasis on clinical studies. In particular, the claimed
health benefits of synbiotic applications and the implications of recent studies on future
design of synbiotics to promote gastrointestinal health are addressed. Chapter 2 describes
our published research on the ecological role of genes that mediate acid resistance in
Lactobacillus reuteri during colonization of the rodent gastrointestinal tract (Krumbeck et
al. 2015). In Chapter 3 our published work on the novel concept of in vivo selection is
introduced, which can be applied to identify bacterial strains that possess enhanced
ecological performance in synbiotic applications (Krumbeck et al. 2015). Chapter 4
describes the results of a human clinical trial that applied a synbiotic combination that has
been selected by in vivo selection.

Finally, Chapter 5 provides a conclusion that

summarizes the findings provided in this thesis.
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Chapter 1

Recent developments on formulating synbiotics to improve gastrointestinal health.

1.1 Purpose of review
Research on combining probiotics and prebiotics as synbiotics to enhance human
and animal health has accelerated in the past ten years. Included are many clinical trials
that have assessed a wide variety of synbiotic formulations. In this review, we summarize
those recent clinical studies as well as other research and commercial applications of
synbiotics. In particular, we address the claimed health benefits of synbiotic applications
and the implications of recent studies on future design of synbiotics to promote
gastrointestinal health.

1.2 Introduction
The impact of the gastrointestinal (GI) microbiota on the health of humans and
animals is now one of the most studied fields in biology and medicine. New discoveries
made during the past 20 years have dramatically changed the way that clinicians and
researchers associate food and diet with health and disease. While the microbiota that
resides in the gut has long been considered as important to health, the methods and
techniques necessary to gain an appropriate appreciation of this complex microbial
ecosystem have just been developed within the last decade.

In addition, how this

microbiota interacts with the host and how the composition and activity of a healthy state

2

microbiota is distinguished from an unhealthy or dysbiotic state had also been
experimentally difficult questions to address. While modern techniques now allow the
recognition of a dysbiotic microbial state, the identification of cause and effect between a
dysbiotic microbiota and a disease phenotype remains challenge.

1.3 Functional importance of the colonic microbiota
The human gastrointestinal tract is colonized by approximately 1014 microbial cells,
with the majority (1011 – 1012 per gram) residing in the colon and less than 102 - 103 per
gram in the stomach and small intestine (1, 2). This microbiota serves several critical
physiological functions. It protects the host from invasive pathogenic microorganisms by
competing with them for nutrients and niches, as well as by resistance against infections
(3–5). Commensal organisms may also produce a variety of antimicrobial substances,
including bacteriocins and other antagonistic peptides and small molecules (6, 7). In
addition, the microbiota aids in the development of the adaptive and innate immune system,
produces essential vitamins, amino-acids and other metabolites, and facilitates utilization
of nutrients, especially polymeric carbohydrates (8). Finally, the microbiota contributes
caloric energy to the host. Assuming a typical European diet is consumed, the gut
microbiota can potentially yield as much as 140-180 kcal a day via fermentation of the 5060 g of carbohydrates that escaped host metabolism (9).
The extent and rate of carbohydrate digestion and utilization in humans depends
primarily on anatomical location. Initially, complex carbohydrates are hydrolyzed in the
mouth via amylases, and starch and glycogen are further hydrolyzed and broken down into
sugars, which are absorbed in the stomach. In the large intestine, indigestible substrates,
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including various dietary fibers and carbohydrates that were not absorbed in the small
intestine, are hydrolyzed and fermented by bacteria. The proximal part of the large
intestine is responsible for most of the absorption of the short chain fatty acids (mainly
acetate, butyrate and propionate) that are produced by the colonic bacteria from fiber
fermentation at a rate of approximately 0.5- 0.6 mole per day (1, 9, 10), depending on the
microbiota composition, the nature of the fermentable carbohydrate, and the dietary intake
(6).
Short chain fatty acids (SCFA) have several beneficial effects on host health (11,
12). As the most important and preferred energy source for colonocytes (13), SCFA
promote epithelial integrity (11). Additionally, SCFA affect the thickness of the mucus
layer, support epithelial cell survival, and regulate expression of tight junction proteins (6,
14). Disruption of gut integrity has been attributed to serious intestinal diseases, including
celiac disease, inflammatory bowel disease, and colorectal cancer (12, 15, 16). The local
and systemic immunomodulatory properties of SCFA include the suppression of NF-κB
activity (17–19) and support of increased infiltration of immune cells into the lamina
propria. In addition, SCFA have anti-inflammatory properties by modulating immune cell
chemotaxis, reactive oxygen species, and cytokine release (11). SCFA also regulate
colonic mobility and blood flow and can influence colon pH, which has a direct impact on
the uptake and absorption of nutrients and electrolytes (20).
Butyrate formation by the colonic microbiota is of particular interest since this
compound has been shown to have multiple biological effects.

Butyrate has anti-

inflammatory properties, inhibits IL-12 and up regulates IL-10 in monocytes (19, 21). In
addition, butyrate has signaling capacities via G-protein coupled receptors (14, 16, 22, 23)
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and increases levels of anorectic hormones like PYY and GLP-1, that contribute to energy
metabolism and appetite control (6). Butyrate also induces apoptosis of neutrophils (24),
and has anticancer activity in several human cell lines (25–27).
The colon offers an especially favorable environment for anaerobic microbes, with
high quantities of nutrients that escaped host digestion, a thick mucus layer secreted by a
higher number of Goblet cells, reduced intestinal motility, and a favorable pH (28). Since
the majority (approximately 70%) of the gut microbiota reside in the large intestine, these
organisms may have a profound effect on energy storage, host metabolism, and intestinal
health (1).

While the microbiota provides many beneficial effects on the host, the

composition of an individual’s microbiota may also predispose that individual for certain
intestinal as well as systemic diseases, including obesity and diabetes. Importantly, the
microbiota is not only shaped by host genetic factors and endogenous factors (gastric acid
and bile), but also by dietary components that favor specific taxa or groups of bacteria in
the colon by promoting their growth or activity. Therefore, establishment of bacteria that
are associated with a stable and healthy microbiota may be facilitated by dietary strategies.
However, short-term dietary strategies have shown that overall the gut microbiota is
exceptionally stable and resilient, since most of the alterations induced to the gut
microbiota by dietary treatments are only temporary and the pre-treatment conditions are
re-established once the treatment is discontinued (29–31). Still, the dietary approach is
now one of the most promising methods for correcting bacterial dysbiosis and restoring
homeostasis. In particular, foods and supplements containing prebiotics, or combined with
probiotics as a synbiotic, have considerable potential for promoting gut health.
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1.4 Addressing intestinal health with pro-, pre- and synbiotics
Among the first dietary products used as intestinal therapeutic agents were
probiotics. Indeed, what we now call “probiotics” have been produced and consumed for
more than 100 years (32, 33), long before the term was actually defined. Probiotics are
currently defined as “live microorganisms that, when administered in adequate amounts,
confer a health benefit on the host” (FAO/WHO 2001-2014). There are hundreds of
probiotic strains and products in the marketplace, and many clinicians recommend
probiotics to patients for a variety of conditions, including antibiotic-associated diarrhea,
management of acute gastroenteritis, general gastrointestinal disorders, treatment of mild
ulcerative colitis, and for improved lactose digestion (34). While consumers have a general
understanding of probiotics (35), the definition itself has been controversial among
researchers and regulators (34). It has been criticized, for example, as being too broad or
not being broad enough (34). Leaving the discussion about the definition itself aside, it is
interesting to note that in Europe, and the U.S., no health claims for probiotic products have
been approved by regulators. In contrast, Canada has accepted a limited number of claims
about the nature of probiotic microorganisms (36), as has Japan (37). In Australia and New
Zealand, products can be labelled as probiotics, but this may change as new legislation was
passed in 2013 (effective in 2016) that regulates nutrition content and health claims on food
labels and in advertisements (38).
Despite the hesitation of regulators to confer health claims for probiotics, clinical
evidence continues to emerge suggesting that probiotics can be effective for a range of
conditions, including constipation, irritable bowel syndrome, and lactose intolerance (6,
39). Systematic and meta-analyses have shown that probiotics may aid the treatment of
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antibiotic associated diarrhea (40), the prevention of necrotizing enterocolitis in preterm
neonates (41), the induction of remission and maintenance of IBD (42), the prevention and
control of hyperglycemia (43), improve levels of total cholesterol HDL and TNF-α in
patients of non-alcoholic fatty liver disease (44), and reduce glucose, insulin, and HOMAIR in diabetes patients (45). In addition, the effectiveness of probiotics for preventing or
reducing severity of infectious and antibiotic-associated diarrhea and respiratory tract
infections has also been reported (6).
In contrast to the century-old history of probiotics, the prebiotic concept was more
recently formally introduced in 1995 by Gibson and Roberfroid. Defined originally as “a
nondigestable food ingredient that beneficially affects the host by selectively stimulating
the growth and/or activity of one or a limited number of bacteria in the colon, and thus
improves host health” (46), the current criteria for prebiotics is now the subject of
considerable debate (47, 48). While the general requirements of a prebiotic have been
retained in the most recently proposed definition, some key elements of the definition,
including specificity and selectively, have been questioned (48). The Canadian Food
Inspection Agency (CFIA) has now established its own definition for prebiotics, but neither
the U.S. Food and Drug Administration (FDA) nor Europe’s European Food Safety
Authority (EFSA) have established a definition.
Prebiotics are comprised of simpler molecules such as inulin, fructooligosaccharides,

galactooligosaccharides,

isomaltooligosaccharides,

and

mannan

oligosaccharides, or more complex compounds such as pectins, resistant starches,
arabinoxylan or human milk oligosaccharides (49). Depending on the nature of the
prebiotic, these substrates may support the growth of certain members of the gut
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microbiota, such as bifidobacteria, lactobacilli, or ruminococcus (50). Prebiotics are
thought to aid their health benefits through several different mechanisms.

These

mechanisms include the induction of compositional or metabolic changes to the resident
microorganisms, by stimulating the activity and/or growth of health-promoting bacteria,
and by the production of SCFA and other end products that reduce the local pH, induce the
production of immunomodulatory cytokines, and stimulate mucin production (51).
Substrates like FOS and GOS may also have fermentation independent health effects, such
as adherence inhibition of pathogens (52).
Systematic meta-analyses showed that, in some cases, a prebiotic treatment reduces
fasting insulin levels (53), can aid the treatment of infectious diseases (54) and diarrhea
(55), and restore bowel function (56). There are also reports that prebiotics may contribute
to abdominal pain, diarrhea, and increased production of gas depending on the doses,
nature of the prebiotic, and the susceptibility of the host (6).

1.5 Synbiotic concepts
When Gibson and Roberfroid first articulated the prebiotic concept more than
twenty years ago, they envisioned that prebiotics and probiotics could be combined as
synbiotics. Later, Kolida and Gibson (2011) described the two general ways synbiotics
could enhance the effects of their parts. Complementary synbiotics are those that contain
probiotics and prebiotics chosen independently of one another, with each responsible for a
particular effect or health benefit. Accordingly, the best case scenario for such a synbiotic
would be that each constituent, i.e., the probiotic and prebiotic, would have a beneficial
effect and that the effects would be additive. For example, the prebiotic would stimulate
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resident strains of bifidobacteria (presumably stains that improved intestinal health), while
the probiotic would be established independently, providing an additional health benefit.
In this complementary approach, the prebiotic component is not necessarily preferentially
fermented by the probiotic strain and could theoretically support other members of the
gastrointestinal microbiota. The probiotic strain would gain no ecological advantage by
being combined with the prebiotic, and indeed, may not be capable of fermenting the
substrate at all.
When the prebiotic is introduced together with a probiotic that cannot ferment the
substrate, the outcome may be highly unpredictable and would likely depend on the
composition of an individual’s gut microbiota. Already it is apparent from human clinical
studies that a bifidogenic response or other changes in the microbiota following prebiotic
supplementation occur in some subjects but not in others. The nature of the responder/nonresponder phenotype (i.e., what makes a responder a responder) remains the subject of
considerable interest.

Davis et al. suggested that specific bacterial strains capable of

fermenting the prebiotic or competing well in the colon might be absent in the nonresponder population (29), but that has not been established yet. The inability of members
of the gut microbiota to compete in the highly competitive gastrointestinal environment
could also affect the responder status of subjects. Indeed, Davis et al. showed that even a
high abundance of taxa that would be expected to ferment a given prebiotic substrate was
not a reliable predictor of whether or not the prebiotic was fermented (29). Salonen et al.
have shown that obese male individuals on a resistant starch diet could be divided into
responders and non-responders based on the shifts in the composition of their gut
microbiota.

In this case a high microbial diversity correlated with a low dietary

responsiveness (57). Similarly Martinez et al. have reported a microbial responder and
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non-responder phenotype in normal weight human subjects who had consumed resistant
starches (58). Kovatcheva et al. divided their study cohort in responder versus nonresponders based on the metabolic response to a dietary fiber treatment (59). A subsequent
analysis of the gut microbiota of both groups showed that the Prevotella and Bacteroides
ratio was significantly higher in the responder group. Due to this responder and nonresponder phenomenon, a prediction of whether or not a subject will have a health
beneficial effect by a dietary treatment is difficult to establish. The response to the
treatment depends not only on the functional and taxonomic composition of the gut
microbiota but possibly also on host factors. These factors include the amount of digestive
enzymes provided by the host, the food transit time, and other potential environmental
constraints, which could limit the increase of certain bacterial numbers, even if the growth
substrate is provided (58). While these host factors may be limiting the success of dietary
interventions to a certain degree, synergistic synbiotics may provide the functional and
taxonomic microorganisms that are not present in non-responders.

In contrast to

complementary synbiotics, synergistic synbiotics consist of a prebiotic substrate that
specifically supports the growth of a cognate probiotic strain in the gastrointestinal
ecosystem (32). Assuming the target strain reaches the colon, this approach potentially
addresses the responder/non-responder problem by providing the strain and its growth
substrate in situ. The presence of an autochthonous member of the gut microbiota capable
of fermenting the prebiotic prior to the treatment is not necessary. However, the synergistic
synbiotics are not limited to addressing the responder/ non-responder phenomenon. One
important limitation of many probiotic and synbiotic applications is the low ecological
success of the probiotic strain (60). In order to become established in the GI tract, the
probiotic must not only secure nutrients and other growth factors, but must also outcompete
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the resident microbiota for these resources. By providing the probiotic partner organism
with a new resource opportunity, in this case a selectively fermentable prebiotic, the
probiotic strain’s competitive fitness can be significantly increased and its persistence
enhanced (32).
A literature search has shown that most of the synbiotic combinations used in
clinical studies and reported in the literature have not been synergistically supporting the
probiotic strain. Indeed, only a few studies have provided evidence that a prebiotic
supports its probiotic counterpart in vivo (Table 1.1), and only one such study was
conducted with human subjects. There are a variety of reasons why it is difficult to achieve
synergism between a probiotic and a prebiotic in vivo. Most importantly, the synbiotics
used in these studies have not been rationally designed, and have instead been formulated
on rather arbitrary bases, such as shelf life, cost, and industrial performance (60), on the
basis of availability, cost, or other marketing reasons. So often probiotic strains do not
utilize the respective prebiotic. Even when in vitro or in situ screenings of synbiotic
combinations are applied, these techniques do not account for the ecological factors that
will affect the probiotic strain in vivo, nor do they account for how other autochthonous
members of the gut microbiota may benefit from the prebiotic substrate (29, 61, 62). It can
be challenging to identify a prebiotic that will specifically and selectively enhance the
probiotic strain of interest. New strategies to develop synergistic synbiotic combinations
now include in vivo selected synbiotic combinations or Multi-taxon Insertion Sequencing,
which have been recently discussed (49).
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Table 1.1. Synergistic synbiotics reported in the literature

Prebiotic
component

Study
subject
s

Increase of probiotic
abundance

P value

Year

Probiotic
component

Health
outcome

Tanaka et
al., 1983
(63)

Bifidobacterium breve
4006

Transgalactosylated
oligosaccharide
(TOS)

Healthy
adults

Pro: 9-10.2 log/g feces;
Syn: 10-10.5 log/g feces§

0.05

Not measured

Wang et
al., 1999
(64)

Bifidobacterium
LaftiTM 8B.

Amylomaize

BALB/
c mice

Pro: 4.3% recovery rate;
Syn: 27.92% recovery
rate in feces

0.05

Not measured

Femia et
al., 2002
(65)

Lactobacillus
rhamnosus
LGG +
Bifidobacteriu
m lactis Bb12

Not
given

Anti-tumoric
activity in
azoxymethane
induced cancer

0.01

Significantly
elevated
natural killer
cell activity in
spleen
mononuclear
cells

0.0001

None

Authors/

Oligofructose
enriched
inulin

Male
F344
rats

LGG: Pro: 4.8 ± 3.4·105;
Syn: 21.1 ±18·105 CFU/g
of feces;
Bb12: Pro: 6.1 ± 8.1·105;
Syn: 8.4 ± 12·105 CFU/g
of feces

4

Ogawa et
al., 2005,
2006 (66,
67)

Lactobacillus
casei subsp.
casei JCM
1134T (Lcc)

Dextran

Krumbeck
et al., 2015
(60)

Bifidobacterium
adolescentis
IVS-1

Galactooligosaccharide
(GOS)

BALB/
c mice

Male
Sprague
Dawley
rats

Pro: 1·10 CFU/mg of
feces;
Syn: 1.4·106 CFU/mg of
feces§

Pro: 7.9 ± 0.1 log10
cells/ g colon content;
Syn: 9.47 ± 0.2 log10
cells/ g colon content

Pro: Probiotic; Syn: Synbiotic
§: Absolute microbial numbers are not given in the original publication and are estimated by the author by careful
evaluation of graphs in the original publication

That there are few reports describing the use of synergistic synbiotics in clinical
trials is somewhat surprising considering the many publications on synbiotics. Just in 2015
alone, more than 90 publications on synbiotics were published (Figure 1.1). Most of these
studies included lactobacilli and bifidobacteria as the probiotic component, and various
oligosaccharides, inulin or dietary fibers as the prebiotic component (68).
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Fig. 1.1. Number of publications on the topic “synbiotic” over the past 15 years.

1.6 Synbiotics and their outcome on human health in clinical studies
The reported literature on synbiotics includes studies from a wide-range of subject
cohorts. Research subjects have included humans of all ages, as well as companion animals
(mainly dogs and cats), and food production animals, such as chicken, cows, pigs, cattle,
rabbits and fish (69–77). Rodent animal models have also been widely used (60, 78–80).
In this review, we focus on human clinical studies and the health claims made for synbiotic
combinations to improve human health.
It is important to note that despite the many health claims made for synbiotic
combinations in the literature and in the commercial market (Figure 1.2), no claims have
actually been approved by regulatory agencies in the U.S. and Europe.
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Fig. 1.2. Health claims made for synbiotics in human populations.
Nonetheless, several meta-analyses and systematic reviews suggest that synbiotic
treatments may provide beneficial health effects (Table 1.2, and 1.3).
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Table 1.2. Overview of published meta-analyses on synbiotic treatments (adapted from
Krumbeck et al., 2016 and updated).
Author/
Year

Disease
phenotype

Studies and
subjects
included

P value

(68)

Ford et al.,
2014
(81)

Hepatic
Encephalopat
hy (HE)

0.004
1 trial (n=60)

IBS and
chronic
idiopathic
constipation

2 trials
(n=198)

(82)

Beserra et
al., 2015
(53)

Clinical
outcome after
elective
surgery

Glycaemia,
insulin
concentration
s and lipid
parameters

Outcome

HE patients

Syn. use reduced
the risk of no
improvement of
Minimal HE.

Probiotic: BL;
Prebiotic: FOS,
vitamins B1, B2, B6,
B12

0.09

Probiotic: BL, BB, LR,
LA, LB,ST , LC;
Prebiotic: FOS

0.003

Probiotic: BL2, LP,
LR, LA; Prebiotic:
FOS

Beneficial for
chronic idiopathic
constipation
treatment.

0.002

Probiotic: LC, LP2,
LP, LM, LA, LB, BL2,
ST, PP, BB, EF, CB,
BM, LS, BB2, LL;
Prebiotic: OAF, OF,
BG, I, P, RS, GOS

The incidence of
postoperative
sepsis was reduced
by syn.

0.03

Probiotic: PP, LM,
LP2; Prebiotic: BG, I,
P, RS

Syn. reduced the
length of
postoperative
antibiotic use.

No reduced
symptoms.
IBS patients

2 trials
(n=160)

8 trials
(n=361)

Kinross et
al., 2013

Study
subjects

Probiotic: PP, LM,
LPSP, LP2; Prebiotic:
BG, I, P, RS

1 trial (n=55)
Shukla et al.,
2011

Type of synbiotic

4 trials
(n=135)

Patients
undergoing
elective
surgery

>0.05

Probiotic: LC, LP2,
LP, LM, LA, LB, BL2,
ST, PP, BB, EF, CB,
BM, LS, BB2, LL;
Prebiotic: OAF, OF,
BG, I, P, RS, GOS

No significant
changes observed
for prevention of
pneumonia, wound
infection, urinary
tract infection,
mortality and
length of hospital
stay.

2 trials
(n=364)

0.04

Probiotic: BL, LC, LR,
ST, BB, LA, LB;
Prebiotic: FOS

Reduced plasma
fasting insulin
concentrations.

3 trials
(n=260)

<0.05

Probiotic: LS2, BL,
LA, BB; Prebiotic: I,
FOS

Reduced plasma
triglyceride
concentrations.

2 or 3 trails
each (n
between 198
and 260)

2, 3 or 4 trails
each (n
between 49
and 104)

Not given

Probiotics: LC, LR,
ST, BB, LA, BL, LB,
LS2; Prebiotic: I, FOS

Adults with
overweight or
obesity

No significant
changes were
observed for total
cholesterol, LDLc, HDL-c and
fasting glucose.
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Table 1.2 continued
Mugambi et
al., 2012
(77)

Growth and
stool
frequency

2 trials
(n=227)
2 trials
(n=122)

0.29

Probiotic: BL, LR, LP;
Prebiotic: GOS,
ScFOS

0.006

Probiotic: BL;
Prebiotic: GOS, FOS

Infants

Syn. support the
treatment of atopic
dermatitis,
particularly mixed
strains of bacteria
are used.

0.03

Chang et al.,
2016
(83)

Atopic
dermatitis
(AD)

(84)

Yang et al.,
2016
(85)

Prevention of
infections
after liver
transplant

Prevention of
infections
after GI
surgery

Children

0.048

2 trials
(n=1320)

Sawas et al.,
2015

Probiotic: LR,BL2,
LA, BB, LC, ST, BI,
LB, LS; Prebiotic:
FOS, lcFOS, GOS,
scGOS, starch

6 trials
(n=369)

4 trials
(n=246)

0.26

<0.001

16 trials
Not given

Syn. failed to
improve growth
rate, but
significantly
improved stool
frequency.

Syn. support the
treatment of atopic
dermatitis in
children older than
1 year.

Probiotic: BL, BB, LR,
PF; Prebiotic: GOS,
ScFOS

Syn. do not support
prevention of AD.

Probiotic: BB, BL2,
LP2, PP, LPSP, LM,
LA, LC, LR, LB2;
Prebiotic: GOS, fiber

Adult patients
receiving a
liver
transplant

Syn. reduced
infection rate of
urinary tract and
intra-abdominal
infections. Syn.
reduced hospital
stay and duration
of antibiotic use.

Patients
undergoing
GI surgery

Subgroup analysis
of synbiotic trials
showed no health
benefits due to
synbiotics

Probiotic: LC, ST, BB,
LA, BL2, LB, LP2,
PP, LM, LP, LS2, BM,
CB;

(n=1,370)
Prebiotic: FOS, GOS,
OAF, OF, BG, I, P, RS

Probiotic type: BB= Bifidobacterium breve; BB2= Bifidobacterium bifidum; BI= Bifidobacterium infantis; BL= Bifidobacterium
longum; BL2= Bifidobacterium lactis; BM= Bacillus mesentericus; CB= Clostridium butyricum; EF= Enterococcus faecium; LA=
Lactobacillus acidophilus; LA2= Lactobacillus affinolactis; LB= Lactobacillus bulgaricus;LB2= Lactobacillus brevis; LC=
Lactobacillus casei; LL= Lactococcus lactis; LM= Leuconostoc mesenteroides; LP= Lactobacillus paracasei; LP2= Lactobacillus
plantarum; LPA= Lactobacillus paracasei; LPSP= Lactobacillus paracasei subsp. paracasei; LR= Lactobacillus rhamnosus; LS=
Lactobacillus salivarius; LS2= Lactobacillus sporogenes; PF= Propionibacterium freudenreichii; PP= Pediococcus pentosaceus;
ST= Streptococcus thermophilus
Prebiotic type: BG= β-glucan; GOS= galacto-oligosaccharides; I= inulin; P= pectin; OF= oligofructose; OAF= oat fiber; RS=
resistant starch; FOS= fructo-oligosaccharides; Sc= short chain; Syn= Synbiotic
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Table 1.3. Overview of systematic reviews on synbiotic treatments.
Author/
Year

Disease
phenotype

Ulcerative
colitis (UC)
maintenance

Ghouri
et al.,
2014
and
SaezLara et
al., 2015

Ulcerative
colitis
induction and
maintenance

Ulcerative
colitis
induction

Studies and
subjects
included

1 trial (n=120)
&

P
value

Type of synbiotic

0.03

Probiotic: BL;
Prebiotic: Psyllium

0.05

Probiotic: BB;
Prebiotic: GOS

1 trial (n=41)
&

1 trial (n=18)
0.05

0.02

Probiotic: BL;
Prebiotic: Synergy I
(I+OF mix)

>0.05

Synbiotic 2000:
Probiotic: LA2, PP,
LP2, LPSP; Prebiotic:
BG, I, P, RS

Not
given

Synbiotic therapy;
Probiotic: BB, BL, LC;
Prebiotic: Psyllium

1 trial (n=35)
&

1 trial (n=24)
*&

SaezLara et
al., 2015

Ulcerative
colitis (UC)

UC
patients

1 trial (n=10)

(87)

Improvement of endoscopic
grading compared to standard
therapy group.
Sigmoidoscopy score not
improved.

Probiotic: BL;
Prebiotic: Synergy I
(I+OF mix)

*#&

Outcome

IBDQ score: improved
quality of life.

0.06

(86, 87)

Management
of Crohn's
Disease (CD)

Study
subjects

Inflammatory markers
improved.
Improved clinical response
compared to placebo.
CD
patients

Patients
with
active
UC

No improvement in
endoscopic, clinical and
laboratory parameters.

Synbiotic was safe and
effective.

*: also discussed in Hedin et al., 2007 (88); #: also discussed in Zigra et al., 2007 (89);
IBDQ: Inflammatory bowel disease questionnaire
Probiotic type: BB= Bifidobacterium breve; BL= Bifidobacterium longum; LA2= Lactobacillus affinolactis; LP2=
Lactobacillus plantarum; LPSP= Lactobacillus paracasei subsp. paracasei; PP= Pediococcus pentosaceus.
Prebiotic type: BG= β-glucan; GOS= galacto-oligosaccharides; I= inulin; P= pectin; OF= oligofructose; RS= resistant starch.

However, comparisons between different trials is rather difficult, since studies often
vary between the specific probiotics and prebiotics used, their respective doses, the
duration of the study, the targeted population, expected and measured effects of treatment.
Even the funding source has been suggested to influence outcomes (90). Of particular
concern for synbiotic trials is when investigators did not determine the treatment effects
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independently. In such an approach it is not possible to establish that improvement of a
clinical endpoint in the synbiotic treatment group was indeed more beneficial than just the
pro- or prebiotic treatments alone. Therefore the synbiotic concept cannot be validated in
that case. The majority of clinical trials have chosen such an approach. A literature
research of synbiotic trials published within the last 15 years (see below), showed that out
of 26 trials presented here, only one provided a prebiotic only, probiotic only, and synbiotic
only group (91), and only one trial provided an additional placebo control group (92).
Out of the 26 trials presented here, only one performed a genus specific analysis of
the microbiota of the subjects (93), and only three of the trials used a species specific
analysis for the applied probiotic (92, 94, 95). All other studies did not conduct any
microbial analyses to confirm the survival or activity of the probiotic component at a strainspecific level or even at higher taxonomical levels. Finally, another common limitation of
these studies is the lack of experimental power, which may result in overstating or
underestimating the actual health benefits of the applied synbiotic. This phenomenon of
disadvantages of synbiotic meta-analyses has been previously recognized and criticized for
probiotic meta-analyses as well (96).
In general, most of the meta-analyses have focused on the disease phenotype rather
than on the exact nature of the treatment. Consequently, these analyses often do not
differentiate between prebiotic, probiotic or synbiotic trials, with very few trials
specifically using synbiotics. However, systematic meta-analyses specifically analyzing
synbiotics are often impossible due the limited number of trials. Other meta-analyses do
not distinguish between a probiotic or synbiotic treatment and combine those trials into one
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analysis, which is not appropriate for assessing the potential health benefits of a synbiotic
treatment (Table 1.4).

Table 1.4. Overview of Meta-analyses synbiotic treatments that combined proand synbiotic trials into one analyses.

Authors/Year

Disease phenotype

Overall outcome

Pitsouni et al.,
2009 (97)

Patients undergoing
abdominal surgery

Pro-/ synbiotic treatment may reduce postoperative infections after
abdominal surgery.

Rossi et al.,
2012 (98)

Patients with chronic kidney
disease

Limited but supportive evidence for the effectiveness of pre- and probiotics
on reducing uremic toxins. No conclusion about synbiotics.

Zhang et al.,
2010 (99)

Patients with acute
pancreatitis

Pre-, pro- or synbiotics treatment shows no statistically significant benefit.
Safety and efficacy: Use pre- pro- or synbiotics with caution in critically ill
patients and patients with severe acute pancreatitis.

Watkinson et
al., 2007 (101)

Patients admitted to adult
intensive units

There is currently a lack of evidence to support the use of pre- pro- or
synbiotics.

He et al., 2013
(102)

Patients undergoing colorectal
resection for cancer

Pro-/synbiotics administration had a positive effect on the incidence of
diarrhea (P = 0.001), the incidence of symptomatic intestinal obstructions (P
=0.008), the incidence of operative total infections (P =0.0010), and
pneumonia infection (P = 0.04).
Pro-/synbiotics administration increased numbers of Lactobacillus (P <
0.00001), and decreased the counts of Enterobacteriaceae.

Dang et al.,
2013 (103)

Prevention of eczema

Pro- and synbiotic treatment may reduce incidence of infant eczema.
Prebiotics alone have no effect.

Lytvyn et al.,
2015 (104)

Prevention of postoperative
infections following
abdominal surgery in adults

Probiotics/synbiotics reduce the risk of surgical site infections compared to
placebo or standard of care and potentially benefit for urinary tract infections
with no increased risk of adverse events, and no occurrence of serious
adverse events reported as related to study product.

Critically ill patients,
including burn, multiple
trauma, pancreatis, diarrhea
patients and general intensive
care unit patients

Clinical trials suggest that probiotics patients may reduce overall infection
rates in critically ill patients.

Petrof et al.,
2012
(105)

Arumugam et
al., 2016 (106)

Decrease of postoperative
sepsis GI surgical patients

Pro-/synbiotics significantly reduced risk of postoperative sepsis by 38%
(P = <0.0001)
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Review of selected clinical trials on synbiotic treatments
As introduced earlier, the study design is crucial when synbiotic treatments are
being assessed for their health beneficial effects. To justify the application of a synbiotic
treatment instead of a probiotic or prebiotic only treatment, appropriate controls must be
used to assess if the synbiotic treatment acts synergistically. Thus, controls must include
a placebo, the probiotic treatment alone, the prebiotic treatment alone, and the synbiotic
combination. Only this study design allows investigators to assess whether or not a
synbiotic treatment is more effective than the probiotic and prebiotic treatments alone and
whether or not synergy is given. In addition, the survival and/or metabolic activity of the
probiotic component should be quantified in a strain-specific manner to ensure survival
and establishment of the probiotic. However, this requires a significantly higher number
of subjects, and only a small number of trials fulfill these criteria.
In the next sections, recent human trials that applied synbiotics to treat specific
clinical disorders are reviewed. These include trials on metabolic syndrome, inflammatory
bowel disease, diarrhea, colon cancer, and inflammatory bowel syndrome

Metabolic syndrome
Metabolic syndrome refers to a group of metabolic disorders that collectively
contribute to heart and other health problems. Risk factors include central obesity,
impaired glucose tolerance, dyslipidemia and hypertension (107, 108). This syndrome is
associated with obesity, type II diabetes, heart disease, and cancer (109).
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Several synbiotic formulations have been used in clinical trials. Eslamparast et al.
conducted a prospective, randomized, double-blind, and placebo-controlled study
analyzing the effect of 250 mg fructooligosaccharide (FOS) and a probiotic cocktail of
seven different strains (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus
thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum,
and Lactobacillus bulgaricus) on 38 subjects suffering from metabolic syndrome (110).
Subjects were instructed to consume the supplement or placebo (maltodextrin) twice daily
for 28 weeks, and were instructed to follow strict dietary recommendations, lower their
energy intake, and increase their physical activity. At the end of the study, individuals in
the synbiotic treatment had significantly improved levels of insulin resistance, fasting
blood sugar, triacylglyceride, and serum high-density lipoprotein levels compared to the
placebo treatment. No difference was observed in body mass index (BMI), low-density
lipoprotein levels, anthropometric parameters, and energy intake/expenditure. The authors
concluded that the synbiotic treatment can increase the efficacy of a dietary therapy in the
management of metabolic syndrome and insulin resistance. While the design and analysis
of this study were adequate for the study goals, an analysis of the gut microbiota was not
included. The authors stated that “because previous studies had shown beneficial effects
of VLS#3 and Lactobacillus longum and fructooligosaccharide, demonstrating their
beneficial effects on intestinal microbiota, this synbiotic capsule was chosen for the present
study as it contained all these strains in addition to others.” However, the mentioned
“Lactobacillus longum” is not a strain that has ever been described in the literature before
and is most likely either a B. longum or a different Lactobacillus strain. Additionally, the
authors claim that VLS#3 was chosen for its previously reported health benefits. But in
the study conducted here, the applied synbiotic mixture did not contain all the strains
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present in VLS#3 and left, seemingly randomly, two strains, B. infantis and L. delbrueckii,
out. Therefore no comparison to other studies using VLS#3 can be made. Leaving these
issues aside, no comparison was made between a pro- and prebiotic treatment alone, thus
not confirming that the synbiotic treatment was more effective than the probiotic or
prebiotic treatment alone.
Lactobacilli, bifidobacteria and FOS were combined as synbiotic treatments for
gastric bypass patients. The synbiotic treatment contained Lactobacillus paracasei LPC37,

Lactobacillus

rhamnosus

HN001,

Lactobacillus

acidophilus

NCFM,

and

Bifidobacterium lactis HN019 (each at 109 CFU) and 6 g of FOS (111). Patients were
divided into a placebo, prebiotic, and synbiotic treatment group. The supplement was taken
for 15 days after which a significant weight loss was seen in the prebiotic group. The BMI
was also lower in the prebiotic and placebo group than in the synbiotic group. Other blood
and inflammatory markers were not different among the groups, and the fecal microbiota
was not addressed. Effects of SCFA production induced by FOS treatment were only
indirectly measured by assessing plasma cytokines, and no effect was detected. Although
clinical benefits for each of the tested strains are reported by the authors, there was no
rationale given by the authors for combining them as a synbiotic. Also, the low number of
bypass patients (n = 3 per group) makes the interpretation of this data rather difficult and
further investigation will be needed.
The effect of a synbiotic consisting of Lactobacillus sporogenes (2.7 × 108 CFU)
and 1.08 g of inulin was tested in 62 type II diabetic patients in a randomized doubleblinded cross-over controlled clinical trial (112). The study lasted three weeks, and patients
were instructed to consume the treatments three times a day. The synbiotic was compared
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to a placebo, and results suggested the synbiotic led to significantly decreased serum
insulin levels (P = 0.03) and serum high-sensitivity C-reactive protein levels (P = 0.01).
Increases in plasma total glutathione (P < 0.001) and serum uric acid levels (P = 0.04) were
also reported. However, no effects on cholesterol levels were observed, and the fecal
microbiota of the patients were not investigated. The same research group tested this
synbiotic in combination with beta-carotene, and a reduced amount of L. sporogenes and
inulin in 102 diabetic patients (113).

In this case cholesterol levels were affected

significantly in addition to insulin compared to a control.

Pro- or prebiotic-alone

treatments were not included, making it impossible to determine if the observed effects
were due to the synbiotic or the individual synbiotic components.

Inulin has been

previously shown to have beneficial effects in the treatment of diabetes (114–116). Finally,
as noted previously (117), “Lactobacillus sporogenes” is not a validly named species and
the applied species here is more likely a Bacillus coagulens.

However, without a

classification analysis, the identity of the strain used in this study cannot be established.
The same synbiotic combination of Lactobacillus sporogenes (40 × 108 CFU,
consumed three times a day) and inulin (2.8 g, consumed three times a day) was tested in
81 diabetic patients (118). The synbiotic, probiotic, or placebo was delivered in form of
bread. After eight weeks of treatment, plasma nitric oxide was increased (P = < 0.0001)
and malondialdehyde levels were significantly reduced (P = 0.001) compared to both
placebo and probiotic only treatments. Since a prebiotic only treatment only was not
included it remains unclear if this effect could have been achieved by inulin only. The
survival of the probiotic strain during the bread making process or storage was not reported,
nor any analysis of the gut microbiota. The actual dose of L. sporogenes per day therefore
remains speculative.
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A synbiotic cocktail containing Lactobacillus casei, Lactobacillus rhamnosus,
Streptococcus

thermophilus,

Bifidobacterium

breve,

Lactobacillus

acidophilus,

Bifidobacterium longum, Lactobacillus bulgaricus (2 x 108 CFU total), and FOS (unknown
amount) was tested for its potential to support a weight loss regime (119). Forty-six
patients of metabolic syndrome consumed the synbiotic or placebo (maltodextrin) for 12
weeks twice a day. All patients experienced significant weight loss, and the synbiotic
treatment reduced the systolic blood pressure (P < 0.05). However, 90% of the subjects in
the synbiotic group used medication to reduce blood pressure compared to 75% in the
placebo group before and throughout the duration of the study. While this difference was
not significant, and could have affected the outcome. The fecal microbiota was not
examined and the nature of the study design precludes any conclusions about the efficacy
of the prebiotic or the probiotic strains applied here.
A study conducted with patients suffering from type II diabetes claimed a health
benefit of a synbiotic combination compared to a placebo (120). However, the value of
this study is limited by the fact that no further details of the nature of either the synbiotic
or placebo treatment was given.

Inflammatory bowel disease
Ulcerative colitis (UC) and Crohn’s disease (CD), the two types of inflammatory
bowel diseases (IBD), are chronic inflammatory pathologies of the gastrointestinal tract.
Both conditions occur in individuals who are genetically susceptible and exposed to
environmental risk factors (121). Even though the etiology of IBD has been extensively
studied, the disease pathogenesis is not fully known, nor is there a cure (122). The
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characteristics of the inflammation are different, with CD being scattered throughout the
GIT, typically involving the distal small intestine and colon with transmural inflammation
and occasionally associated with granulomas, whereas in UC the inflammation is usually
confined to the mucosa of the colon (123, 124). Both UC and CD are characterized by a
relapsing and remitting course leading to a very significant reduction in life quality during
the disease (125).
Several synbiotic formulations have been used in clinical studies to treat IBD. In
Furrie et al., Synergy 1 (6 g of inulin/oligofructose) and 2 x 1011 CFU Bifidobacterium
longum were administered to UC patients (93). One of the strengths of this study was that
the probiotic strain was isolated from a healthy human subject and had been assessed for
its aerotolerance, acid tolerance, resistance to bile salt, and adherence to epithelial cells.
Its ability to use the prebiotic substrate as an energy source was also established in vitro.
The organism was further shown to alter the cytokine expression in a HT29 epithelial cell
line and reduce proinflammatory cytokine levels in vitro. For the clinical study, 18 patients
were divided into synbiotic and placebo groups, each receiving the respective treatments
twice daily for four weeks. The synbiotic treatment led to reduced inflammation and
regeneration of epithelial tissue compared to the placebo group, reduced mRNA levels of
human beta defensins, and lowered levels of tumor necrosis factor α and interleukin 1 α.
Although survival of the probiotic strain was not measured in a strain-specific manner,
bifidobacteria-specific rRNA levels were increased 42-fold in the synbiotic group
compared to approximately 5-fold in the placebo group. Unfortunately, this study did not
investigate the effects of the probiotic independently.
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Another B. longum synbiotic clinical trial was performed by Fujimori et al. In this
study, a B. longum strain (2 x 109 CFU) was combined with eight grams of psyllium as the
prebiotic component. Subjects were UC outpatients (n = 120) (91). This trial did include
probiotic and prebiotic only treatment groups in the study design to allow for comparisons.
While most tested blood markers showed no differences among the three treatments, Creactive protein was significantly decreased (P = 0.04) and the total protein level in the
blood samples increased (P = 0.03) in the synbiotic group. Hemoglobin and hematocrit
only increased in the probiotic group (P = 0.04). Total inflammatory bowel disease
questionnaire scores showed significant improvement only for the synbiotic group. The
investigators concluded that the synbiotic treatment led to a greater life-quality than the
pre- and probiotic treatments alone.

However, this study did not investigate the

mechanisms responsible for this improvement nor was the survival of the probiotic
determined. Therefore no conclusion about the nature of the synbiotic can be drawn, i.e.
if the synbiotic acted synergistic or complementary.
In another clinical study, the effect of a Bifidobacterium breve-GOS synbiotic on
subjects with mild to moderate UC was assessed (94). Synbiotics contained B. breve (109
CFU, Yakult) and 5.5 g of galactooligosaccharide. Forty-one patients were treated with a
placebo or the synbiotic for one year.

End-points included endoscopic scores and

myeloperoxidase levels in lavage solutions; both were significantly lower in the synbiotic
treated group. An analysis of the fecal microbiota by plate counting was also performed
for subjects in the synbiotic group before and after the treatment. Of all assessed microbes,
only Bacteroidaceae were significantly decreased after the synbiotic treatment. The
abundance of Bifidobacterium remained the same, and B. breve was only detected after the
treatment but not before (5.75 ± 1.65 log10 CFU/g feces). Therefore, it can be concluded
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that B. breve survived the passage through the GI tract. Whether or not the applied
prebiotic was supporting the probiotic could not be determined from this study.
Interestingly, here no bifidogenic effect was observed due to galactooligosaccharide
treatment. This is contrary to results previously reported (126).
A combination of 6 g of Synergy 1 (inulin/oligofructose) and 2 x 1011 CFU
Bifidobacterium longum showed improvements in Crohn’s disease in patients that
continued using their conventional CD medication (95). Compared to a placebo, the
synbiotic significantly reduced TNF-α gene expression (P = 0.041), disease activity
indexes (P = 0.02), and histological scores (P = 0.018) after six months of treatment. The
microbiota of tissue biopsies was analyzed in both species- and genus-specific manner.
Interestingly, 8 out of 13 patients had increased numbers of Bifidobacterium longum and
bifidobacteria at the three month time point compared to the baseline in the synbiotic group,
increasing to 11 patients after six months. The nature of this responder/non-responder
phenomenon was not addressed.
Chermesh et al. investigated the potential of Synbiotic 2000 to prevent
postoperative recurrence of CD (127). This formulation contained 1010 CFU Pediococcus
pentoseceus, 1010 CFU L. raffinolactis, 1010 CFU L. paracasei subsp. paracasei 19, and
1010 CFU L. plantarum 2362 and as fermentable fibers 2.5 g of β-glucans, 2.5 g of inulin,
2.5 g of pectin, and 2.5 g of resistant starch. The frequency of the treatment was not stated.
Of 30 enrolled patients, nine patients completed the study, which lasted 24 months.
Synbiotic 2000 had no effect compared to the placebo on endoscopic or clinical relapse,
nor the postoperative occurrence of CD. However, it significantly improved weight
increase and normalization of hemoglobin levels at the three month follow up time point.
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No analysis of the gut microbiota was done, nor were reasons given for the selection of the
synbiotic combination. Of the prebiotic components none were correlated to any health
benefits by the authors. Only fructooligosaccharides were mentioned as beneficial in
general. Unfortunately, this study had a small sample size, lacked a pro- or prebiotic
control arm, and used a seemingly arbitrarily selection process to determine the synbiotic
combination.
The plant fiber, psyllium, was combined as a synbiotic with bifidobacteria and
lactobacilli, and used to treat CD patients (128). The synbiotic contained 9.9 g of psyllium
and 3 × 1010 CFU Bifidobacterium breve, 3 × 1010 CFU of Lactobacillus casei, and 1.5 ×
1010 CFU of Bifidobacterium longum. Ten active CD patients were enrolled in this 13
month trial. The trial was not placebo controlled and subjects were allowed to discontinue
using psyllium during the trial if abdominal bloating occurred. All subjects were allowed
to reduce the pro- and/or prebiotic treatment on their own will, thereby individualizing the
treatments. Subjects also received aminosalicylates and prednisolone at varying doses. All
subjects continued taking the probiotic treatment, but their doses varied between 12 and 73
× 1010 CFU. Four subjects discontinued the prebiotic treatment, and for the remaining six
patients the doses varied between 3.3 and 9.9 g per day. Based on the clinical outcome,
the authors divided the subjects into complete responder, partial responder, and nonresponders. Eight complete responders lowered their Crohn’s Disease activity index scores
by more than 70 points and six achieved remission. Patients who discontinued the
synbiotic treatment and those following it through the whole duration of the study were
found in the responder as well as the non-responder group. Therefore, no correlation
between a synbiotic treatment and a health improvement could be determined.
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Rossi et al. conducted a observational study applying SynGutTM (Bifidobacterium
lactis W51, Lactobacillus acidophilus W22, Lactobacillus plantarum W21, Lactococcus
lactis W19, and inulin) to 96 IBS patients for two months (129). While this study had no
control group, no pro- or prebiotic group, and no standardized scoring system, it reported
an improvement of IBS symptoms in 74% of the participants.

Diarrhea
Diarrheal diseases are often caused by infectious agents, which lead to lose, or
liquid, bowel movements with increased frequency, water content, and volume.
Worldwide, diarrhea is the leading cause of hospitalizations, morbidity, and mortality
(130).
The potential of Lactobacillus acidophilus, Lactobacillus rhamnosus,
Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (2.5 x 109 CFU
total), combined with 625 mg of fructooligosaccharide as a synbiotic, was tested in children
with acute diarrhea (130). Treatment with oral rehydration salts (ORS) and intravenous
therapy was also provided. Compared to a control group (receiving only ORS and/or
intravenous therapy), the synbiotic combination significantly shortened the duration of
diarrhea (P < 0.0001) and shortened the hospital stay (P = 0.002). The gut microbiota of
these children was not analyzed.
In a similar study, children with acute rotavirus diarrhea were treated with
Lactobacillus sp., Streptococcus sp., Bifidobacterium sp. (1 x 109 CFU total) and 990 mg
of FOS (131). A standard fluid therapy and nutritional support were provided. A total of
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35 children were enrolled in the synbiotic group and were compared to a placebo group.
The duration of diarrhea was significantly shorter in the synbiotic group (P < 0.0001), and
for half of the patients receiving a synbiotic treatment, intestinal mucosal healing was
reported 50 hours after the synbiotic administration. The gut microbiota was not analyzed.
No further descriptions were given to explain why half of the group responded to the
treatment.
An arabinogalactan and xylooligosaccharide mixture was used to formulate a
synbiotic that also included Lactobacillus paracasei B21060 (2.5 x 109 CFU). The
prebiotics were present at 500 mg and 700 mg, respectively. Subjects included 55 children
with acute diarrhea, who also received ORS treatment.

The synbiotic showed a

significantly higher resolution rate (P = 0.005) than the placebo group after the first 72
hours (132). This study allowed for additional treatments (e.g., diosmectite, domperidone
or racecadotril) given by the parents after the first 72 hours, which may have influenced
the total duration of diarrhea. No analysis of the fecal microbiota was performed. The
additional treatments may have influenced the efficacy of the synbiotic treatment.
A combination of Streptococcus thermophilus, Lactobacillus bulgaricus (9.7 x 108
CFU), Bifidobacterium animalis subspecies lactis (Bb-12) (5 x 109 CFU), and 1g of inulin
was assessed for its potential to prevent diarrhea, vomiting and other infections in young
children (133). One hundred and forty-nine children participated in this placebo controlled
double-blind study.

After 16 weeks of treatment, synbiotic treated children had

significantly fewer days of fewer, but significantly more days with watery stools (P < 0.05).
No analysis of the microbiota was performed and it remains unknown which components
of the treatment might have caused this effect.
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To assess the potential to prevent and/or shorten the occurrence of traveler’s
diarrhea, 196 healthy adults received a synbiotic combination named Agri-King Synbiotic
(AKSB). This preparation contained fructooligosaccharide, 4.5 x 109 CFU Enterococcus
faecium SF68 and 5 x 109 CFU Saccharomyces cerevisiae CNCM I 4444 consumed twice
daily (134). This paper does not state the amount of fructooligosaccharide present in the
AKSB capsules. A literature research suggests that this preparation contains 115 mg of
fructooligosaccharide per capsule (135). A phase I study had shown that AKSB was safe
and also that both strains were washed out within seven days after the treatment was
discontinued. Study subjects traveling to Asia, Africa, South and Central America were
instructed to consume the synbiotic or placebo treatment one to two times daily, and to
continue the treatment if diarrhea should occur. Approximately half of the study cohort
experienced traveler’s diarrhea, but no benefit of the synbiotic treatment was detected. To
justify the combination of E. faecium and S. cerevisiae the authors stated that E. faecium
was capable of competing with other Gram-negative bacteria. However, the authors do not
show evidence for this here and instead refer to another paper that analyzed this
phenomenon in stored meat samples and not for the gut microbiota (136). No further
comments were made regarding S. cerevisiae or fructooligosaccharide.

Colon cancer
Colorectal cancer is the third most common form of cancer and has a very high
mortality.

In addition to genetic factors, environmental factors including radiation,

chemical carcinogens, and diet contribute to tumorigenesis in the colon (137). Current
treatments are associated with a high risk of complications and a low success rate.
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Investigators have suggested that by maintaining a healthy weight, diet, and physical
activity, up to one third of colon cancers may be prevented (138). Numerous pro-, pre-,
and synbiotic studies using rodent models suggest that these treatments may have
preventive and therapeutic properties. However, human studies are difficult to perform
and therefore rare.
Rafter et al. and Roller et al. assessed a combination of Lactobacillus rhamnosus
GG (1 x 1010 CFU), Bifidobacterium lactis Bb12 (1 x 1010 CFU) and 12 or 10 g of Synergy
1 on colon cancer and polypectomized patients in two similar phase II anti-cancer studies
(139, 140). The synbiotic treatment was compared to a placebo in a 12 week trial. Fecal
water obtained from the cancer patients did not improve barrier function in Caco-2 cells,
but did increase production of interferon γ. For polypectomized patients, several benefits
were observed among the synbiotic group, including significant decreased DNA damage
in colonic mucosa, reduced proliferation, and decreased secretion of IL-2. The fecal water
improved barrier function in Caco-2 cells and significantly reduced necrosis in HCT116
cells. The investigators also assessed survival of each of the probiotic strains in an
independent study with healthy human subjects who consumed rifampicin resistant
mutants of each strain (139). Rifampicin resistance was used to identify the probiotics in
a strain specific manner in the fecal samples. A full recovery of both strains in healthy
subjects was reported. For the study patients, a fecal analysis was not performed at the
strain level, but at the genus level. The number of Lactobacillus and Bifidobacterium
consistently increased in the synbiotic group for both cancer and polypectomized patients
over the 12 week trial, while Clostridium numbers decreased. Since a probiotic only
treatment was not applied, a synergy between the probiotic strains and Synergy 1 could not
be confirmed based on this data. Roller et al. did not analyze the fecal microbiota, but
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referred to another study that reported that only 10 % of the consumed amount of LGG and
Bb12 survived the GI tract in the same synbiotic treatment (141). Neither study analyzed
the probiotic and prebiotic components alone.
In a four week cross-over trial the effect of the synbiotic combination of 12.5 g of
resistant starch and 5 x 109 CFU Bifidobacterium lactis was investigated on twenty healthy
subjects (92). Even though these patients were healthy, the effect of the dietary treatments
on markers of early colorectal carcinogenesis was assessed. A placebo, a prebiotic only,
and a probiotic only arm were also included. Full analyses of the fecal microbiota were
conducted using DGGE and quantitative real-time PCR to assess levels of Bifidobacterium
lactis. The DGGE banding patterns showed that the synbiotic treatment introduced
significantly more changes to the gut microbiota than the placebo or the pro- or prebiotic
treatments alone. Interestingly the probiotic treatment led to higher numbers of B. lactis
than the synbiotic treatment (8.8 x 107 versus 5.4 x 107 B. lactis/g feces). Therefore a
synergistic relationship between this strain of B. lactis and the applied resistant starch is
not likely. No differences were detected for the SCFA profile, fecal ammonia or pH, serum
inflammatory markers, or epithelial variables among the treatments.

This study

demonstrates how even significant changes introduced to the gut microbiota by a dietary
intervention do not necessarily lead to a change in disease associated phenotypes.

Irritable bowel syndrome
Irritable bowel syndrome (IBS) is an intestinal disorder characterized by abdominal
pain, bloating, diarrhea, alternate constipation, distention, or a combination of these
symptoms. The cause of this illness has not been established, but visceral hypersensitivity,
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genetics, the gut microbiota, constant low-grade inflammation, and environment are
contributing factors (81). Approximately 11 % of the world’s population may be affected
by IBS, with higher occurrences among women and younger individuals (142, 143).
Physiological interventions, dietary manipulations, pharmacologic agents, and modulation
of the gut microbiota are part of current treatments for IBS (144).
In one double-blinded, randomized and placebo-controlled study, a synbiotic
mixture of 5 × 109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus,
2×109 Lactobacillus gasseri,1×109 Bifidobacterium infantis, 1×109 Bifidobacterium
longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus, 1×109
Lactobacillus sporogenes, and 5×109 Streptococcus thermophilus in combination with 2.2
g Synergy 1 (inulin/oligofructose) was tested for its potential to reduce symptoms of IBS
(145). Sixty-four patients were enrolled and treated for four weeks. No overall satisfactory
relief was achieved with the synbiotic treatment. However the synbiotic did improve
quality of life scores, and the severity of flatulence was significantly decreased.
Interestingly, the authors provided a rationale for selecting this particular synbiotic
combination. Namely, the product is readily available, has a history of safe use, and there
was only one other study using single-strain synbiotic mixture for the treatment of IBS.
Nonetheless, effect on the gut microbiota was not studied.
A recent study examined the effect of Lactobacillus acidophilus (1.8 x 107 CFU/g),
Bifidobacterium animalis subsp. lactis Bb-12 (2.5 x 107 CFU/g), and Beneo dietary fibers
(2%) on the quality of life and IBS symptoms of 76 constipation-predominant IBS patients
(146). The synbiotic was delivered twice daily in 180 g of fermented milk for four weeks.
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Several markers of IBS symptoms improved after four weeks, but there was no difference
between the synbiotic and the placebo (fermented milk).
Bittner et al. tested the efficacy of the synbiotic Prescript-AssitTM in a two week
randomized, placebo-controlled study, followed by a two week open label treatment and a
follow up 60 weeks later (147, 148). Prescript-AssitTM is a combination of 29 soil-based
microorganisms, including several Anthrobacter, Bacillus, Brevibacterium, Pseudomonas,
and Streptomyces strains. The prebiotic components are not well defined, except that one
of them is leonardite. A total of 25 patients completed the first two week study, and 22
completed the 60 week follow up. The authors concluded that Prescript-AssitTM was
capable of reducing short-term and long-term symptoms of IBS in the study cohort. These
symptoms included general ill feeling/nausea, indigestion/flatulence, and colitis. Since the
synbiotic composition was not clearly defined, an assessment of the synergy of this
synbiotic cannot be made. The fecal microbiota of the patients was not analyzed and
therefore no conclusions regarding the mode of action of this synbiotic can be inferred.
Interestingly, the applied organisms are mostly found in soil are not considered members
of the human gut microbiota. Whether or not these organisms are capable of reaching the
colon or interacting with the autochthonous microbiota remains unknown. Unfortunately,
a rationale for choosing soil organisms in a human trial is not given.
The efficacy of Flortec, a synbiotic combination containing 5 x 109 CFU
Lactobacillus paracasei B21060, xylo-oligosaccharides, glutamine, and arabinogalactone,
was tested in a parallel-arm, double blind study in patients of IBS (149). Patients were
instructed to consume the synbiotic or prebiotic treatment twice a day for twelve weeks
and were asked to report GI symptoms on a daily basis. No placebo control or probiotic
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only arm was included. A total of 167 IBS patients were enrolled in this study, however,
55 discontinued the treatment prematurely. The main reason to withdraw was a perceived
lack of benefit (33 % of the cases). For the remaining patients, no differences were
observed between the prebiotic and the probiotic treatment groups. Compared to the
baseline, both treatments led to a decrease in IBS scores after one week. There was,
however, a significant difference among the number of patients that had at least one bowel
movement per day with 70 % in the synbiotic group and 35 % in the prebiotic group. An
analysis to assess how a responder differed from a non-responder was not conducted.
Subsequently, 47 patients who had a diarrhea predominance were analyzed as a subgroup.
The number of bowel movements and IBS score significantly decreased due to the
synbiotic treatment compared to the baseline and the prebiotic group. In this study, patients
were allowed to use a “rescue treatment”. Approximately 8 % of the study subjects used
such a treatment, which was not closer defined then “medications effecting gastrointestinal
motility and/or perception”. These additional treatments were not taken into account
during the assessment of the syn- and prebiotic treatments. Collectively, the absence of
both a placebo control arm and an analysis of the gut microbiota makes it difficult to
establish the effectiveness of the synbiotic.
Dughera et al. conducted an open-label, uncontrolled, and multi-center study in ten
Italian gastroenterological centers (150). The applied synbiotic was Zir Fos®, containing
5 x 109 CFU of Bifidobacterium longum W11 and 2.5 g of Fos-Actilight, a short-chain
fructooligosaccharide. A total of 129 patients with constipation-predominant IBS were
enrolled and received the treatment for three months. Measured symptoms included
abdominal pain, bloating, well-being, stool shape, stool frequency, concomitant treatments
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and comorbidity. The results showed that the synbiotic treatment significantly reduced
abdominal pain and bloating, and induced a higher stool frequency (P < 0.0001).
This same synbiotic (i.e., Bifidobacterium longum W11 and Fos-Actilight) was
tested on 636 patients with constipation-variant IBS (151). A clear statement about
duration of the treatment was not given, only that the treatment lasted for at least 36 days.
The dose was the same as in the study above (150), and the treatment effects were evaluated
at the end of the study and at a one month follow up visit. The results are similar to those
reported by Dughera et al., in that the treatment resulted in significantly decreased bloating
and abdominal pain (P < 0.0001) and increased stool frequency significantly. Most (~84%)
of the patients reported improved symptoms at the end of the treatment, but at the followup evaluation the number decreased to 63 %.
In neither trial were the fecal microbiota analyzed nor were control groups with
probiotic, prebiotic, or placebo treatment included. Based on these studies no conclusion
can be drawn about a synergy between the probiotic and prebiotic.

The ideal human trial to assess health benefits of a synbiotic treatment
The development and selection of successful synbiotic combinations is a very
complex issue (32). As noted above and previously recommended by Kolida and Gibson
(32), synbiotic trials have to be carefully designed and controlled in order to demonstrate
the additive effect of each component, and to assess the minimum effective dose of each
component of the synbiotic in order to achieve the desired health benefit, while avoiding
side effects. As demonstrated here and previously (32), most studies did not provide the
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necessary controls to confirm an additive or synergistic effect of the synbiotic.
Importantly, the rationale for how the synbiotic had been formulated is rarely stated. In
contrast, an ideal clinical trial would include synergistic synbiotics that had been shown to
survive passage through the GI tract and also had an ability to become established in the
GI environment. Considering ecological criteria is also important when formulating
synbiotic combinations, including demonstrating that the probiotic strain is capable of
metabolizing the given prebiotic under competitive conditions. Changes introduced to the
gut microbiota should also be assessed to determine if cross feeding or other ecological
events had occurred, e.g. niche competition, niche partitioning, or niche exclusion with the
resident microbiota. It is also critical to validate that the probiotic had been enriched using
strain-specific probes or primers in quantitative PCR assays. The experimental design
should include treatments consisting of each component of the synbiotic. Once the
characteristics of the pro- and prebiotic are established independently as well as in
combinations and an additive effect of the components has been demonstrated,
randomized, controlled and double-blinded human trials should be conducted, with
prebiotic, probiotic, and synbiotic treatments and a placebo control. Survival of the test
strains and changes in the composition of the gut microbiota should be assessed, in addition
to measuring the health or clinical biomarkers of interest. The study cohort needs to be
sufficiently large to assure adequate power for the statistical analysis. Ideally, the synbiotic
should be compared to another a similar synbiotic containing a different strain.
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1.7 Commercial synbiotics: recent developments and future prospects
The functional foods market, that includes gastrointestinal health products, is
estimated to be worth more than US $ 43 billion. Currently, the US, Europe, and Japan
represent 90 % of the global functional food market (152). Within the US market, probiotic
products had an estimated revenue of US $ 3.4 billion in 2013, and already in 2014 sales
of probiotic products were the fasted growing of all supplements with a 22 % increase and
US $ 10 billion revenue (153). It is therefore the most popular functional food ingredient
after minerals and vitamins (154). The market revenue for prebiotics is estimated at US $
334 million, and synbiotics at 69 million. These numbers are expected to increase with the
new markets in the Middle East, China, India and New Zealand (35).
Despite the substantial market opportunities for these products, researchers,
clinicians, and regulatory agencies continue to emphasize several important issues. In
particular, demonstrating that products are safe and effective remains a top priority.
Manufacturers are especially motivated to develop appropriate health claim strategies
(155). This situation is complicated by different health claim regulations that vary from
one country to another and the degree of evidence required to support a health claim (156).
Currently, neither EFSA nor the FDA have approved any health claims made for pre-, proor synbiotic combinations.

Moreover, probiotic and synbiotic products must be

distinguished between a pharmaceutical product and a food product (157). The FDA
guidelines state that if any agent, including probiotics, is ingested for the purpose of curing,
mitigating, treating, diagnosing or preventing disease, it is classified as a “drug” and must
undergo the regulatory process similar to any new pharmaceutical.

This can be a

burdensome process for probiotic/synbiotic foods, especially since the majority of food
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products are not produced in pharma grade facilities and the FDA may require phase I
safety studies for new synbiotic products. In Europe the European Nutrition and Health
Claims regulations intend to: (i) ensure that claims are “clear, accurate and based on
scientific evidence”; and (ii) prohibit foods that bear “claims that could mislead
consumers”. Ultimately, high-quality human intervention studies are necessary to support
any health claims of a product (156).
Another obstacle for the food industry is the lack of consumer understanding of
these products. Although consumers apparently understand probiotics, at least in general,
they are less familiar with prebiotics (or confuse it with probiotics), and even fewer
understand synbiotics (35, 47).

Therefore some products are not even marketed as

synbiotics, but rather as probiotics. Nonetheless many synbiotic products are on the
market. To date, most synbiotic-containing foods claim to improve general gut health or
the body’s natural defense mechanisms by supporting the immune system or lowering
blood cholesterol.
Synbiotic products are most commonly presented to consumers as powders or
cultured dairy products like yogurts or smoothies. Prebiotics can be used in most food
applications, but the environmental sensitivity of probiotics limits their practical use in
non-refrigerated foods, since the survivability of the probiotic strains dictates which
synbiotics can be developed (35). However, new microencapsulation technologies that
protect the bacteria against otherwise detrimental processing treatments could lead to a
variety of new synbiotic products, including desserts, candy, juices, cheeses, or chocolate
(158–162). Interestingly many pre- and synbiotic products contain rather small amounts
of the prebiotic component (on a per serving basis), which may be too low to induce a
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health effect. Low doses are used, in part, to avoid adverse gastrointestinal complaints
(163), but perhaps also for cost reasons.
Interestingly, despite the new products introduced into the marketplace and
questions concerning safety and efficacy, synbiotic foods have a long history of save
consumption. As reviewed by Ashwani et al., many indigenous synbiotic foods can be
found around the world, including Central America, India, Eastern Europe, China and
Africa (164). Most of these synbiotic preparations are fermented beverages, either with
defined starter cultures, or by “spontaneous fermentation” (165). However, the uncertainty
of the actual microbial composition likely results in inconsistent final food products,
unsuitable for industrial sale. Nonetheless, these indigenous synbiotic foods have market
potential if produced on an industrial scale and with appropriate quality standards (164).

1.8 Remaining questions and specific aims
Disturbances of the microbial composition in the gastrointestinal tract have been
associated with deterioration of host health and functions. These developments may either
be directly induced by the gut microbiota, via an altered metabolite synthesis, or via the
host immune system (6). While the microbiota composition in the human gastrointestinal
tract is remarkably stable, it can be successfully modulated by certain synbiotic treatments.
These treatments could offer great advantages to human health when selected on a rational
basis. However, there are currently many potential limitations that hinder the development
of synergistic synbiotic formulations. There is a need to validate the potential health
benefits of synbiotics in carefully controlled human clinical trials. Additionally the future
development of new synbiotic combinations should focus on the development of
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synergistic synbiotics that prioritize the ecological properties and requirements of the
probiotic strain.
The work presented in this thesis aims to answer three important questions, which
are relevant for our understanding of how the gut microbiota is shaped and how we can
establish successful concepts for the modulation of the gut microbiota.
The first objective of this thesis was to gain insight into the complex interplay
between the host and intestinal microbes. For this approach we chose Lactobacillus
reuteri, which is a commonly used probiotic strain. L. reuteri has been shown to be a true
symbiont in rodents and densely colonizes the forestomach of mice (166, 167). The aim
of this study presented in Chapter 2 was to systematically determine which genes of L.
reuteri 100-23 contribute to tolerance towards host gastric acid secretion. A better
understanding of microbial colonization factors in their host contributes to our
understanding of ecological requirements for novel probiotic strains. If these and other
findings are truly understood and applied to the rational selection of synbiotic strains, the
next generation of synbiotic combinations may have a greater ecological advantage and
could be more competitive than current synbiotic combinations on the market.
The second objective of this thesis was to test if rationally selected synbiotic
applications have a higher potential to establish probiotic strains in the gastrointestinal
tract. To answer this question, Chapter 3 analyses the potential of a novel technique to
select synergistic synbiotic combinations. In this study we characterized the potential of
an in vivo selected combination of Bifidobacterium adolescentis and GOS in a rat model.
After the ecological advantages of in vivo selected synbiotics had successfully been
established, the third objective was to test the potential of this synbiotic combination in
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human subjects in Chapter 4 in comparison to a commercial synbiotic. The rationally, in
vivo selected synbiotic was established in the GI tract of the subjects in significantly higher
numbers then the commercial synbiotic.
Together, the studies performed for this thesis present a comprehensive
examination of the role of the stomach and dietary factors, such as probiotics, prebiotics
and synbiotics, on the establishment of bacteria in the gastrointestinal tract.
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Chapter 2

Characterization of the ecological role of genes mediating acid resistance in
Lactobacillus reuteri during colonization of the gastrointestinal tract.

Preface
This chapter has been previously published: Characterization of the ecological role of
genes mediating acid resistance in Lactobacillus reuteri during colonization of the
gastrointestinal tract. Janina A. Krumbeck, Nathan L. Marsteller, Steven A. Frese, Daniel
A. Peterson, Amanda E. Ramer-Tait, Robert W. Hutkins, and Jens Walter. Environmetal
Microbiology (2015). doi:10.1111/1462-2920.1310

2.1 Summary
Rodent-derived strains of Lactobacillus reuteri densely colonize the forestomach
of mice and possess several genes whose predicted functions constitute adaptations towards
an acidic environment. The objective of this study was to systematically determine which
genes of L. reuteri 100-23 contribute to tolerance towards host gastric acid secretion.
Genes predicted to be involved in acid resistance were inactivated, and their contribution
to survival under acidic conditions was confirmed in model gastric juice. Fitness of five
mutants that showed impaired in vitro acid resistance were then compared through
competition experiments in ex-germ-free mice that were either treated with omeprazole, a
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proton-pump inhibitor that suppresses acid secretion in the stomach, or left untreated. This
analysis revealed that the urease cluster was the predominant factor in mediating resistance
to gastric acid production. Population levels of the mutant, which were substantially
decreased in untreated mice, were almost completely restored through omeprazole,
demonstrating that urease production in L. reuteri is mainly devoted to overcome gastric
acid. The findings provide novel information on the mechanisms by which L. reuteri
colonizes its gastric niche and demonstrate that in silico gene predictions and in vitro tests
have limitations for predicting the ecological functions of colonization factors in bacterial
symbionts.

2.2 Introduction
A complex and diverse collection of microorganisms colonizes the gastrointestinal (GI)
tract of mammals, affecting the health and immune status of the host. Among other functions, these
microbial communities enhance energy absorption from ingested food, contribute to the
development of their host’s immune system, and provide colonization resistance against pathogens
(Sekirov et al., 2010). As a result of co-evolution, the bacteria that reside in the mammalian gut
have developed a high degree of ecological fitness and specialization (Oh et al., 2010; Frese et al.,
2011; O’Callaghan and O’Toole, 2013). Given the importance of the gut microbiota to the health
of its host, there is currently much interest in formulating strategies that modulate its composition.
However, remodeling this complex ecosystem requires an understanding of the mechanisms by
which specific gut microbes colonize the GI tract and the factors that distinguish resident
autochthonous members of the microbiota from allochthonous ones (Walter, 2008).
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Among the bacteria that are autochthonous to several mammalian species is Lactobacillus
reuteri (Walter, 2008). L. reuteri forms high populations in the rodent stomach that are maintained
throughout the life of the animal. Colonization is achieved, in part, by the ability of the organism
to adhere to the surface of the non-secretory epithelium present in the forestomach, resulting in
formation of a biofilm-like structure (Walter et al., 2007; Frese et al., 2013). The ability of L.
reuteri strains to form these biofilms is strictly dependent on their host origin, with only rodent
isolates being capable of forming biofilms (Frese et al., 2013). This translates to a higher ecological
fitness of rodent strains when colonizing the mouse gastrointestinal tract (Frese et al., 2011). L.
reuteri is therefore an example of a bacterium that maintains a tight, host-specific relationship with
its mammalian host (Oh et al., 2010), and hence serves as a model to study ecologically important
traits that facilitate host-microbe symbiosis in mammals at the molecular level (Frese et al., 2011;
Tannock et al., 2005).
A combination of comparative genomic and transcriptomic analyses have been used to
identify genes that were overexpressed during gut colonization and contributed to host specificity
and biofilm formation in rodent strains of L. reuteri (Frese et al., 2011, 2013; Schwab et al., 2014;
Wilson et al., 2014). Several of these genes (Table 2.1) are predicted to be involved in acid
resistance, reflecting the acidic pH in the gastric niche, which varies depending on food loading
and emptying (McConnell et al., 2008) from pH 4 and 5.7 in the lumen (Ward and Coates, 1987),
and between pH 3.5 and 4 in the forestomach (Ward and Coates, 1987; Gärtner, 2001; Teixeira et
al., 2014). In particular, the presence of the urease gene cluster is mostly specific to rodent strains
and its expression was induced during colonization of the mouse gut, without contributing to
biofilm formation (Frese et al., 2011, 2013). Wilson and colleagues confirmed its induction in vivo
and showed that the cluster contributed to ecological performance in Lactobacillus-free mice
(Wilson et al., 2014). In addition, genes encoding glutamate decarboxylase and glutaminase were
also found to be overexpressed during stomach colonization (Schwab et al., 2014; Wilson et al.,
2014). The dlt operon, which contributes to acid resistance through the incorporation of D-alanine
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esters into cell wall-associated teichoic acids, is essential for L. reuteri colonization of the
gastrointestinal tract (Walter et al., 2007). Several other acid resistance mechanisms (glutamate
decarboxylase, glutaminase and arginine deaminase) support growth of L. reuteri during sour
dough fermentation (Su et al., 2011; Teixeira et al., 2014).
Although it is established that gastric acid constitutes a potent barrier to bacterial pathogens
(Tennant et al., 2008), little is known about how lactobacilli autochthonous to the stomach
overcome this environmental filter. Of the genes predicted to be involved in acid resistance, only
the urease cluster and the dlt operon have been studied in colonization experiments in mice (Walter
et al., 2007; Wilson et al., 2014). However, the mechanisms by which these factors facilitate
colonization have not been determined, and other functions, independent of acidity, could explain
the importance of these factors in vivo. In addition, it is unknown which of the other acid resistance
factors present in L. reuteri contribute to acid resistance during stomach colonization. The goal of
this study was therefore to determine the ecological significance of acid-resistance genes present
in L. reuteri 100-23 during gut colonization, and to systematically determine to what degree they
contribute to tolerance to host gastric acid secretion. To achieve this, we compared the ecological
fitness of mutants in ex-germ-free mice treated with omeprazole, a proton-pump inhibitor that
raises the pH of the stomach from approximately pH 3 to 5 (depending on food loading) to
approximately 6.8 to 7.0 (Betton et al., 1988), with mice that were left untreated.

2.3 Results
2.3.1 Selection of genes of L. reuteri 100-23 predicted to be involved in acid resistance
Genes selected for this study are listed in Table 2.1 and included: (i) the gene
encoding for the α-subunit of the urease enzyme (ureC).

This gene cluster, which

hydrolyses urea to ammonia, which increases the pH (Cotter and Hill, 2003), is mainly
found in rodent strains of L. reuteri but is absent in other isolates and is overexpressed
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during gut colonization (Frese et al., 2011; 2013; Wilson et al., 2014); (ii) arginine
deiminase (Adi), which increases acid resistance by intracellular consumption of protons
and ammonia production (Arena et al., 2002; Cotter and Hill, 2003; Rollan et al., 2003;
Vrancken et al., 2009; Teixeira et al., 2014); (iii) the glutamate decarboxylase (GadB),
which is specific to L. reuteri strains isolated from rodents (Frese et al., 2011) and induced
in vivo (Wilson et al., 2014), and further implicated in acid resistance during growth in
sourdoughs (Su et al., 2011; Teixeira et al., 2014); (iv) the cystathionine γ-lyase (Cgl),
which catalyses several reactions transforming compounds such as L-cystine, Lcystathionine, L-homoserine, or L-cysteine (De Angelis et al., 2002; Wang, 2002). Lcysteine is degraded into pyruvate, hydrogen sulfide and ammonia, the latter of which
could increase the pH (Wang, 2002); (v) the dltA gene, which is involved in D-alanyl
esterification of teichoic acids associated with cell walls, is an important colonization factor
of L. reuteri (Walter et al., 2007) associated with in vitro acid resistance in L. reuteri
(Walter et al., 2007) and other organisms (Boyd et al., 2000; Kristian et al., 2005); and (vi)
homologues of a two-component regulatory system consisting of a histidine sensor kinase
(lisK, lr69622) and response regulator (lisR, lr69623), which has been previously shown to
be involved in acid response regulation in Listeria monocytogenes and Lactobacillus
acidophilus (Kallipolitis and Ingmer, 2001; Cotter and Hill, 2003; Azcarate-Peril et al.,
2005). At the protein level, the LisR and LisK homologues have 76 % and 47 % similarity
to the proteins in L. acidophilus, whereas they show less than 32 % similarity to other twocomponent systems (cemAKR, bfrKRT, and lr70529/lr70530) described for L. reuteri 10023 (Frese et al., 2011; Su and Gänzle, 2014). As a negative control, a mutant with an
inactivated high molecular mass surface protein (lsp mutant) was included in our studies,
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as this adhesin contributes to ecological performance in vivo but is not predicted to be
involved in acid resistance (Walter et al., 2005).
Table 2.1. Genes selected for functional characterization
Gene

Protein

Description

Putative
Function

Reason for Study

lr70114

UreC

Urease enzyme, α
subunit

Acid
resistance

Host specific (Frese et al., 2011; Wilson et al.,
2014), upregulated in biofilms (Frese et al.,
2013) and in vivo (Frese et al., 2011; Schwab
et al., 2014; Wilson et al., 2014), and involved
in acid resistance and critical for ecological
success (Kakimoto et al., 1990; Cotter and
Hill, 2003; Wilson et al., 2014).

Ir71325

GadB

Glutamate
decarboxylase

Acid
resistance

Upregulated in biofilm in L. reuteri 100-23
(Wilson et al., 2014) and involved in acid
resistance (Su et al., 2011; Teixeira et al.,
2014).

Ir69360

Cgl

Cystathionine
lyase

Reactive
oxygen
resistance (Lo
et al., 2009)

Upregulated in biofilm in L. reuteri 100-23
(Frese et al., 2013) and in acid-adapted B.
longum biotype longum (Sánchez et al.,
2007); pathway produces ammonia (Lo et al.,
2009), which may have buffering capacity.

Ir71377

Adi

Arginine
deiminase

Acid
resistance

Upregulated in the stomach when compared
to the cecum in conventional mice (Schwab et
al., 2014) and involved in acid resistance in L.
reuteri 100-23 (Teixeira et al., 2014).

Ir69622

LisK

Histidine sensor
kinase of twocomponent
regulatory system

Twocomponent
regulatory
system

Involved in acid response regulation in
Listeria monocytogenes (Kallipolitis and
Ingmer, 2001; Cotter and Hill, 2003) and
Lactobacillus acidophilus (Azcarate-Peril et
al., 2005).

Ir69623

LisR

Response
regulator of twocomponent
regulatory system

Twocomponent
regulatory
system

Involved in acid response regulation in
Listeria monocytogenes (Kallipolitis and
Ingmer, 2001; Cotter and Hill, 2003) and
Lactobacillus acidophilus (Azcarate-Peril et
al., 2005).

Ir1649Ir1652

DltA

D-alanylation of
lipoteichoic acids

Acid
resistance,
biofilm
formation

Involved in acid resistance in several
organisms (Boyd et al., 2000; Kristian et al.,
2005; Lebeer et al., 2008) and strongly
contributes to ecological performance in L.
reuteri 100-23 during gut colonization
(Walter et al., 2007).

γ-
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2.3.2 In vitro characterization of putative acid resistance genes
Isogenic mutants (Table 2.2) of each gene were generated by insertional
mutagenesis and compared with the wild- type for survival in simulated gastric juice at pH
1.5 and 2 (Fig. 2.1A–F). Depending on the gene tested, the gastric fluid was supplemented
with the substrate necessary for the particular pathway. The analysis revealed that the
ureC, adi, cgl, gadB and dlt mutants were all impaired in their ability to tolerate acidic pH.
For the ureC, Cgl, gadB and dltA mutants, the inhibitory effect of acidic conditions
appeared to be similar at pH 1.5 and 2. Exceptions were the adi mutant, which was more
impaired at pH 2 (Fig. 2.1B), and the dlt mutant, which was considerably more impaired
in its survival at pH 1.5 than at pH 2 (Fig. 2.1E). The omission of urea, arginine, glutamic
acid or cysteine reduced the survival rates of the wild-type to those of the respective
mutants (grown with the substrates), showing that acid resistance is facilitated by these
substrates. The two-component system with similarity to LisRK did not contribute to acid
resistance (Fig. 2.1F). As expected, the lsp mutant was not impaired in survival in gastric
juice (data not shown).
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Table 2.2. Strains used in this study

Lactobacillus reuteri 100-23

Isolate of rat gastrointestinal tract

Wesney
(1979)

Lactobacillus reuteri 100-23c

Plasmid-cured derivate of strain 100-23

McCOnnell
colleagues (1991)

Lactobacillus reuteri 100-23 ure C mutant

Urease α-subunit inactivated

Frese and
(2013)

Lactobacillus reuteri 100-23 lsp mutant

Large surface protein inactivated

Walter and colleagues
(2005)

Lactobacillus reuteri 100-23 cgl mutant

Cystathionine γ-lyase inactivated

Frese and
(2013)

Lactobacillus reuteri 100-23 gadB mutant

Glutamate decarboxylase inactivated

This study

Lactobacillus reuteri 100-23c lisR mutant

Response regulator of two-component
regulatory system involved in acid
resistance in Listeria monocytogenes and
Lactobacillus acidophilus

This study

Lactobacillus reuteri 100-23c lisK mutant

Histidine sensor kinase of two-component
regulatory system involved in acid
resistance in Listeria monocytogenes and
Lactobacillus acidophilus

This study

Lactobacillus reuteri 100-23c dlt mutant

D-alanylation of lipoteichoic acids in the
bacterial cell wall inactivated

Walter and colleagues
(2007)

Lactobacillus reuteri 100-23c adi mutant

Arginine deiminase inactivated

This study

Escherichia coli EC1000

Contains copy of pVW01 repA gene

Russell
and
Klaenhammer (2001)

and

Tannock
and

colleagues

colleagues
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Fig. 2.1. Determination of the capacity of genes (Table 2.1) to confer survival under acidic
conditions. The viability of strains was determined after incubation in artificial gastric
fluid at pH 2 and 1.5 for 6 h at 37°C. Survival of (I) wild-type strains incubated without
the substrate of the respective enzyme and (II) mutant strains incubated with the respective
substrate are shown relative (%) to that of the wild-type strain incubated with the respective
substrate. (A) ureC; (B) adi; (C) cgl; (D) gadB; (E) dltA; and (F) lisR and lisK. Because
there is no added substrate for the dltA, lisR and lisK genes, only the survival of the mutants
was compared with the wild-type. Data are shown as means with standard deviations of
triplicate independent experiments (biological replicates).
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2.3.3 Importance of acid resistance genes during colonization of the mouse GI tract
The ecological importance of the five genes found to contribute to acid resistance
in vitro (see above) was subsequently tested via competition experiments of mutant and
wild-type strains in germ-free mice that were treated with omeprazole or left untreated.
Therefore, for genes that contribute to acid resistance in vivo, omeprazole would lead to an
increase in competitive fitness of the mutants. Controls received either a sham treatment
[containing only the dimethylsulphoxide (DMSO), polyethylene glycol and water used to
dissolve the omeprazole] or no treatment (bacteria only). A schematic summary of the
experimental design is depicted in Fig. 2.2A.
The analysis revealed that the inactivation of ureC had a large impact on the
tolerance of L. reuteri 100-23c towards host gastric acid secretion (Fig. 2.2B). Without the
neutralizing effect of omeprazole, the ureC mutant represented around 0.1% of the L.
reuteri population in the gut after 8 days of colonization. Omeprazole treatment restored
the population of the ureC mutant to 29.8% ± 11 of the total lactobacilli population detected
in the forestomach and 50.2% ± 15 in the cecum. The omeprazole solvent, polyethylene
glycol, has weak buffering capacity, which likely is responsible for the increase of mutant
abundance in mice on the sham treatment (Fig. 2.2B).
The adi mutant was only slightly impaired in vivo. When in direct competition with
the wild-type strain, the mutant represented 26.9% ± 13 of the total lactobacilli in the
forestomach and 35.7% ± 17 in the cecum. No significant differences were observed for
omeprazole or sham treatment (Fig. 2.2C). The inactivation of gadB also only led to a
slight impairment in vivo (Fig. 2.2D), with the mutant comprising 19.5% ± 11 and 13.0%
± 10 of the total lactobacilli population in forestomach and in the cecum, respectively.
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Omeprazole treatment had no detectable effect in the forestomach (23.5% ± 14), but
significantly enhanced survival in the cecum (31.3% ± 25).

Fig. 2.2. Mouse competition experiment with mutant and wild-type strains in ex-germ-free
C57BL/6J mice treated with omeprazole, sham or no treatment. A. Conceptual summary
of the experimental design for mouse experiments. Mice were divided into three groups.
Group 1 mice were treated daily with omeprazole, whereas group 2 mice were gavaged
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with the polyethylene glycol, water and DMSO sham. Group 3 mice served as the control
animals and received no treatment. All treatments were administered for 8 days. On day
two, all mice received a single gavage with a 1:1 mixture of wild-type and mutant. The
proportions of total lactobacilli composed of each mutant in the forestomach and cecum of
mice co-inoculated with wild-type and mutant strains were shown.

B–G. In vivo

competition experiment between wild-type and ureC mutant (B); wild-type and adi mutant
(C); wild-type and gadB mutant (D); wild- type and cgl mutant (E); wild-type and dltA
mutant (F); wild-type and lsp mutant (G). Data are shown as means with standard errors of
the mean. Significance of P ≤ 0.05 is denoted by a single asterisk (*), P ≤ 0.01 as two
asterisks (**), and P ≤ 0.001 by three asterisks (***). Circles and triangles represent the
forestomach and cecum, respectively, of a single mouse.
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The cgl mutant showed a high degree of impairment when competing with the wildtype in both the forestomach (4.8% ± 3) and the cecum (7.5% ± 6), demonstrating that this
gene is ecologically relevant in vivo (Fig. 2.2E). Similar findings were obtained for the dlt
mutant, which was highly impaired (Fig. 2.2F), an observation consistent with previous
findings in Lactobacillus-free mice (Walter et al., 2007). In both mutants, omeprazole did
not influence the ecological performance. Thus, it appears that both cgl and dltA encode
for ecologically relevant colonization factors that are not involved in providing resistance
to gastric acid secretion.
The lsp mutant lacks a putative adhesin that is not involved in acid resistance. We
included this mutant to determine unspecific effects of omeprazole on the competiveness
of mutant strains in general. As shown previously (Walter et al., 2005), the lsp mutant was
impaired in vivo, forming around 10% of the population. However, as expected, no
difference between the three treatments was observed (Fig. 2.2G).
Altogether, these experiments demonstrate that the urease gene cluster is the only
factor that mediates resistance against gastric acid secretion in L. reuteri 100-23 during
stomach colonization, and that no other acid resistance factor was able to compensate for
its loss under the given experimental and dietary conditions.

2.3.4 Urease activity is regulated by pH
The in vivo competition experiments demonstrated the importance of the urease
gene cluster as an acid-related colonization factor for L. reuteri 100-23 in the rodent
forestomach. To characterize the regulation of this cluster, the wild-type strain was grown

84

in mMRS broth supplemented with 1% urea and growth and urease activity was monitored
for 24 h (Fig. 2.3A). The addition of urea caused a slightly decreased growth rate, but led
to a rapid increase in pH after 12 h of incubation. The final pH after 24 h was 7.4 with urea
supplementation, compared with pH 3.9 without urea in the media (P < 0.0001). This
alkalization of the supernatant was not observed for the ureC mutant (data not shown).
There was no detectable urease activity in the first 8 h. However, urease activity became
detectable after 10 h when the pH approached pH 4 (Fig. 2.3A).

Fig. 2.3. A. Bacterial growth (OD 600) of L. reuteri 100-23 (continuous line, empty
symbols, left ordinate axis) and the pH of the media (dotted line, full symbols, right
ordinate axis) with (triangle symbol) and without urea (square symbol). B. Urease activity
over time in cell lysates of wild-type strain 100-23 grown with and without 1% urea in
mMRS media, gray and white bars respectively. C. Urease activity in cell lysates of wildtype strain 100-23 in induction experiment. mMRS media adjusted to pH 4, 5 or 6 with and
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without 1% urea supplementation, gray and white bars respectively. n = 3, means and
standard deviations are shown. Treatments with different letters (a, b, c) are significantly
different from one another (P ≤ 0.05).

Urea supplementation had no significant effect on the urease activity at any time
point. These findings suggest that urease activity in L. reuteri was not induced by the
substrate but by rather acidic conditions. To confirm that induction of urease activity in L.
reuteri 100-23 occurs via acidity and not urea, cells were grown for 6 h in mMRS,
centrifuged and re-suspended in fresh mMRS media adjusted to pH 4, 5 or 6. Cells were
incubated for another 2 h before urease activity was measured. Cells after 6 h of growth
were used for these experiments as L. reuteri did not show any urease activity until 10 h of
growth (Fig. 2.3A), allowing the determination of conditions that induce urease activity.
This experiment demonstrated that urease activity was induced at pH 4, unaffected at pH
5 and not detectable at pH 6 (P < 0.01). The presence of urea did not enhance urease
activity. Transcript analysis revealed that expression of ureC was 124 times higher at pH
4 compared with pH 6 independently of the presence of urea. These findings demonstrate
that the urease activity in L. reuteri is regulated on the transcriptional level.
Two-component systems are commonly used by lactic acid bacteria for
environmental sensing and signal transduction and are often involved in the acid stress
response (Cotter and Hill, 2003). Lactobacillus reuteri 100-23 possess homologues to the
LisRK system, which has been implicated in mediating acid resistance in L. monocytogenes
(Cotter et al., 1999) and L. acidophilus (Azcarate-Peril et al., 2005). To test if the lisRK
genes are involved in regulating urease activity, we compared culture supernatant pH of
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the lisK and lisR mutants during growth in the presence of urea. The lisR mutant was also
tested in the same pH induction experiment described above. Neither the lisK nor the lisR
mutation had an effect on the buffering capacity during growth in the presence of urea, and
urease activity was still induced by low pH in the lisR mutant in the pH induction
experiment (data not shown). Hence, it was concluded that this two-component regulatory
system is not involved in the regulation of the urease gene cluster, which is consistent with
the finding that the lisR and lisK mutants were not impaired in simulated gastric juice (Fig.
2.1K). Therefore, it is currently unknown how L. reuteri senses acidic pH and induces
gene expression of the urease cluster.

2.4 Discussion
The rodent stomach consists of two parts: forestomach and corpus.

The

forestomach represents about two thirds of the total stomach volume and is lined by a
squamous stratified epithelium.

The corpus is lined by a glandular and secretory

epithelium covered by a mucus layer (Gärtner, 2001) and harbours the H+ /K+ protonpumps responsible for the low pH in the stomach (Fig. 2.2A). Lactobacillus reuteri
colonizes the forestomach epithelium, but it is also found throughout the digestive tract,
including the cecum, where pH values are closer to neutral. However, the spatial patterns
of L. reuteri populations throughout the mouse digestive tract suggest that cells in the
cecum are likely allochthonous to this site and originated from cells colonizing the stomach
(Walter, 2008). This notion was supported by the findings of this study; cecal mutant
proportions always mirrored those of the forestomach, independently of gene function (Fig.
2.2B–G). This agrees with previous findings concerning the dlt (Walter et al., 2007), gtfA,
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inu, (Walter et al., 2008), lsp, msrB (Walter et al., 2005) and ftf (Sims et al., 2011) mutants.
The forestomach of mice is therefore the primary habitat of L. reuteri, which makes acid
resistance a key factor for successful colonization.
Accordingly, several pathways and factors have been identified and functionally
characterized to contribute to acid resistance in L. reuteri (Fig. 2.4). However, our
experiments in omeprazole-treated mice identified the urease gene cluster as the
predominant factor necessary for L. reuteri 100-23 to tolerate host gastric acidic secretion
(Figs 2.2B and 2.4A). Inactivation of the ureC gene resulted in the lowest levels of
colonization (around 0.1%) of all mutants tested here. This finding, consistent with
observations in Lactobacillus-free mice (Wilson et al., 2014), demonstrated the paramount
ecological importance of the urease cluster. Restoration of mutant proportions to around
30% and to 50% with omeprazole in the forestomach and cecum, respectively, indicated
that host acid secretion is the main ecological factor decreasing mutant levels, and that
urease production of L. reuteri is almost completely devoted towards resistance to host
gastric acid production. Furthermore, the percentage of mutant strains was significantly
lower in the forestomach in omeprazole treated mice compared with the cecum. One could
speculate that ureC has a residual function in the forestomach that is unrelated to host acid
production. Instead, ureC may contribute to resistance against the build-up of acidic
metabolic end-products in the biofilm generated through bacterial fermentation. Overall,
our findings show that host acid secretion exerts a substantial selective pressure on the L.
reuteri population, even in the non-secretory forestomach, and that urease production
serves as an adaptive phenotype to overcome this pressure.
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Fig. 2.4. Overview of metabolic pathways of genes assessed in this study. A. The urease
gene converts urea to ammonia and CO2. Ammonia is exported from the cytoplasm using
the UreI transporter, thus buffering the cell from its surrounding environment. B.
Glutamate is imported into the cell by an antiport system and converted to GABA using
the glutamate decarboxylase pathway while generating a ΔΨ and ΔpH. H+ consumption
raises the intracellular pH.

Adapted from Su and colleagues (2011) and Price and

colleagues (2012). C. L-arginine is imported using an L-arginine–ornithine antiporter and
converted into citrulline and ammonia by the arginine deiminase enzyme. Citrulline is
further catalysed to ornithine and ammonia, while consuming H+. Ammonia is exported
from the cytoplasm potentially using the UreI transporter. D. D-Alanine is coupled to a
DltC carrier protein, exported across the cytoplasmic cell membrane and used for
esterification of teichoic acids associated with the cell wall. This esterification results in a
positive charge of the cell wall. Adapted and simplified from Peschel and colleagues
(1999). E. Cysteine is converted to ammonia, hydrogen sulfide and pyruvate by the
cystathionine γ-lyase. Ammonia is exported from the cytoplasm using the potentially via
the UreI transporter, thus buffering the cell from its surrounding environment. F. F1 -F0 -
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ATPase-producing ATP using a ΔΨ and ΔpH, which is generated, in part, by the glutamate
decarboxylase pathway. Dashed arrows indicate that more than one step is involved in the
pathway.

Although the other four genes (gadB, cgl, adi and dltA) evaluated here also
contributed to both survival in the in vitro gastric model and ecological performance in
mice, our findings indicate that they do not contribute to tolerance of host gastric acid
secretion during forestomach colonization. Mutants for two of the genes, gadB and adi,
were only marginally impaired, comprising >20% of the population in competition
experiments. The gadB gene has been identified as the most important mechanism of acid
resistance in Escherichia coli (Feehily and Karatzas, 2013) and was previously shown to
contribute to acid resistance (Teixeira et al., 2014) and ecological performance of L. reuteri
100-23 during growth in sourdough (Su et al., 2011). In our experiments, omeprazole
treatment did lead to small but significantly higher levels of the gadB mutant in the cecum,
suggesting that the gene contributed to acid survival during transit into the cecum but not
the forestomach. These findings may be explained by GadB of L. reuteri being active
primarily at pH 2.5 (Teixeira et al., 2014), a feature that may confer a survival benefit when
the stomach lumen becomes very acidic. Expression of gadB is required for the conversion
of glutamate to CO2 and g-aminobutyric acid (GABA) (Su et al., 2011); this function is
independent of its role in acid resistance. When glutamate is exchanged with GABA by
an antiporter- system, a ΔΨ and ΔpH are generated. This proton motive force generated
by GadB provides a mechanism for conserving ATP that would otherwise be required to
fuel the F1 F0 ATPase (Su et al., 2011) (Fig. 2.4B and F). The loss of the proton motive
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force may also explain the impairment of this mutant during transit because less energy
may be available for the cells to launch a stress response towards the acidic conditions in
the stomach lumen.
The arginine deiminase pathway is widely distributed among bacteria (SenouciRezkallah et al., 2011), triggered in L. reuteri CRL 1098 by low pH (Rollan et al., 2003),
and over-expressed in the Lactobacillus population colonizing the stomach of conventional
mice when compared with the cecum (Schwab et al., 2014). This pathway consumes
intracellular protons and raises the cytoplasmatic pH when converting L-arginine and H2O
to ammonia and citrulline, which is further catalyzed to ornithine, ammonia and CO2
(Konings, 2002; Teixeira et al., 2014) (Fig. 2.4C). In vivo, however, the adi mutant was
only marginally impaired, and the gene did not confer resistance against host acid secretion.
In contrast to the gadB and adi mutants, the ecological performance of the dlt and
cgl mutants was substantially impaired in vivo. Contrary to the consistent involvement of
the dltA gene in acid resistance of L. reuteri and other organisms in vitro (Boyd et al., 2000;
Kristian et al., 2005; Walter et al., 2007; Lebeer et al., 2008), host acid production was not
the factor that reduced mutant populations in mice. An alternative function of the dlt
operon is to increase resistance to cationic antimicrobial peptides by generating a positive
net charge of the cell surface (Kristian et al., 2005; Walter et al., 2007). This positive
charge leads to a decreased binding of positively charged antimicrobial peptides, e.g.
defensins, which may result in increased cell lysis and impaired ecological performance in
vivo (Walter et al., 2007) (Fig. 2.4D). A recent study showed that a reduction of the
negative cell surface charge through Lipid A dephosphorylation mediates resistance to
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antimicrobial peptides in the Gram-negative Bacteroides thetaiotaomicron (Cullen et al.,
2015). The dlt operon could have a similar function in L. reuteri.
Although bacterial cystathionine γ-lyases have not been associated with acid
resistance, the cgl mutant of L. reuteri 100-23c was impaired in the in vitro acid resistance
assays (Fig. 2.1C). Among other reactions, these enzymes catalyze the transformation of
L-cysteine and water to hydrogen sulfide, pyruvate and NH4+ (Wang, 2002; Lo et al., 2009)
(Fig. 2.4E). Although expression of the cgl gene is upregulated in L. reuteri 100-23
growing in biofilms in vitro (Frese et al., 2013) and in acid-adapted B. longum subsp.
longum (Sánchez et al., 2007), our mouse experiments did not support a role for cgl in
overcoming gastric acid secretion. In L. reuteri BR11, this pathway was shown to improve
oxidative stress defense and is required for thiol production (Lo et al., 2009); it could be
important during forestomach colonization. This study establishes the cgl gene as an
important colonization factor of L. reuteri 100-23, but further research is needed to
elucidate the mechanism by which this gene contributes to gut colonization.
Together with our previous phylogenetic and comparative genomic studies on L.
reuteri (Oh et al., 2010; Frese et al., 2011), this work provides novel insight into the
ecology and evolution of a vertebrate gut symbiont, and the mechanisms by which a hostspecific lifestyle can emerge. Urease is commonly used by bacteria from different phyla
to tolerate stomach acidity (e.g. in Helicobacter pylori) and in some pathogens (e.g.
Clostridium perfringens and Yersinina enterocolitica), urease is considered a virulence
factor that facilitates survival during gastric transit (Mora and Arioli, 2014). Lactobacillus
reuteri has acquired the urease cluster, which is extremely rare in the genus Lactobacillus
(Zheng et al., 2015), by horizontal gene transfer (Frese et al., 2011). The cluster has then
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been stably maintained within rodent lineages of the species (Walter et al., 2011). The
findings presented here now provide an explanation for the conservation of this trait among
rodent strains – it constitutes an essential colonization factor that provides a key adaptation
to the gastric niche in rodents. During the evolutionary process, it appears that L. reuteri
has tailored transcriptional regulation of the cluster towards the environmental conditions
of the murine stomach. Transcriptional expression of the urease cluster is strictly regulated
by pH (Fig. 2.3), allowing the organism to respond to the variation in gastric pH and only
produce urease when the habitat becomes too acidic. Urea, in contrast, is always present
as it enters the stomach by diffusion and through the saliva (Burne and Chen, 2000), and it
was therefore not required for L. reuteri to evolve a mechanism of substrate induction.
Substrate availability through the rodent host is also a likely reason why urease formation
evolved to become more important than GadB and Adi, as the latters’ substrates (glutamate
and arginine) must be provided in the diet where supply is not reliable. Urea hydrolysis is
therefore a key facet of host adaptation (and potentially even co-evolution) in the L.
reuteri–rodent symbiosis, and the absence of the phenotype in most non-rodent strains
(Walter et al., 2011) is likely an important reason for their low ecological performance in
the mouse GI tract (Oh et al., 2010; Frese et al., 2011).
In conclusion, the findings obtained during this study demonstrated that urease
production is essential and sufficient for L. reuteri 100-23 to cope with host gastric acid
secretion. Other genes, such as adi, clg, dltA and gadB, and genes encoding for glutaminase
[which were overexpressed in acid resistance tests in vitro (Teixeira et al., 2014) and in the
forestomach (Wilson et al., 2014) but were not studied here due to the presence of several
copies in the genome] might contribute to resistance against acidic bacterial metabolic end-
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products, or may become more important in a different dietary context. However, in the
experiments conducted here, none of these genes was able to complement the loss of ureC
in mediating resistance to host gastric acid secretion, which appears to exert a major
selective pressure.

This study provides a better understanding of the phenotypic

adaptations of vertebrate gut symbionts that contribute to both a highly successful lifestyle
and specialization towards a particular host. Most importantly, it demonstrates that gene
annotations and in vitro tests have limitations to predict the exact ecological functions of
colonization factors of bacterial gut symbionts.

2.5 Experimental procedures ethics statement
All mouse experiments were approved by the Institutional Animal Care and Use
Committee of the University of Nebraska (Project ID 731).

2.5.1 Bacterial strains and media used in the study
All strains of L. reuteri and E. coli are listed in Table 2. Lactobacilli were grown
anaerobically at 37°C in de Man, Rogosa and Sharpe (MRS) medium medium (Difco™;
Le point-de-Claix, France) supplemented with 10 g l−1 maltose and 5 g l−1 fructose (referred
to as mMRS). For gene inactivation in L. reuteri 100-23c (plasmid-free derivative of strain
100-23), E. coli EC1000 was used as a cloning vector and grown aerobically in Luria–
Bertani media (Difco™; Sparks, MD, USA) at 37°C. Erythromycin (200 μgml−1 for E. coli,
5 μgml−1 for lactobacilli), kanamycin (40 μgml−1 for E. coli) and chloramphenicol (7.5
μgml−1 for lactobacilli) were used for the propagation of recombinant strains.
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2.5.2 Determination of genes predicted to be involved in acid resistance of L. reuteri
100-23
Several different approaches were used to select genes of interest for this study.
First, we identified genes that were specific to rodent strains of L. reuteri (Frese et al.,
2011) and predicted to be involved in acid resistance. Second, putative acid resistance
genes that were upregulated in vivo compared with in vitro cultures were identified (Frese
et al., 2013; Wilson et al., 2014). Third, genes coding for metabolic path- ways that
produce ammonia (Lo et al., 2009) and two- component systems involved in acid resistance
in other bacteria were also considered (Kallipolitis and Ingmer, 2001; Cotter and Hill,
2003). One additional criterion for the selection of genes was that the gene had to be a
single copy gene to generate the knock-out mutants according to the method described by
Walter and colleagues (2005).

2.5.3 Derivation of mutants
Genes of interest were inactivated by insertional mutagenesis by site-specific
integration of the plasmid pORI28 into the target sites in the L. reuteri 100-23c genome
(Walter et al., 2005). Internal regions of the genes of interest were amplified using the
primers in Table S1 for each mutant.

Each knockout mutation was confirmed by

polymerase chain reaction (PCR) using primers flanking the target region of each gene.
Strains were routinely maintained in mMRS medium containing 5 μgml−1 of erythromycin,
unless the mutant was used for the in vitro acid survival assay. Growth curves showed no
growth impairments in any of the mutants (data not shown).
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2.5.4 In vitro acid survival assay
To simulate the acidic conditions in the mouse stomach, an artificial gastric fluid
developed by Cotter and colleagues (2001) was used. The experiment was performed with
wild- type L. reuteri 100-23c and all mutants; bacterial survival was monitored over time.
To evaluate acid resistance, lactobacilli were grown in mMRS (pH 6.5) for 12–16 h,
harvested by centrifugation and washed in PBS. Pre-warmed gastric fluid was adjusted to
pH 1.5 and 2 with HCl, and inoculated with approximately 108 cells ml−1. Samples were
incubated at 37°C and quantified by serial plating after 0, 1, 2, 3 and 6 h. To assess the
importance of the ureC, adi, gadB and LisK/R genes, assays were performed in gastric fluid
with and without 1% urea, 20 mM arginine, 20 mM glutamic acid or 20 mM cysteine
respectively. The role of lsp and dlt genes was assessed without supplementation of the
gastric fluid. To gain an insight on the effect of gene inactivation on survival and to allow
for a better comparison between experiments, cell numbers of the wild-type strain plus
supplement was set to 100%. Based on that value the cell numbers of wild-type without
the respective substrate and mutant strains with the substrate was expressed as percent of
those obtained with the wild-type incubated with the substrate. Experiments were done in
triplicate of biological replicates.

2.5.5 Determination of genes’ role in in vivo acid resistance
Germ-free C57BL/6J mice (males and females) were bred and reared in flexible
film isolators and maintained under gnotobiotic conditions at the University of NebraskaLincoln and were randomly assigned to one of three treatment groups. Mice in group 1
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received a daily oral gavage of 400 μmol of omeprazole kg−1 (6-methoxy-2-[(4-methoxy3,5- dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole; Sigma) for 8 days
(Tennant et al., 2008). Omeprazole was dissolved in 50 μl of a DMSO-polyethylene glycol
solution (90% DMSO, 4.5% polyethylene glycol and 5.5% water) and was filter sterilized
(Zavros et al., 2002). Mice in group 2 were orally gavaged daily with the DMSO–
polyethylene glycol vehicle and otherwise treated the same way as group 1 animals. Mice
in group 3 did not receive any treatment. On day two, each mouse was inoculated with 106
cells in a 1:1 ratio of 100-23c wild-type and a mutant strains in a single oral gavage. The
inoculum was also plated on mMRS plates with and without erythromycin (5 μgml−1) to
confirm equal representation of the two strains. Mice had access to food and water ad
libitum. After 8 days, mice were euthanized and forestomach and cecum contents were
serially diluted and plated on mMRS with and without erythromycin (5 μgml−1) to
determine the ratio of the wild-type and mutant strains in the samples. A total of 6–11
mice per each group (omeprazole, sham, control) were used per experiment.

The

experiment was repeated twice with the gadB mutant because the first experiment showed
a trend towards a higher survival rate due to omeprazole treatment compared with the sham
in the forestomach. However, this tendency was not confirmed (Fig. 2.2D). It should be
noted that polyethylene glycol possesses weak buffering capacity, which may therefore
impact acid exposure to the lactobacilli. Therefore, the amount of solution was kept as low
as possible (50 μl total).

For all analysed gene clusters, it was assumed that the

corresponding substrates, i.e. glutamic acid, arginine, urea etc., were present in the
forestomach as they are supplied by the diet, or in the case of urea, enter the stomach by
diffusion (Burne and Chen, 2000).
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2.5.6 Determination of pH regulation of urease activity
Lactobacillus reuteri 100-23c was grown for 6 h in mMRS at 37°C, centrifuged
and re-suspended in fresh mMRS media adjusted to pH 4, 5 or 6 with HCl (before sterile
filtration). Cells were incubated for another 2 h at 37°C, and subsequently 10 ml of L.
reuteri 100-23c culture was centrifuged for 5 min at 15 000 × g and stored in 10% glycerol
at −20°C until determination of urease activity.

2.5.7 Measurement of urease activity
Cell solutions were thawed on ice, washed twice with citrate buffer (pH 4) and
disrupted with 0.3 g sterile silica beads (0.5 mm) at maximum speed in a cell mill (MiniBeadbeater Biospec product) for three 1 min intervals. Tubes were cooled on ice for 2 min
between intervals to prevent overheating. Samples were centrifuged at 10 000 × g for 2
min. Supernatant was collected and stored at −20°C until the assays were performed.
Urease activity in the supernatant was determined by conversion of urea to ammonia, as
described previously (Chaney and Marbach, 1962). Citrate buffer (pH 4) containing 167
mM urea was mixed in equal volumes with cell supernatant and incubated at 30°C for 30
min. Ammonia was quantified by the Berthelot reaction (Chaney and Marbach, 1962). To
determine protein, cell pellets were washed twice with 10 mM Tris (pH 8) and disrupted
as described above. Protein concentration was determined according to Lowry and
colleagues (1951). Urease activity is expressed as microgram of ammonia formed per
microgram of protein.
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2.5.8 RNA extraction from L. reuteri cell cultures
Lactobacillus reuteri 100-23 was grown for 6 h in mMRS media at 37°C, and cells
were collected by centrifugation for 10 min at 3214 × g and re-suspended in fresh mMRS
media adjusted to pH 4, 5 or 6 with HCl. Cells were incubated for another 30 min at 37°C,
and subsequently mixed with RNAprotect bacterial reagent (Qiagen, Valencia, CA, USA)
at a ratio of 1 to 5. The solution was incubated for 5 min at room temperature, centrifuged
and stored at −80°C until used for RNA isolation. Total RNA was isolated after the cell
pellet was washed with RNase-free PBS buffer and re-suspended in 100 μl of lysis buffer
(30 mM Tris–HCl; 1 mM EDTA, pH 8.0; 15 mg ml−1 lysozyme; 10 U ml−1 mutanolysin;
and 100 μgml−1 Proteinase K).

Samples were treated as previously described

(Rattanaprasert et al., 2014) and subsequently transferred to an RNeasy Mini spin column
(Qiagen, Hilden, Germany). Mixtures were centrifuged for 15 s at 14 000 × g and the
eluate discarded. 350 μl of Buffer RW1 was added and centrifuged as before. There was
80 μl of DNase I incubation mix applied to the RNeasy column and incubated at room
temperature for 15 min. And, 350 μl of RW1 buffer was added and centrifuged as
described above. The flow-through was discarded, 500 μl of Buffer RPE added and
centrifuged. 500 μl of Buffer RPE was added again and centrifuged for 2 min at 14 000 ×
g. RNeasy column was placed in a new 2.0 ml collection tube and centrifuged for 1 min
at 14 000 × g. RNeasy column was placed in a new 1.5 ml collection tube and RNA eluted
with 50 μl of RNase-free water. Samples were centrifuged for 1 min at 12 000 × g.
According to the manufacturer’s protocol (Applied Biosystems/Ambion, Austin, TX,
USA) the purified RNAwas subsequently treated with the TURBO DNA-free kit. RNA
was quantified using the Qubit® RNABRAssay kit (Invitrogen, Carlsbad, CA, USA), and
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RNA integrity was validated on a 1% agarose gel. The absence of DNA contamination
was confirmed by real-time PCR.

2.5.9 Determination of gene expression by quantitative reverse transcription PCR
(qRT-PCR)
The purified RNA was reverse transcribed using the SuperScript® VILO™ cDNA
Synthesis Kit (Invitrogen) according to the manufacturer’s instructions with minor
modifications as described by Frese and colleagues (2013). qRT PCR was performed using
an Eppendorf Mastercycler Realplex2 machine (Eppendorf AG, Hamburg, Germany) and
Quanti-Fast SYBR Green PCR kits (Qiagen, Valencia, CA, USA).

The ureC and

glyceraldehyde 3-phosphate dehydrogenase primers (Table S1) were previously validated
using serial 10-fold dilutions of pooled cDNA to determine specificity and efficiency
(Frese et al., 2013). For each 25 μl qRT-PCR reaction, 12.5 μl of 2x Quantifast SYBR
Green Mastermix, 1 μl of cDNA and 10 μMol of each primer were used. The DNA was
denatured at 95°C for 5 min and followed by 40 two-step cycles of 10 s at 95°C, then 30 s
at 60°C. Each PCR product was validated on an agarose gel and by inspection of their
melting curves. Gene transcripts of the urease α-subunit were quantified relative to the
glyceraldehyde-3-phosphate

dehydrogenase

housekeeping

quantification was performed using the method by Pfaffl (2001).

gene,

and

relative
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2.5.10 Statistical analysis
Data are expressed as means ± standard deviations unless otherwise stated.
Statistical analyses were carried out using GRAPHPAD PRISM 5 (GraphPad Software,
California, USA). If only two groups were compared, Student’s t-tests were per- formed.
ANOVA and Tukey’s post-tests were used for multiple comparisons. Significance of P ≤
0.05 is denoted by a single asterisk (*), P ≤ 0.01 as two asterisks (**), and P ≤ 0.001 by
three asterisks (***).
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Chapter 3

In vivo selection to identify bacterial strains with enhanced ecological performance
in synbiotic applications.

Preface
This chapter has been previously published: In Vivo Selection to identify bacterial strains
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Rasineni, Amanda E. Ramer-Tait, Edward N. Harris, Robert W. Hutkins, and Jens Walter.
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3.1 Abstract
One strategy for enhancing the establishment of probiotic bacteria in the human
intestinal tract is via the parallel administration of a prebiotic, which is referred to as a
synbiotic. Here we present a novel method that allows a rational selection of putative probiotic strains to be used in synbiotic applications: in vivo selection (IVS). This method
consists of isolating candidate probiotic strains from fecal samples following enrichment
with the respective prebiotic. To test the potential of IVS, we isolated bifidobacteria from
human subjects who consumed increasing doses of galactooligosaccharides (GOS) for 9
weeks. A retrospective analysis of the fecal microbiota of one subject revealed an 8-fold
enrichment in Bifidobacterium adolescentis strain IVS-1 during GOS administration. The
functionality of GOS to support the establishment of IVS-1 in the gastrointestinal tract was
then evaluated in rats administered the bacterial strain alone, the prebiotic alone, or the
synbiotic combination. Strain-specific quantitative real-time PCR showed that the addition
of GOS increased B. adolescentis IVS-1 abundance in the distal intestine by nearly 2 logs
compared to rats receiving only the probiotic. Illumina 16S rRNA sequencing not only
confirmed the increased establishment of IVS-1 in the intestine but also revealed that the
strain was able to outcompete the resident Bifidobacterium population when provided with
GOS. In conclusion, this study demonstrated that IVS can be used to successfully
formulate a synergistic synbiotic that can substantially enhance the establishment and
competitiveness of a putative probiotic strain in the gastrointestinal tract.
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3.2 Introduction
The mechanistic role of the gastrointestinal (GI) microbiota and its metabolites in
maintaining human health has been well demonstrated (1–3). Gut microbes provide several
important benefits for their host, including provision of nutrients, development and
maturation of the immune system, and protection against pathogens via colonization
resistance (4). However, the gut microbiota may also contribute to obesity, inflammatory
and autoimmune diseases, and other chronic disease states (5–7). Such diseases are often
associated with compositional alterations in the fecal microbiota, a condition referred to as
“dysbiosis” (8). Given that the presence of specific types of bacteria and their relative
abundance within the gut are considered to affect host health, there is much interest in
devising strategies that modulate gut microbiota composition and potentially redress
disease related dysbiotic patterns (9).
Dietary approaches currently available to modulate the gut microbiota include
prebiotics (10–12), fermentable fibers (13, 14), probiotics (or live biotherapeutics) (15),
and synbiotics, which are a combination of a probiotic and a prebiotic (11, 16). According
to Kolida and Gibson (16), synbiotics can be either complementary or synergistic.
Complementary synbiotics consist of a probiotic and a prebiotic selected to independently
confer benefits to the host. In contrast, synergistic synbiotics are comprised of a prebiotic
chosen specifically for the selected probiotic to stimulate its growth, activity, and survival
in the gastrointestinal tract (16).
Synergistic synbiotics therefore hold the potential to improve the establishment of
a specific bacterial strain when introduced into the gastrointestinal tract. Unfortunately,
successful synergistic synbiotic combinations are not well established in the literature
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despite a large number of studies. To our knowledge, only two reports describe a synbiotic
combination in which the prebiotic significantly enhanced the stability, persistence, or
metabolic activity of a specific probiotic strain in vivo (17–19). As noted by Kolida and
Gibson (16), this low success rate may be explained by the selection of most synbiotic
combinations on an arbitrary basis, including shelf life, industrial performance,
availability, and cost. Indeed, few synbiotic preparations are formulated based on a rational
selection of both the prebiotic and the probiotic (12, 16), such as via in vitro or in vivo
screens assessing the ability of the probiotic to utilize the prebiotic (17–21). Even if
synbiotic formulations were based on these criteria, synergism between the probiotic strain
and the prebiotic was rarely observed in human and animal trials (22–24).

These

observations suggest that the probiotic strains were unable to utilize the selected prebiotic
to expand their populations under the prevailing ecological conditions in the
gastrointestinal tract. We therefore propose that synergistic synbiotics are likely to be more
successful if selection of the probiotic organism is based on ecological criteria.
In this report, we introduce the concept of in vivo selection (IVS) to identify
putative probiotic strains with enhanced ecological performance when used in synbiotic
applications. The concept consists of isolating putative probiotic strains from fecal or
intestinal samples after enriching for them with dietary administration of the prebiotic. We
reasoned that such strains would likely be able to successfully utilize the prebiotic in vivo
within the constraints of the competitive gastrointestinal environment. To test IVS, we
isolated bifidobacteria from fecal samples of human individuals who had consumed the
prebiotic galactooligosaccharide (GOS) during a previous human trial (25). A combination
of approaches was used to select a candidate probiotic strain (Bifidobacterium adolescentis
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strain IVS-1) enriched by GOS in vivo. We then tested the synergistic potential of this
strain and GOS when administered as a synbiotic combination in a rat model of high- fatdiet-induced nonalcoholic fatty liver disease (NAFLD). A NAFLD model without severe
inflammatory disease was chosen, as inflammation would potentially confound the
ecological analysis due to its effects on gut microbiota composition. Although no direct
physiological benefits were observed in the rats, the results from the gut microbiota
analysis demonstrated that IVS can be used to select a synergistic synbiotic combination
that substantially increases the ecological performance of the bacterial strain in vivo.

3.3 Materials and methods
3.3.1 Isolation of in vivo-enriched bifidobacteria from humans.
In a previous study (25), fecal samples were collected from subjects who consumed
cumulative doses of GOS (0, 2.5, 5, and 10 g per day for 3 weeks each). Throughout the
study, fresh fecal samples were collected and immediately plated onto Rogosa LS agar to
enumerate bifidobacteria. Bacterial counts were used to identify GOS responders (i.e.,
individuals who experienced significant increases in numbers of bifidobacteria), and
colonies were picked during the period in which 10 g GOS day-1 was consumed. Colonies
were purified by successive liquid and plate cultures, and stock cultures were prepared and
stored at -80°C. A total of 28 individual colonies (2 to 3 per subject) were propagated. To
classify isolates, DNA was extracted by using the phenol-chloroform extraction method
(26), and the 16S rRNA gene was amplified by using the 8F and 1391R universal primers.
The amplification product was purified (QIAquick PCR purification kit; Qiagen Inc., MD)
and sequenced by a commercial provider (Eurofins MWG Operon, Huntsville, AL).
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Identity was determined by comparing sequences to sequences in the GenBank database;
species were assigned based on the best match.

3.3.2 In vitro growth on GOS.
Each isolate was screened for its ability to use GOS as a growth substrate in an
MRS broth culture. Growth experiments were performed with basal MRS broth containing
2% (wt/vol) glucose or GOS (Purimune; GTCNutrition, Golden, CO). The latter contained
92% GOS, with residual carbohydrates being mainly lactose. Control cultures were
therefore also grown on basal MRS broth supplemented with the same amount of lactose
as that present in the commercial GOS (giving a final concentration of 0.16% lactose).
Cultures were incubated anaerobically at 37°C, and growth was determined by optical
density measurement at 600 nm. Strains that grew on GOS to cell densities similar to those
on glucose were considered GOS fermenters.

3.3.3 Strain-specific primer design and validation.
The genome of B. adolescentis IVS-1 was sequenced to draft status by using a
standard shotgun library prep kit on a Roche GS FLX sequencer at the former Core for
Applied Genomics and Ecology (CAGE) (University of Nebraska, Lincoln, NE).
Sequencing resulted in 65,460 reads that were assembled de novo by using the gsAssembler
(Newbler) module of the GS-FLX Off- Instrument software suite. This resulted in draft
sequences of 148 contigs with ~15-fold coverage.
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Unique genes in B. adolescentis IVS-1 were identified by comparing the annotated
genome with other available B. adolescentis genomes in the JGI database (using the
Phylogenetic Profiler for Single Genes tool in IMG). From this analysis, the clustered
regularly interspaced short palindromic repeat (CRISPR)-associated helicase Cas3 was
selected as the target gene, and a putative primer pair was designed by using Primer 3
software (27). Candidate primers were evaluated for hairpin and dimer formation by using
Netprimer (Premier Biosoft International, Palo Alto, CA). The selected forward (F) primer
TTGCTTTTGCTCTGGAACATAC

and

reverse

(R)

primer

GTAATGAGGTAATACTGCGTCC were validated in silico by performing a BLAST
search against the NCBI database. These primers were also validated experimentally by
quantitative real-time PCR (qRT- PCR) using DNA from 10 different Bifidobacterium
strains related to strain IVS-1 (each having >96% identity at the 16S rRNA gene level).
These strains included Bifidobacterium adolescentis ATCC 15703, Bifidobacterium
adolescentis

L2-32,

Bifidobacterium

Bifidobacterium

longum

DJO10A,

longum

subsp.

Bifidobacterium

longum
longum

ATCC

15707,

ATCC

15697,

Bifidobacterium longum subsp. longum F8, Bifidobacterium longum subsp. longum
JDM301, Bifidobacterium sp. strain 113, Bifidobacterium sp. strain 12_1_47BFAA, and
Bifidobacterium sp. strain HMLN14. Furthermore, to test if primers could select against
fecal bacterial communities in both humans and rats, DNA from 23 human fecal samples
and 10 Sprague-Dawley rat fecal samples from an independent study were tested. Human
fecal materials analyzed included the baseline samples (i.e., before GOS supplementation)
from 18 subjects from a previous study by Davis et al. (25) as well as five other human
fecal samples from an independent study.
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3.3.4 Quantitative real-time PCR.
qRT-PCR was performed by using a Mastercycler Realplex2 instrument
(Eppendorf AG, Hamburg, Germany). Each PCR was performed with 25-μl volumes using
real-time master mix containing SYBR(5 Prime Inc., Gaithersburg, MD) and either genusspecific primers for Bifidobacterium, F primer TCGCGTC(C/T)G GTGTGAAAG and R
primer CACATCCAGC(A/G)TCCAC (25, 26), or the strain-specific primers for B.
adolescentis IVS-1 (described above), each at a concentration of 0.8 μM. Annealing
temperatures of 58°C and 61°C were used for the genus- and strain-specific PCRs,
respectively. Standard curves for absolute quantification of bacterial cell numbers were
prepared by using cultures of B. adolescentis IVS-1 grown overnight (14 h), as described
previously (25, 26).

3.3.5 Administration of the probiotic, prebiotic, and synbiotic to rats.
A freeze-dried powder of Bifidobacterium adolescentis IVS-1 was produced by a
contract manufacturer (Culture Systems, Mishawaka, IN). The powder contained 5 x 1010
CFU g-1 and was stable during the entire course of the study. For delivery to the rats, the
powder was suspended in drinking water (double-distilled water) to reach a concentration
of 3 x 107 cells ml-1. GOS was diluted in water at a concentration of 0.033 g ml-1, and the
synbiotic was prepared by mixing both IVS-1 and GOS in the abovementioned
concentrations. All preparations were prepared fresh daily in drinking water for the
duration of the experiment. Cell viability and stability were validated by plating samples
on MRS medium at different time points. This analysis revealed that IVS-1 was highly
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stable in drinking water, with levels dropping <1 log over 24 h. The addition of GOS did
not influence the viability of the probiotic in drinking water (data not shown).

3.3.6 Rat study design.
Synergism of the synbiotic preparation was tested in a rat model of NAFLD (28).
Four-week-old male Sprague-Dawley rats were obtained from Charles River Laboratories
(Wilmington, MA) and acclimated for five days prior to study initiation. All animals were
housed in pairs in individually vented cages mounted on a rack with positive airflow. The
room environment was maintained at 20°C to 21°C with a 12-h light-dark cycle. Prior to
the start of the study, all rats received a standard rat chow and autoclaved, double-distilled
water ad libitum during the five day acclimation period. All animal procedures were
approved by University of Nebraska—Lincoln IACUC.
Rats were randomly assigned to one of five treatments, with three to six rats per
group. Groups one through four were fed a high-fat diet (60%kcal from fat) (AIN-58G9
TestDiet) (see Table 3.S1 in the supplemental material), while group five received a
standard diet (12% fat) (AIN-58G7 TestDiet) for eight weeks. After four weeks of feeding,
groups were assigned to one of the following supplement treatments. Rats in groups one
and five received no additional treatment.

Group two rats received drinking water

supplemented with 3.3% GOS to give ~1 g of GOS day-1 rat-1. Group three rats were given
drinking water supplemented with ~1 x 109 CFU of B. adolescentis IVS-1 day-1 rat-1.
Group four rats received both the GOS and IVS-1 (synbiotic mixture), at the same doses
as those given to groups two and three. All treatments were prepared fresh daily and
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administered for four weeks. The daily water intake per rat was significantly different
among groups and was used to calculate the absolute doses of probiotic cells per day (P =
0.001) (see Table 3.S2 in the supplemental material). Rats fed the probiotic drank
significantly more water (41.9 ± 8.6 ml) than did rats fed the synbiotic (35.4 x 4.5 ml),
resulting in a significantly higher dose of IVS-1 in the probiotic group (1.26 x 109 CFU
versus 1.06 x 109 CFU; P = 0.0001). GOS consumption was not significantly different
between the prebiotic- and synbiotic-fed groups (P = 0.2063) (see Table 3.S2 in the
supplemental material).
Body weights were determined weekly throughout the study.

All rats were

necropsied after eight weeks of study. Blood, cecum, colon content, liver, and epididymal
fat pads were collected, and the cecum and colon content were immediately frozen in liquid
nitrogen and stored at -80°C until further use.

3.3.7 Evaluation of host physiological parameters in rats.
Liver lipid extraction was performed according to methods described previously by
Folch and colleagues (29).

Aliquots of lipid extract were saponified to quantify

triglycerides (TGs) by using the TG diagnostic kit (Thermo dimethyl adipimidate kit;
Thermo Electron Clinical Chemistry, Louisville, CO). Data are reported as μg TGmg-1 (wet
weight) liver tissue. To evaluate liver damage, plasma alanine aminotransferase (ALT)
and alkaline phosphatase (ALP) enzyme levels were measured, which are indicators of
hepatocyte damage/leakage and cholangiocyte stress, respectively (30, 31). Blood was
collected into heparinized tubes at necropsy, and ALT and ALP levels were quantified by
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using a Mammalian Liver Profile rotor in a VetScan VS2 analyzer (Abaxis, Union City,
CA). Levels of tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein
1 (MCP-1) were quantified as measures of systemic inflammation by using a Milliplex rat
magnetic bead multiplex assay (Merck Millipore, Billerica, MA) according to the
manufacturer’s protocol.

3.3.8 Illumina 16S RNA sequencing and sequence analysis.
Colonic and cecal contents were flash-frozen in liquid nitrogen at necropsy, and
DNA was extracted as described previously (26), with one modification: the lysis buffer
contained 20mM Tris-HCl (pH 8), 2mM EDTA, 1.2% Triton X-100 (pH 8.0), and 20 mg
ml-1 Lysozyme (MP Biomedicals, Solon, OH). Amplicon sequencing of colonic contents
was performed by the University of Minnesota Genomics Center, and all samples were
sequenced together in the same run. First, theV5-V6region of the 16SrRNA gene was
amplified with primer pair 784F (5’-RGGATTAGATACCC-3’) and 1064R (5’CGACRRCCATGCANCACCT-3’) in a 25μl PCR mixture containing 5 μl of template
DNA, 5μl of 2x HotStarTaqPCRmaster mix, a final concentration of primers of 500 nM,
and 0.025 U μl-1 HotStarTaq polymerase (Qiagen Inc.). Amplification reactions included
an initial denaturation step at 95°C for 5 min followed by 20 to 25 cycles of denaturation
(50 s at 94°C), annealing (30 s at 40°C), and elongation (30 s at 72°C). Next, samples were
diluted 1:100 in water for input into library tailing PCR. The PCR was analogous to the
one conducted for initial amplification except for a Taq polymerase concentration of 0.25
U μl-1, and the PCR conditions consisted of an initial denaturation step at 95°C for 5 min
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followed by 10 to 15 cycles of denaturation (50 s at 94°C), annealing (30 s at 40°C), and
elongation (1 min at 72°C).
PCR products were quantified by using the Quant-iT PicoGreen double-stranded
DNA (dsDNA) assay kit (Life Technologies). A subset of the amplicon libraries was spot
checked on a Bioanalyzer High-Sensitivity DNA chip (Agilent Technologies, Santa Clara,
CA) for correct amplicon size. Next, samples were normalized to 2 nM and pooled. The
total volume of the libraries was reduced by the use of a SpeedVac, and amplicons were
size selected at 420 bp ± 20% by using the Caliper XT system (PerkinElmer, Waltham,
MA). Afterwards, library pools were cleaned with 1.8 x AMPureXP beads (Beckman
Coulter, Brea, CA) and eluted in water. The amount of DNA in the final pool was
quantified with PicoGreen and normalized to 2 nM for input into the Illumina MiSeq
platform (v3 kit) to produce 300-bp paired-end sequencing products. Clustering was done
at 10 pM with a 5% spike of PhiX. The generated sequences were quality filtered with
Illumina software at the University of Minnesota Genomics Center. Twenty-two of 24
samples met all quality control criteria and were used for the microbial community
analysis.

3.3.9 Microbial community analysis.
Reads

were

trimmed

to

240

bp

with

the

FASTX-Toolkit

(http://hannonlab.cshl.edu/fastx_toolkit/), and paired- end reads were merged with the
merge-illumina-pairs application (https: //github.com/meren/illumina-utils/) (P value of
0.03, enforced Q30 check, perfect matching to primers, and no ambiguous nucleotides al-
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lowed).

Files exceeding 30,000 reads were subsampled to this number in Mothur

v.1.31.162 to standardize the sequencing depth across samples. Subsequently, USEARCH
v7.0.100163 was used to generate operational taxonomic units (OTUs) with a 98%
similarity cutoff. OTU generation included the removal of putative chimeras identified
against the Gold reference database, in addition to the chimera removal inherent to the
OTU clustering step in UPARSE. After quality control and chimera removal, samples
contained an average of 25,718 ± 941 sequences. The resulting sequences were also
taxonomically characterized from phylum to genus levels with Ribosomal Database Project
(RDP) Classifier with the MultiClassifier v1.1 tool. All phylotypes were computed as
percent proportions based on the total number of sequences in each sample.

3.3.10 Statistical analysis.
Results are expressed as means ± standard deviations (SD) unless otherwise stated.
To analyze bacterial composition, diversity differences, and host physiological parameters,
one-way analyses of variance (ANOVA) with repeated measures in combination with
Tukey’s post hoc tests were applied. To achieve normality for data that were not normally
distributed, values were subjected to log10 transformations. If only two groups were
compared, Student’s t tests were performed. Spearman’s correlations were used to assess
correlations between bacterial groups. To account for type I errors, the false discovery rate
was used. A P value of < 0.05 and correlation coefficient (r) values of > 0.60 (in absolute
values) were considered significant. Analyses of variance and false discovery rate control
were performed by using SAS/STAT (SAS Institute Inc., Cary, NC, USA), while
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correlations were determined by using GraphPad Prism version 5.0 (GraphPad Software,
La Jolla, CA, USA).

3.3.11 Nucleotide sequence accession number.
The genome sequence of B. adolescentis IVS-1 has been deposited in the
DDBJ/EMBL/GenBank data- base under accession number JRNZ01000000.

3.4 Results
3.4.1 In vivo selection of B. adolescentis IVS-1.
In a previous study (25, 32), we reported a significant and remarkably specific
enrichment of Bifidobacterium populations in human subjects during dietary
supplementation with GOS (as demonstrated by 454 sequencing, genus-specific qRT-PCR,
and quantitative culture), which is in agreement with data from other GOS feeding studies
(33–38). Cultural enumeration of fecal samples during the human trial allowed us to
identify individuals in which bifidobacteria were enriched by GOS and from whom strains
likely to utilize GOS in vivo could be selected. This novel strategy for selection and
recovery of autochthonous strains enriched by a prebiotic is referred to as in vivo selection
(IVS) (Fig. 3.1A). Using the IVS approach, a total of 28 presumptive bifidobacterial
colonies from 11 subjects were isolated and classified by sequencing of the 16S rRNA
genes. Eight isolates were classified as Bifidobacterium adolescentis, eight were classified
as Bifidobacterium longum, three were classified as Bifidobacterium pseudocatenulatum,
and one was classified as Bifidobacterium bifidum. Of the remaining isolates, four
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belonged to the Coriobacterium genus, one could be classified only to the family level
(Lachnospiraceae), and three could not be sequenced due to insufficient growth. All
strains resulting in pure cultures were also screened for their ability to ferment GOS during
in vitro growth, and 13 were classified as GOS fermenters, 12 were classified as nonfermenters, and three could not be propagated to be tested (data not shown). Out of the 13
strains able to ferment GOS, five were classified as B. longum, five were classified as B.
adolescentis, one was classified as B. bifidum, one was classified as B. pseudocatenulatum,
and another one was classified as Lachnospiraceae. None of the isolated Coriobacterium
strains were classified as fermenters.
Based on the culture data, 454 sequencing (32), and the GOS fermentation tests, we
selected one strain and designated it IVS-1. This strain originated from a subject who
showed a strong bifidogenic response to GOS (Fig. 3.1B).

Based on 16S rRNA

sequencing, IVS-1 had 98.4% identity (100% query coverage and an E value of zero) with
the 16S rRNA gene of B. adolescentis ATCC15703T and was therefore allotted to this
species. However, the strain belongs to a distinct phylogenetic cluster (Bifidobacterium
species II cluster) detectable by using the V1-V3 region of the 16S rRNA gene (32). This
cluster was significantly enriched by GOS in all subjects, including the individual from
whom IVS-1 was isolated (Fig. 3.1C). The ability of B. adolescentis IVS-1 to utilize GOS
was demonstrated by growth in MRS broth containing 2% GOS (see Fig. 3.S1 in the
supplemental material). The established metabolic benefits of the species B. adolescentis
serve as another rationale for the selection of IVS-1 for future applications (39, 40).
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Fig. 3.1. In vivo selection to identify putative probiotic strains to be used in synbiotic
applications. A. Concept of in vivo selection. B. Proportion of fecal bifidobacteria in a
human individual consuming GOS (included in chews) in four increasing doses (0, 2.5, 5,
and 10 g) during a human feeding trial (25), as determined by 454 pyrosequencing of 16S
rRNA tags. C. Proportion of Bifidobacterium lineage species II in the same individual, as
determined by pyrosequencing. D. Cell numbers of B. adolescentis IVS-1 in the same
individual, as quantified by strain-specific qRT-PCR.

To verify that B. adolescentis strain IVS-1 was specifically enriched by GOS in
vivo, we devised a strain-specific qRT-PCR approach with primers based on the genome
sequence of IVS-1.

Primer specificity was validated against ten closely related
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Bifidobacterium strains, fecal DNA from all subjects included in the human feeding trial
(25) and five additional human individuals, and ten fecal samples from Sprague-Dawley
rats from an independent experiment. A detectable PCR product was obtained only with
DNA from B. adolescentis IVS-1 and the fecal sample from which the strain was isolated.
This finding indicated that the primers were highly strain specific and that strain IVS-1 was
present only in the human subject from whom it was isolated.
The strain-specific qRT-PCR system was then used to quantify the abundance of
IVS-1 in fecal samples from this subject during the GOS feeding study. This analysis
revealed that IVS-1 levels were increased 8-fold during both the 5-g and 10-g GOS dose
periods compared to the 0-g period (P < 0.001) (Fig. 3.1D), before returning to baseline
levels immediately after GOS consumption ended.

Collectively, these results

demonstrated the utility of IVS to select a bacterial strain enriched in the human
gastrointestinal tract through dietary administration of a prebiotic.
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Fig. 3.2. Test of a synbiotic combination of B. adolescentis IVS-1 and GOS in a high-fatdiet rat model. A. Experimental design of the rat study. Rats were fed either a standard
diet or a high-fat diet for 8 weeks, supplemented with or without a probiotic (IVS-1), a
prebiotic (GOS), or a synbiotic (IVS-1 plus GOS) for the last 4 weeks. B. Quantification
of absolute cell numbers of bifidobacteria in colonic and cecal contents by genus-specific
qRT-PCR. C. Strain-specific qRT-PCR was used to quantify absolute numbers of B.
adolescentis IVS-1 in colonic and cecal contents.

3.4.2 Test of the synbiotic combination using rats on a high-fat diet.
We systematically tested synergism between strain IVS-1 and GOS when used as
a synbiotic in rats fed a high-fat diet (Fig. 3.2A). Decreases in numbers of bifidobacteria
are often observed during high-fat-diet feeding (41–43). To determine if our synbiotic
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strategy could redress this decrease, we employed a rat model of high-fat-diet-induced
NAFLD where rats develop steatosis (fatty liver) but do not show an increase in body
weight, develop liver inflammation, or progress to nonalcoholic steatohepatitis (NASH)
(28). In our study, all high-fat-diet-fed rats developed steatosis (i.e., liver triglyceride
levels of > 50 μg mg-1 of tissue) and had slightly increased plasma ALP levels compared
to rats fed a standard diet (see Table 3.S2 in the supplemental material).

Dietary

supplements significantly influenced triglyceride liver contents; however, high-fat-diet-fed
rats did not develop the histopathological liver inflammation characteristic of NASH (data
not shown) and did not have increased plasma ALT levels (see Table 3.S2 in the
supplemental material). Plasma tumor necrosis factor alpha (TNF-α) and monocyte
chemoattractant protein 1 (MCP-1) levels were not significantly elevated in the high-fatfed rats compared to the controls (see Table 3.S2 in the supplemental material), indicating
a lack of systemic inflammation. Together, these data indicated that all rats receiving a
high-fat diet developed NAFLD but not severe inflammatory disease that would confound
the evaluation of synbiotic synergy and gut microbial ecology.

3.4.3 Experiments in rats demonstrate strong synergism between IVS-1 and GOS.
To test the functionality of the prebiotic to support the establishment of B.
adolescentis IVS-1 in the rat intestine, rats fed a high-fat diet were administered either IVS1 alone, GOS alone, or the synbiotic combination; all findings were compared to results
for the high-fat controls (Fig. 3.2A). Consistent with data from previous studies (41, 42),
high-fat feeding decreased the abundance of bifidobacteria in both the colon and cecum of
the rats, although this reduction did not reach statistical significance (Fig. 3.2B and Table

129

3.1).

Genus-specific qRT-PCR analysis revealed that the prebiotic, but not IVS-1,

significantly increased the total number of bifidobacteria in the cecum (Fig. 3.2B). These
findings indicate that the introduction of IVS-1 alone did not increase Bifidobacterium
abundance above baseline levels (~108 cells/g), whereas the prebiotic substrate was able to
support the resident population. Compared to IVS-1 and GOS alone, the combination of
the two dramatically increased the total number of bifidobacteria in the cecum (P < 0.01
between synbiotic and prebiotic treatments; P < 0.001 between synbiotic and probiotic
treatments) (Fig. 3.2B).
Strain-specific qRT-PCR analysis of B. adolescentis IVS-1 clearly demonstrated a
synergistic effect of IVS-1 and GOS in the colon and in the cecum. Even though rats
receiving IVS-1 alone consumed significantly more IVS-1 on a daily basis than did rats
given the synbiotic due to increased drinking water consumption (P < 0.0001) (see Table
3.S2 in the supplemental material), the synbiotic led to an almost 2-log increase in the level
of IVS-1 in the colon and cecum (9.47 ± 0.2 log10 cells g-1 and 9.43 ± 0.2 log10 cells g-1,
respectively) compared with the probiotic treatment (7.9 ± 0.1 and 7.44 ± 0.3 log10 cells g1

in the cecum and colon, respectively) (P < 0.0001) (Fig. 3.2C). No IVS-1 was detected

in rats fed the standard diet, the high-fat diet, or the prebiotic alone.

3.4.4. 16S rRNA sequencing confirms synergism between IVS-1 and GOS in vivo.
We analyzed the 16S rRNA tags obtained via Illumina sequencing to gain a
community-wide perspective on treatment effects on the resident gut microbiota. The
ability of probiotic and synbiotic treatments to establish IVS-1 in rats was assessed based
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on the abundance of an operational taxonomic unit (OTU) representing the species B.
adolescentis (OTU_2). This species was undetectable in rats that did not receive the
probiotic treatment but constituted 3.4% of the microbiota in rats fed IVS-1 (Fig. 3.3A and
Table 3.1). This finding indicates that the B. adolescentis population observed in rats was
due solely to the administration of IVS-1. This finding was expected, as this species is not
a member of the normal rat microbiota. Sequences representing B. adolescentis were
enriched to 37.0% in rats receiving the synbiotic treatment, indicating a significant
enhancement of the probiotic (in terms of abundance) due to the addition of the prebiotic
(P = 0.0159). Without GOS, IVS-1 was only the eighth most abundant OTU in the rats’
colonic microbiota, while it became the most abundant OTU when given together with
GOS, having an abundance almost four times higher than that of the second most abundant
OTU (a Blautia species, at 9.7%) (Fig. 3.3A). This finding demonstrated that IVS-1 could
be introduced as the dominant member of the rat gut microbiota when GOS was also
provided.
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Table 3.1: Proportions of bacterial taxa significantly influenced by dietary treatments
Mean % bacterial abundance ± SDc
Standard
Control
Prebiotic
diet
High-Fat
(HF)
Diet (HF)

Probiotic
(HF)

Synbiotic
(HF)

ANOVA
P- value

Phylum
Firmicutes
Actinobacteria

87.6±5 A
8.9±6 AB

88.8±9 A
3.6±2 A

76.9±8 A
19.6±8 BC

87.8±5 A
7.6±4 A

59.3±7 B
39.1±7 C

<0.0001
<0.0001

Family
Clostridiaceae
Incertae Sedis XIV
Streptococcaceae
Erysipelotrichaceae
Bifidobacteriaceae
Coriobacteriaceae
Rikenellaceae

3.9±6
3.7±6
12.7±5
16.8±11
5.9±7 A
0.6±0
0.9±1 A

0.5±1
7.5±10
21.3±5 A
21.3±17
1.3±1 A
0.3±0
0.1±0

0.8±1
11.0±15
9.3±1
9.2±1 A
17.0±9
1.0±1
0.3±0

5.4±6 A
1.1±2 A
8.9±6 B
26.5±10 B
4.1±2 A
1.9±3 A
0.1±0

0.2±0 B
17.3±12 B
6.6±2 B
8.3±3 A
37.8±7 B
0.2±0 B
0.0±0 B

0.0061
0.0342
0.0045
0.0226
0.0017
0.0263
0.0181

Genus
Clostridium
Blautia
Holdemania
Bifidobacterium
Lactococcus
Alistipes

3.9±6
3.4±6
0.1±0
5.9±7 A
12.4±4
0.9±1 A

0.5±1 A
7.4±10
1.0±2 A
1.3±1 A
21.0±5 A
0.1±0

0.8±1
11.0±15
0.9±0
17.0±9
9.1±1
0.3±0

5.3±6 B
0.9±1 A
0.0±0 B
4.1±2 A
8.7±6 B
0.1±0

0.2±0 A
17.2±12 B
0.0±0 B
37.8±7 B
6.3±2 B
0.0±0 B

0.0122
0.0431
0.0117
0.0017
0.0045
0.0181

0.0±0 A

0.0±0 A

0.0±0 A

3.4±2 BC

37.0±7 BD

<0.0001

12.4±4
0.4±1 A

21.0±5 A
0.1±0 A

9.1±1
0.0±0 B

8.6±6 B
ND

6.3±2 B
0.1±0

0.0045
0.0002

3.7±3

2.3±3

2.3±2

9.1±7 A

0.5±1 B

0.0279

0.0±0 A

0.1±0 AB

1.5±1 BC

0.0±0 AB

9.7±6 CF

0.0003

ND

0.0±0 A

ND

1.1±2 B

0.0±0 A

0.0022

3.8±6
5.8±7

0.5±1 A
0.9±1

0.7±1
16.6±8 A

5.3±6 B
0.6±1

0.2±0 A
0.0±0 B

0.0128
0.0293

ND

1.0±1 A

ND

0.0±0 B

ND

0.0121

Taxonomic group

OTUs a
OTU_2 (B. adolescentis,
99%)
OTU_1 (L. lactis, 100%)
OTU_626
(Lachnospiraceaeb)
OTU_7 (Turicibacter
sanguinis, 97%)
OTU_14 (Blautiab)
OTU_33 (L. intestinalis,
99%)
OTU_9 (Clostridium sp.b)
OTU_6 (B. pseudolongum,
97%)
OTU_44 (C. cocleatum,
99%)
a

Percent homologies to the closest type strain in the database are shown in parentheses. If the strain could

not be assigned to a type strain (<97% homology), RDP Classifier was used to determine the most likely
genus, and the RDP Classifier value is shown (80% cutoff).
b

OTU without closely related type strain (<97% homology) classified with RDP Classifier. c Values with

different uppercase letters are significantly different from each other. HF, high fat; ND, not detected.

132

3.4.5 Community-wide characterization of effects on gut microbiota.
GOS treatment alone promoted a remarkably specific bifidogenic response, leading
to an increase in the abundance of only one OTU related to Bifidobacterium pseudolongum
(OTU_6) (Table 3.1 and Fig. 3.3A). These findings confirm the highly specific bifidogenic
response of GOS, which was previously demonstrated in humans (32).
Although IVS-1 treatment alone did not significantly increase the abundance of the
genus Bifidobacterium, it induced a significant increase in the abundance of
Bifidobacterium adolescentis at the species level (Table 3.1). Of note, several unexpected
changes were also detected, such as enrichment of the family Clostridiaceae, the genus
Clostridium, and an OTU within this genus (OTU_9). Furthermore, the abundance of an
OTU related to Lactobacillus intestinalis (OTU_33) increased, while that of an OTU
related to Lactococcus lactis (OTU_1) decreased (Table 3.1).
Synbiotic treatment significantly increased the proportion of Actinobacteria (P <
0.0001), the family Bifidobacteriaceae (P < 0.0017), and the genus Bifidobacterium (P <
0.0017) (Table 3.1). These shifts were almost completely equivalent to shifts of OTU_2,
showing that the above-described alterations at higher taxonomic levels were due to the
enrichment of IVS-1. The establishment of IVS-1 was associated with an increase in the
abundances of the genus Blautia and one OTU within this genus (OTU_14). In addition,
there was a reduction in the abundances of the phylum Firmicutes (P < 0.0001) and families
within this phylum, including Clostridiaceae, Streptococcaceae, and Erysipelotrichaceae.
The abundances of the genera Clostridium and Lactococcus and OTUs within these genera
were also decreased (Table 3.1).
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Fig. 3.3. Characterization of the rat colonic microbiota composition by Illumina
sequencing of 16S rRNA tags. A. Analysis of colonic microbiota at the OTU level. OTUs
representing at least 1% of total sequences are shown individually, while OTUs
representing <1% are grouped. OTUs in colors other than light blue were significantly
influenced by the dietary treatment. B. Principal coordinate analysis (Bray-Curtis distance)
of beta diversity. C. NMDS plot of beta diversity based on Bray-Curtis distance. SD,
standard diet.

134

To assess both the alpha and beta diversities of the community in the colon,
different diversity indexes were calculated from the data. Specifically, Shannon’s index
and the number of observed OTUs were used to determine the alpha diversity, and principal
coordinate analysis (PCoA) and nonmetric multidimensional scaling (NMDS) plots based
on Bray-Curtis distance were used to visualize the similarity between samples for each
treatment.
On average, 135.41 ± 34.4 OTUs per sample were identified. Alpha diversity based
on Shannon’s index was not significantly influenced by the treatment; however, there was
a tendency for reduced diversity in the synbiotic group. This was caused by a slight
reduction in community evenness, likely due to the expansion of a single species (B.
adolescentis) (data not shown). Two independent approaches were used to analyze the
beta diversity of the microbiota communities among treatments. PCoA and NMDS, based
on Bray-Curtis distances of beta diversity, revealed that communities from rats fed the
synbiotic clustered separately from the microbiomes of rats fed all the other treatments,
which clustered together (Fig. 3.3B and C). This finding demonstrated that only the
synbiotic treatment caused a global shift in microbiota structure.

3.4.6 Systematic analyses of associations between members of the gut microbiota.
To identify potential interactions between IVS-1 and members of the gut
microbiota, and among other bacterial members, we performed correlation analyses on all
taxon combinations in the data set. Correlations were performed by using bacterial
abundance data from all treatments. Strong negative correlations between the family
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Bifidobacteriaceae and the family Clostridiaceae (Fig. 3.4A), the genera Bifidobacterium
and Lactococcus (Fig. 3.4B), and the genera Bifidobacterium and Akkermansia (Fig. 3.4C)
were observed. In addition, strain IVS-1 levels (OTU_2) showed a negative correlation
with Lactococcus lactis (Fig.3.4D) and a very tight negative association with resident B.
pseudolongum (r = -0.64; P = 0.0004) (Fig. 3.4E). These negative associations suggest
direct or indirect competition between these bacterial taxa. Positive associations between
both Bifidobacteriaceae and Bifidobacterium and the genus Blautia were detected,
suggesting a synergistic relationship, which may be supported by the addition of GOS
(Table 3.1 and Fig. 3.4F).
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Fig. 3.4. Correlation analysis of colonic taxa present in rats fed a high-fat diet
supplemented with or without a probiotic (IVS-1), a prebiotic (GOS), or a synbiotic (IVS1 plus GOS) or a standard diet. Bacterial quantities are expressed as percent abundances
of total bacteria as determined by 16S rRNA sequencing. Spearman’s correlations between
Bifidobacteriaceae and Clostridiaceae (A), Bifidobacterium and Lactococcus (B),
Bifidobacterium and Akkermansia (C), Bifidobacterium adolescentis IVS-1 and
Lactococcus lactis (D), Bifidobacterium adolescentis IVS-1 and Bifidobacterium
pseudolongum (E), and Bifidobacterium and Blautia (F) were determined.
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3.5 Discussion
Synergistic synbiotics are a promising concept to modulate the composition of the
gut microbiota and promote the establishment of probiotic organisms in the gut (16).
Despite this potential, however, there are few in vivo human or animal studies providing
evidence that prebiotics can be used to support specific probiotic strains. Unfortunately,
most synbiotic studies, including work in rats (44–49), mice (50–52), pigs (53–57),
chickens (58, 59), and humans (60), did not employ strain-specific detection methods and
therefore did not provide information on the potential synergism between pre- and
probiotics. Of the in vivo studies that did discriminate the probiotic strain, most still did
not demonstrate that in vivo performance could be enhanced by a prebiotic. This accounts
for experiments using synbiotic formulations in humans (61), rats (62, 63), and other
animal models (64). These findings suggest that, with few exceptions (17–19), probiotic
strains are unable to compete against the resident gut microbiota, which is inherently
resistant to outside colonizers (65), even when an exogenous growth substrate in the form
of a prebiotic is provided.
Several reasons may explain the low success rates of synergistic synbiotics when
evaluated in vivo, even for combinations in which the probiotic strain is able to utilize the
prebiotic substrate in vitro. First, to become established in the gut, the probiotic strain must
be able to occupy an ecological niche. This means that strains must not only outcompete
the resident microbiota for the prebiotic substrate but also secure other nutrients that might
be growth limiting (such as amino acids, lipids, vitamins, minerals, and nucleotides, etc.).
In addition, probiotic strains must tolerate the prevailing environmental conditions in the
digestive tract (including pH, bile acids, IgA, and defensins). Ultimately, in vitro tests are

138

unable to predict the ability of a probiotic to benefit from a prebiotic substrate within the
constraints of the competitive gastrointestinal environment. In contrast, the IVS approach
described here overcomes many limitations of in vitro tests used to formulate synbiotics
because it provides a basis for identifying bacterial strains that are able to utilize the
prebiotic substrate under the same ecological conditions in which they are intended to
function.
In this study, we employed IVS and selected a synbiotic combination that was
tested in a rat model of NAFLD. Although the synbiotic did not influence host phenotypes,
it was highly efficient at enhancing population levels of the probiotic strain, making it the
most dominant OTU in the gut (Fig. 3.3A and Table 3.1). These findings provide a proof
of concept for the potential of in vivo selection to identify synbiotic combinations that are,
in ecological terms, highly synergistic. In addition to enhancing the abundance of strain
IVS-1, the synbiotic used here also redressed the high-fat-diet-induced reduction in the
level of bifidobacteria detected in rats that is often reported in the literature (41–43).
Therefore, although no metabolic benefits were seen in the rat model used in our study, the
synbiotic may be beneficial in other scenarios, as bifidobacteria are considered healthpromoting organisms (6, 26, 66–68).
The community-wide analysis provided evidence that synergism between GOS and
strain IVS-1 increased the competitive fitness of the strain in the rat intestinal tract. B.
pseudolongum, which is a natural member of the rat GI tract (69), was detected in relative
abundances of 5.8 % and 0.9 % in rats fed the standard and high-fat diets, respectively.
Although the probiotic treatment did not affect levels of B. pseudolongum, the prebiotic
treatment increased the abundance of this species to 16.6 %, indicating that B.
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pseudolongum utilized GOS in vivo. However, the parallel addition of strain IVS-1 with
GOS completely excluded B. pseudolongum, and a strong negative correlation between
this species and IVS-1 was observed (r = -0.67; P = 0.0006) (Fig. 3.4E). These findings
indicate that IVS-1 not only had a higher affinity for GOS in vivo than the resident
Bifidobacterium species but also utilized GOS to increase its competitiveness and
effectively outcompete a closely related resident species. This finding is consistent with
the niche exclusion model, which states that the organism most efficient at using limited
nutrients outcompetes its competitors for the same niche (70). Strong inverse correlations
between bifidobacteria and Clostridiaceae, Lactococcus, and Akkermansia (Fig. 3.4A to
C) were also observed. It is likely that these associations are also due to niche competition
and are potentially enhanced by GOS administration. Bifidobacteria produce short-chain
fatty acids that are inhibitory to other bacteria either by lowering the pH or via direct
antimicrobial effects (e.g., acetic acid) (71). In summary, these findings demonstrate that
the competitive fitness of strain IVS-1 was increased by GOS, which supports the
conclusion that IVS can select synbiotic combinations with extremely high synergism. To
what degree the increased competitive interactions between IVS-1 and the resident
microbiota impact host health is difficult to predict and likely context dependent, but they
clearly should be considered in future studies.
Correlation analyses revealed only one positive association among members of the
rat microbiota, between the bifidobacteria (at the family and genus levels) and the genus
Blautia. The abundance of OTU_14, an uncultured Blautia strain, was also significantly
increased by GOS and in the synbiotic treatment (Table 3.1). The positive correlation
between Bifidobacterium and Blautia (Fig. 3.4F) indicates a synergistic effect between the
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two taxa. The significant increase in the abundance of Blautia in the synbiotic treatments
further suggests a syntrophic interaction between IVS-1 and Blautia, as GOS is consumed
mainly by bifidobacteria (72), and the genus Blautia is not reported to utilize GOS. In
contrast, the genus Blautia contains bacteria that are hydrogenotrophic acetogens, which
utilize H2 and CO2 as energy sources (73). Although bifidobacteria do not produce these
gases, cross-feeding between bifidobacteria and butyrate-producing colon bacteria can
result in H2 and CO2 production (74), which might explain the positive correlations
between Bifidobacterium and Blautia. However, additional experiments are necessary to
establish the mechanism by which GOS can enhance the populations of Blautia in the gut
and the positive associations between this genus and IVS-1.
In this study, we have shown how IVS can be used to formulate a highly synergistic
synbiotic that can substantially enhance population levels and the competitiveness of a
putative probiotic strain in the gastrointestinal tract and establish it as the dominant member
of the gut microbiota in a conventional animal model. To our knowledge, this has not yet
been reported in the probiotic literature. The process of IVS is broadly applicable and can
easily be extended to other host species, body sites, prebiotic substrates (or dietary fibers),
or target organisms. For example, it may be possible to use IVS to enhance other putative
health-promoting genera such as Akkermansia, which has been shown to respond to
prebiotics in vivo (75). While we selected B. adolescentis IVS-1 during a human trial that
did not determine the physiological effect of GOS, IVS might be especially powerful when
combined with a human clinical trial that determines the beneficial effect of a prebiotic on
the host as the primary selection criterion. Therefore, to develop synbiotics for specific
health applications, the IVS concept should be extended to select bacterial strains that not
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only responded to the prebiotic but whose expansion correlated with beneficial
physiological effects for the host. Such an approach would have the potential to identify
health-promoting strains whose metabolic activity in vivo could be increased through a
prebiotic. This might also result in synbiotic applications with greater health effects than
those of the prebiotic alone, especially in the subset of humans who do not respond to the
prebiotic (14, 32). A human study testing the synbiotic combination identified here (and
comparing it with a synbiotic that includes a Bifidobacterium strain that can ferment GOS
but was not selected by IVS) is currently in progress. Clearly, the application of IVS is
likely to enhance the ecological performance of probiotic strains or live biotherapeutics
within the habitats in which they are thought to function, and the technology could be
readily applied in the design of microbiota-modulating therapies.

142

3.6 Supplemental material
Table 3.S1. Composition of standard and high-fat diets.
Nutritional profile

High-Fat Diet

Standard Diet

Protein [%]

24.2

17.6

Fat [%]

34.7

5.2

Fiber (max) [%]

5.5

3.9

Carbohydrates [%]

27.8

68.3

Energy (kcal/g)

Kcal / %

Kcal / %

From Protein

0.969 / 18.6

0.705 / 18.3

From Fat (ether extract)

3.122 / 59.9

0.464 / 12.1

From Carbohydrates

1.113 / 21.4

2.733 / 71.0
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Table 3.S2. Body weight, relative epididymal fat pad weight, consumed drinking water,
consumed IVS-1 and GOS, and host physiological markers.
Standard
Diet

High-Fat
Diet

High-Fat
Diet
Prebiotic

High-Fat
Diet
Probiotic

High-Fat
Diet
Synbiotic

P - value
ANOVA

Average body
weight [g rat-1]

475 ±19

449 ±46

499 ±81

496 ±62

502 ±51

0.5446

Average relative
epididymal fat pad
weight [% rat-1]

0.84 ±0.2

1.04
±0.4

1.12 ±0.3

1.01 ±0.2

1.08 ±0.5

0.8267

Average water
consumption [ml
rat-1 day-1]

29.3 ±4.1b

35.6
±4.5a

36.3 ±4.9a

41.9 ±8.6c

35.4 ±4.5a

<0.0001

Average IVS-1
consumption [CFU
rat-1 day-1]

NA

NA

NA

1.26 x 109 a

1.06 x 109 b

0.0001#

Average GOS
consumption [g rat-1
day-1]

NA

NA

1.20

NA

1.17

0.2063#

Triglyceride content
[µg TG mg-1 tissue]

17.8 ±4.3a

70.7
±1.4b

62.7 ±1.2bc

53.5 ±0.8c

92.4 ±2.4d

<0.0001

Alkanine
Phosphatase (ALP)
[units liter-1]

227 ±83

399 ±55

464 ±127

458 ±167

460 ±120

0.0646

Alanine Transferase
(ALT) [units liter-1]

34 ±13

42 ±11

36 ±5

37±7

41 ±4

0.6418

TNF-α [pg ml-1]

14.2 ±2.3

14.1
±2.6

16.2 ±3.2

16.7 ±7.9

13.8 ±1.4

0.4718

MCP-1 [pg ml-1]

224 ±25

228 ±37

239 ±21

248 ±63

243 ±36

0.6345

*

*

as a threshold for steatosis was a liver triglyceride levels greater than 50 µg/mg of tissue
NA: not applicable
#
Student’s t-test was applied
Values with different letters are significantly different from each other
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Figure 3.S1. Growth of Bifidobacterium adolescentis IVS-1 in basal MRS supplemented
with GOS, 0.16% lactose (residual sugar present in the commercial GOS), or basal MRS
without carbohydrates.
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Chapter 4

Functional characterization of a rationally selected synbiotic application in obese
adults.

4.1 Abstract
One strategy for enhancing the establishment of probiotic bacteria in the human
intestinal tract is via the parallel administration of a prebiotic. Such combinations are
referred to as synbiotics.

We have developed a rationally formulated synbiotic

combination based on in vivo selection (IVS). This approach employed ecological criteria
to select a highly synergistic synbiotic combination, specifically, Bifidobacterium
adolescentis strain IVS-1 and galactooligosaccharides (GOS).

This synbiotic was

previously shown to be synergistic in a rat model (1), and we have now tested the ability
of this synbiotic to improve the abundance of bifidobacteria, and specifically of the
probiotic strain, in obese human subjects. The study was designed as a randomized,
placebo controlled, parallel arm clinical trial. When the rationally selected synbiotic was
compared to a commercial synbiotic (Bifidobacterium lactis Bb12 and GOS), the
synergistic synbiotic combination led to significantly higher levels of the probiotic strain
in the gastrointestinal tract of the subjects than the control. In conclusion, this study
demonstrated that IVS can be used to successfully formulate a synbiotic that can enhance
the establishment and competitiveness of a putative probiotic strain in the human
gastrointestinal tract.
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4.2 Introduction
The contribution of the gut microbiome to human and animal health is now well
established (2–4). Indeed, there are substantial efforts aimed at designing dietary strategies
that modify the composition of the gut microbiota with the goal of preventing disease and
promoting health (5, 6). In particular, probiotic bacteria and prebiotic fibers, as well as in
a combined form as synbiotics, have been tested in clinical trials to treat a range of
conditions, including IBS (7, 8), IBD (9–12), lactose intolerance (13, 14), and other
gastrointestinal (GI) diseases and disorders (15–18).
In addition to GI diseases, the development of several systemic conditions,
including metabolic endotoxemia and metabolic syndrome, are also associated with a gut
dysbiosis that could potentially be redressed through dietary modulations. Evidence from
human and animal studies suggests that a constant low grade inflammation of the GI lining
may precede or initiate the development of metabolic disorders (19). The origin of this
inflammation may be caused by alterations in the composition of the gut microbiota, which
is directly involved in controlling the host’s gut barrier function, and increases systemic
exposure to pro-inflammatory free fatty acids (20, 21). While the exact process of
decreased barrier function and increased permeability due to the gut microbiota remains
unclear, data from animal studies suggest that several mechanisms are included. For
example, changes in the abundance of certain members of the gut microbiota lead to
changes in the production and availability of short chain fatty acids, which are absorbed by
the gut epithelial cells. Additionally, the gut microbiota affects the distribution of tight
junction proteins, such as ZO-1 and Occludin, and influences the endocannabinoid system
tone, leading to a higher expression of anandamide and cannabinoid receptor 1 (22, 23).
These factors lead to increased intestinal permeability and subsequently to an increased
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translocation of microbe-derived lipopolysaccharides (LPS) into the bloodstream. This
induces metabolic endotoxemia, which eventually leads to metabolic syndrome (22, 24,
25).
Several studies have established that Bifidobacterium spp. have beneficial effects
in the pathology associated with impaired barrier function by reducing gut permeability
and improving epithelial cell barrier function (6, 24, 26–29). Specifically, Bifidobacterium
adolescentis administration to rats ameliorated insulin sensitivity, white fat accumulation,
and liver weight (30), and significantly lowered rates of bacterial translocation (27). This
species was also shown to attenuate the formation of reactive oxygen species, activate
nuclear factor κB (NFκB), and reduced markers of inflammation in the rodent liver (31).
Similarly, administration of Bifidobacterium longum reduced GI inflammation and
metabolic syndrome, and reduced levels of LPS and interleukin beta in a rat model (32).
Another species, Bifidobacterium breve reduced triacylglycerol content, decreased serum
TNF-α levels, and restored serum LPS levels to levels that were observed in control rats
(33). It also suppressed accumulation of epididymal fat pad and body weight, improved
fasting levels of glucose and insulin, and improved total cholesterol values in a mouse
model (34). Finally, supplementation of newborn mice with Bifidobacterium infantis and
Bifidobacterium bifidum significantly lowered intestinal endotoxin levels compared to
control mice (35), and B. infantis normalized gut permeability and decreased colonic IFNγ secretion in IL-10-deficient mice (26).
Collectively, these reports suggest that dietary strategies that support both the size
and physiologic activity of Bifidobacterium populations in the human GI tract could be
effective for a range of metabolic disorders. Ordinarily, the abundance of these bacteria in
adults is relatively low (< 3%) (36), and negatively correlates with high-fat and low fiber
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diets, which are common in Westernized societies (24, 37). This low abundance of
bifidobacteria may be addressed by dietary treatments such as probiotics, prebiotics, or
synbiotics. The consumption of prebiotic carbohydrates, such as galactooligosaccharide
(GOS) and other fibers, have been shown to increase autochthonous bifidobacteria in
infants (38, 39) and adults (40–42). However, not all subjects respond to prebiotic
interventions, even at high doses (36, 43, 44), and the subjects may not possess a particular
Bifidobacterium strain of interest. One strategy to enrich for bifidobacteria, even in nonresponders, would be to administer the prebiotic together with a Bifidobacterium strain that
is capable of metabolizing the prebiotic component in vivo. Such pairings are referred to
as synergistic synbiotics (45).
However, the rational selection of these synbiotic strains is critical as the potential
of the probiotic strains to become established in vivo is significantly limited due to
colonization resistance conferred by the resident or commensal microbial population, the
host, and other abiotic factors. Allochthonous strains may, for example, lack adaptive traits
necessary to become competitive and physiologically active in the GI environment. Their
ability to compete with the autochthonous microbiota in the GI tract is also compromised
by niche exclusion, colonization resistance, nutrient availability, the host’s immune
system, and the prevailing environmental conditions in the digestive tract (46). These
abiotic and biotic ecological factors have a major influence on the ability of allochthonous
organisms (including most probiotics) to reach, and then become established in the human
GI tract, even if only transiently. Indeed, studies have shown that bacterial strains that are
allochthonous to the GI tract are washed out shortly after administration is discontinued,
and pre-treatment conditions are quickly re-established (36, 47–50). By selecting bacterial
strains that are autochthonous, adapted to the host GI environment, the colonization
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resistance towards the strains based on these abiotic and biotic factors may be attenuated.
Moreover, incorporating strains autochthonous to the adult GI tract, such as B.
adolescentis, as a synbiotic might also be expected to enhance their probiotic function and
colonization success.
We recently described a novel method for the selection of an autochthonous strain
of B. adolescentis that was enriched in vivo by GOS (1). When this strain, B. adolescentis
IVS-1, was fed to rats, its abundance reached 3.4 % of the total bacterial gut microbiota.
However, when combined with GOS as a synbiotic, abundance of strain IVS-1 increased
to more than 35 %. To determine if this rationally selected synbiotic would also show
enhanced colonization in humans, we tested it in a parallel arm placebo controlled clinical
trial with obese adults. Our goal was to assess the potential of this in vivo selected strain,
combined with GOS as a synbiotic to establish bifidobacteria and redress metabolic
aberrancies, with gut permeability as the primary endpoint. We compared establishment
with a widely used commercial strain, B. animalis subsp. lactis Bb12, which has been used
in synbiotic applications with GOS (48, 51, 52). Each strain was provided as individual
treatments as well as combined with GOS as synbiotics. We compared the ability of the in
vivo selected rationally designed synbiotic to the commercial synbiotic to alter the gut
microbiota in obese individuals, and tested if GOS supported the colonization of the
probiotic strains. This report focusses on the impact of the dietary treatments on the gut
microbiota, while an assessment of the ability of each synbiotic to improve intestinal
permeability and endotoxemia is currently ongoing.
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4.3 Methods:
Subjects. This study was designed as a randomized, placebo-controlled, parallel-arm
clinical trial conducted at Rush University Medical Center (RUMC). Women and men
between 18 and 60 years with a BMI of 30.0 - 40.0 kg/m2 were recruited. Subjects were
permitted to have elevated liver enzymes due to fatty liver and metabolic syndrome, but
were otherwise considered as healthy. Exclusion criteria included (1) prior intestinal
resection, (2) patient history of GI diseases except for hiatal hernia, GERD, hemorrhoids,
(3) severe renal disease defined by creatinine more than twice normal, (4) markedly
abnormal liver function defined by ALT/AST over 4 times normal levels or elevated
bilirubin (5) antibiotic use within the last 12 weeks prior to enrollment, (6) lean or
overweight (BMI < 30 kg/m2), (7) intolerant to aspirin, (8) regular use of aspirin, (9)
excessive alcohol intake (>2 drinks for men, 1 drink for women daily), (10) presence of
chronic metabolic disease (cardiovascular disease, insulin requiring diabetes or
uncontrolled diabetes, cancer, etc.), (11) a plan to have a major change in dietary habit
during the following 6 months, (12) consumption of probiotics, prebiotics or synbiotics
without an appropriate 4 week washout period, (13) lactose intolerance or malabsorption,
(14) subjects younger than 18 or older than 60, (15) unwillingness to consent to the study.

Study design. A total of 105 subjects were recruited and randomly assigned to one of six
treatment groups (Table 4.1). The randomization was controlled for age and race. Three
visits were required for each subject (Figure 4.1). At Visit 1, potential subjects were
screened for eligibility and provided with a form for a 3-day diet record, all supplies for
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stool collection, and instructions for specimen handling and for completing these tasks
before the next visit.

Table 4.1. Treatment groups
Treatment group

Treatment

Group A

Lactose control

Group B

1 x 109 CFU B. adolescentis IVS-1

Group C

1 x 109 CFU B. animalis subsp. lactis Bb12

Group D

1 x 109 CFU B. adolescentis IVS-1 + GOS

Group E

1 x 109 CFU B. animalis subsp. lactis Bb12 + GOS

Group F

Galactooligosaccharide (GOS)

Subjects were instructed to store stool samples in Styrofoam coolers with freezer packs
until delivery to the hospital. The samples were not allowed to be older than 24 hours if
stored at -20°C, and not older than 5 hours if stored at room temperature. At visit 2, study
subjects provided the completed food record and the baseline stool sample. Subjects were
provided with one of the six treatments and consumed their randomly assigned supplement
daily for three weeks as instructed. At the end of three weeks, subjects returned to the
clinic to provide stool, as previously described.

At the visit after 3 weeks of

supplementation, the subject provided a stool sample, 3-day food records, and completed
GI symptom questionnaires regarding adverse events. The latter included a standardized
survey that rates bowel movement, stool consistency, discomfort, flatulence, abdominal
pain, and bloating on a scale from 1 (best) to 10 (worst) (44). Weight, height, waist
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circumference, and blood pressure were measured, and BMI was calculated at each visit.
Blood pressure was measured using an automated cuff with the average of three
assessments used for statistical comparisons. Four weeks after the last treatment was
consumed subjects provided a wash-out stool sample. Subjects gave a written informed
consent before the study procedure.
Eleven subjects (two in group A, four in group B, two in group C, one in group D,
and two in group E) did not follow all protocol requirements and were subsequently
excluded from the per protocol analysis presented here. These subjects were included in
an intend to treat (ITT) analysis, which can be found in the supplements.

Fig. 4.1. Time line for synbiotic trial.

Dietary treatments. The prebiotic, GOS, was obtained from Friesland Foods (sold under
the trade name, Vivinal®). This product contained 72.5 % of GOS, 22.8 % lactose, and
4.7 % mono-sugars (galactose and glucose). It was previously established that a dose of 5
g per day of GOS was sufficient to induce a bifidogenic response (40). Therefore the total
amount of GOS powder was raised to 6.9 g to achieve a 5 g GOS treatment. The material
was packaged in sachets in the Food Processing Product Development Lab (UNL). An

166

additional 0.1 g of lactose was added to achieve the same weight as the other preparations.
The sachet material was impermeable to oxygen and moisture.
The two organisms that were used in this feeding study were Bifidobacterium
adolescentis IVS-1 and Bifidobacterium animalis subsp. lactis Bb-12. The latter was
obtained from Chrs. Hansen as a high cell density powder. Strain IVS-1 was produced
from a contract manufacturer (Danwell Technology, Garden Grove, CA). The probiotic
powder was stored for up to six month at -18°C and showed stable CFU numbers (data not
shown). Probiotic mixtures were portioned into sachets, each contained 0.1 g of cell
powder (1010 CFU/g). In addition, 6.9 g of lactose were added as a carrier/control, for a
total dose of 7.0 g. Synbiotics contained 6.9 g of Vivinal® and 0.1 g of probiotic (either
B. adolescentis IVS-1 or B. animalis Bb12), for a total dose of 7.0 g. Placebo samples
contained 7.0 g of lactose. Subjects were provided with enough samples for the entire
length of the study and were instructed to consume each dose on a daily basis, either mixed
with food or liquid, but no tab water. The subjects were instructed to store samples in a
cold (-18 °C) environment.

Analysis of fecal microbiota. Fecal samples were aliquoted and stored at -80°C until
further analysis.

The DNA was extracted as previously described (29).

Amplicon

sequencing was performed at the University of Minnesota Genomics Center. All samples
were amplified and sequenced in a single run. The V5-V6 region of the 16S rRNA gene
was amplified as previously described (1). Quality filtering performed by the University
of Minnesota Genomics Center showed that more than 96 % of the samples met all quality
control criteria. All reads were trimmed to 240 base pairs using the FASTX-Toolkit. The
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reads were quality controlled, merged, OTU clustered, and taxonomically assigned, as
previously described (1). If a sample exceeded 37,000 reads it was subsampled using
Mothur v.1.31.162 to standardize the sequencing depth across samples. After processing
samples contained an average of 22,012.7 ± 6,623 sequences.

Quantitative real-time PCR (qPCR). qPCR was performed by using a Mastercycler
Realplex2 instrument (Eppendorf AG, Hamburg, Germany). Each PCR was performed
with 25-μl volumes using real-time master mix containing SYBR (5 Prime Inc.,
Gaithersburg,MD) and either genus-specific primers for Bifidobacterium (40), or the
strain-specific primers for B. adolescentis IVS-1 (1), as described previously. For strain
specific detection of B. animalis subsp. lactis Bb12 the PCR mixture contained 25 μl of
PCR reaction mix (QuantiFast® Probe PCR Kit, QIAGEN, Hilden, Germany), 0.3 μmol of
each primer (BAL-23S-F 5’-CAGGTGGTCTGGTAGAGTATACCG-3’ and BAL-23S-R
5’-ACGGCGACTTGCGTCTTG-3’), 0.25 μmol of probe (BAL-23S-P 5’-FAMCGCCCACGACCCGCAAG-TAMRA-3’), and 5 μl DNA as previously described (53).
The target of these primers and probe is the elongation factor Tu (tuf) gene of Bb12. The
specificity of the primers and probe for Bb12 was validated experimentally by qPCR using
DNA from 11 different Bifidobacterium strains related to strain Bb12. These strains
included Bifidobacterium adolescentis IVS-1, Bifidobacterium adolescentis ATCC 15703,
Bifidobacterium adolescentis L2-32, Bifidobacterium longum subsp. longum ATCC
15707, Bifidobacterium longum DJO10A, Bifidobacterium longum ATCC 15697,
Bifidobacterium longum subsp. longum F8, Bifidobacterium longum subsp. longum
JDM301, Bifidobacterium sp. strain 113, Bifidobacterium sp. strain 12_1_47BFAA, and
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Bifidobacterium sp. strain HMLN14.

Furthermore, to test if primers could strain

specifically select against fecal bacterial communities in humans, baseline DNA samples
from subjects in groups C (Bb12 + lactose) and group E (Bb12 + GOS), and 10 randomly
selected samples from other subjects, were tested.
Standard curves for absolute quantification of bacterial cell numbers were prepared
by using cultures of B. animalis subsp. lactis Bb12 and B. adolescentis IVS-1 grown
overnight (14 h).

Statistical analysis. All data present in the main body of the text was analyzed based on
a per protocol analysis. Subjects that were recruited but violated the protocol in any way,
for example took antibiotics, stored the treatments at room temperature, etc., were excluded
from the analysis. These subjects were included in an intend to treat (ITT) analysis, which
can be found in the supplements. Data is presented as mean ± SEM for variables that can be
considered normally distributed (or median and range for variables not normally distributed).
Group means were compared by ANOVA and post-hoc tests except when data was not
normally distributed, in which case nonparametric analyses of medians was done using the
Kruskal-Wallis test. Correlation analysis were done using the Spearman’s correlation test
for parametric analysis. Chi-square tests or Fisher’s Exact Tests were used for incidence
data. P <0.05 is considered statistical significant. If only two groups were compared,
Student’s t tests were performed.

For analysis of the gut microbiota the data was

normalized by log10 transformation. To account for type I errors, a false discovery rate was
used. A P value of < 0.05 and correlation coefficient (r) values of > 0.50 (in absolute
values) were considered significant. Genera above 0.5 % and OTUs above 1 % abundance
on average were considered for correlations. Correlation graphs were generated for
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parameters that showed significant correlations and were visually inspected. If the removal
of one single data-point caused the association to become non-significant, the data point
was considered an outlier and removed. All analyses used SPSS (Chicago, IL), GraphPad
Prism version 5.0 (GraphPad Software, La Jolla, CA, USA), R studio (R Core Team, 2014),
or SAS/STAT (SAS Institute Inc., Cary, NC, USA).

4.4 Results
4.4.1 Subject demographics and clinical characteristics
The subject cohort for this study was primarily female (71 %), middle-aged, nonHispanic or Latino, and African American (Table 4.2). All subjects were obese, with
participants in group D (IVS-1 + GOS) classifying as extreme obese, in group E (Bb12 +
GOS) and F (GOS) as Class II obese, and in group A (Lactose), B (IVS-1+ lactose), and C
(Bb12 + lactose) as class I obese. Subjects in group D had a significantly higher body mass
index (BMI) than subjects in group B (P = 0.049). The average waist circumference was
40 inches.

4.4.2 Test of synergy of GOS in addition to IVS-1 or Bb12.
Our first goal was to determine if the ability of two strains of bifidobacteria to
become established in the GI tract of obese adults would be enhanced by the addition of
GOS. The strains included B. adolescentis IVS-1 that had previously been isolated from a
GOS-enriched subject, and B. animalis subsp. lactis Bb12, a widely used commercial
probiotic. Both strains were capable of fermenting GOS in vitro (1, 54). Treatment groups
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included subjects who consumed each of the two test strains alone (groups B and C),
subjects who consumed the synbiotics (i.e., test strains combined with GOS; groups D and
E), a GOS-only group (F), and a placebo (lactose) group (A). Strain-specific qPCRs were
used to quantify bacterial cell levels for those groups that received either one of the test
strains alone or as synbiotics using the corresponding strain specific primers for IVS-1 and
Bb12. Because Bifidobacterium adolescentis is a common species in the adult GI tract, it
was necessary to establish that the IVS-1 primers were specific for this strain.
Results confirmed that no signal was detected in any baseline sample in subjects of
group B (IVS-1 alone) or D (IVS-1 + GOS) (Figure 4.2A), or in the baseline of another
additional 20 subjects that were randomly selected (data not shown). Therefore, it was
concluded that any IVS-1 that was detected by qPCR after the treatment was given to the
subjects, was indeed the probiotic strain selected for this study.
A similar approach was used to test the specificity of the Bb12 primers and probe.
The primers and probe had been previously designed (53) and are the standard used by
Chr. Hansen to identify their probiotic product. The strain Bb12 is a commonly used
probiotic in dairy products. It was detected in three subjects before the treatment was
started. Analysis of food diaries of these subjects, however, did not identify any indication
of Bb12 product consumption.
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Table 4.2. Demographic and metabolic characteristics of study subjects1
Total
Sample
(n=94)

Group A
Control
(n=17)

Group B
IVS-1
(n=18)

Group C
Bb12
(n=164)

Group D
IVS1+GOS
(n=16)

Group E
Bb12+GOS
(n=17)

Group F
GOS
(n=16)

Female,
N (%)

71 (75.5)

13 (76.5)

9 (64.3)

12 (75.0)

11 (78.6)

12 (75.0)

12 (75.0)

Age, years,
mean ± SD

44.3±11.2

44.3±11.2

44.3±11.2

44.3±11.2

44.3±11.2

44.3±11.2

45.9±9.6

Hispanic/
Latino

9 (9.6)

0 (0.0)

2 (14.3)

2 (14.3)

2 (12.5)

2 (11.8)

1 (6.3)

NonHispanic/
Latino

85 (90.4)

17 (100.0)

12 (85.7)

12 (85.7)

14 (87.5)

15 (88.2)

15 (93.8)

White

31 (33.0)

5 (29.4)

8 (57.1)

4 (28.6)

3 (18.8)

6 (35.3)

5 (31.3)

African
American

58 (61.7)

10 (58.8)

6 (42.9)

7 (50.0)

13 (81.3)

11 (64.7)

11 (68.8)

5 (5.3)

2 (11.8)

0 (0.0)

3 (21.4)

0 (0.0)

0 (0.0)

0 (0.0)

≤ 12 years

20 (21.3)

3 (17.6)

1 (7.1)

2 (14.3)

6 (37.5)

2 (11.8)

6 (37.5)

> 12 years

74 (78.7)

14 (82.4)

13 (92.9)

12 (85.7)

10 (62.5)

15 (88.2)

10 (62.5)

Body weight,
kg4

100.0 (25.7)

96.8 (17.7)

94.8 (14.6)

98.5 (32.2)

118.0 (36.7)

112.8 (31.8)

102.3 (18.3)

BMI, kg/m2,5

36.7 (8.5)

34.0 (4.5)

33.9 (6.2)
A

35.5 (10.3)

41.6 (12.4)
B

40.5 (7.1)

36.8 (5.6)

Waist
circumference, inches

45.0 (7.3)

44.0 (11.0)

43.5 (4.4)

43.0 (9.9)

47.8 (12.3)

47.0 (8.7)

45.0 (3.2)

Demographic
Characteristics
Gender

Race, n (%)

Ethnicity, n (%)

Other2
Education, n (%)

Clinical
Characteristics3

1Sample

based on those that were randomized to treatment and completed the post-treatment visit (Visit 4)

2White

ethnicity includes 2 Hispanic and 1 Middle Eastern participant; Black/African American ethnicity incudes 1
mixed ethnicity participant

3All

clinical characteristics are listed as median (IQR)

4Significant

difference based on Kruskal-Wallis, but no differences based on post-hoc pairwise comparisons after
adjustment for multiple comparisons.
5Different

letters indicate significant differences between treatment groups
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The results showed that compared to the baseline and washout in the fecal samples,
both strains reached significant increases in total numbers (P < 0.001 in group B (IVS-1 +
lactose), D (IVS-1 + GOS), and E (Bb12 + GOS); P <0.01 in group C (Bb12 + lactose)),
in the presence as well as absence of GOS (Figure 4.2A). In group B (IVS-1 alone), an
average of 6.99 ± 1.2 log10 of IVS-1 cells g-1 was detected and in group D, receiving the
synbiotic IVS-1 plus GOS, cell levels reached 7.22 ± 1.6 log10 of IVS-1 cells g-1. Group C
received the commercial strain Bb12, which was detected at absolute numbers of 5.83 ±
0.7 log10 of Bb12 cells g-1 and in group E (Bb12 + GOS) Bb12 numbers reached 6.11 ± 0.7
log10 of Bb12 cells g-1.
The numbers of the two probiotic strains for each treatment at each time point were
then compared directly (Figure 4.2B). IVS-1 colonized the GI tract at a significantly higher
number than the commercial probiotic Bb12 in the probiotic only treatments (P = 0.0056).
Although GOS enriched for both strains, Bb12 and IVS-1, relative to the test strains alone,
in both cases this trend was not significant (P = 0.7382 and P = 0.3034, respectively). In
contrast, when comparing the two synbiotics, GOS significantly increased the number of
IVS-1 by more than one log compared to the commercial Bb12 synbiotic (7.22 ± 1.6 log10
and 6.11 ± 0.7 log10 respectively, P = 0.0195). This result demonstrates an ecological
advantage of IVS-1 over Bb12 and a limited effect of GOS supplementation on either
strain. After a four week washout period, Bb12 could not be detected in group C subjects,
and only in three subjects at a very low number in the synbiotic group (group E). One of
these subjects already had Bb12 present in the baseline sample. In the IVS-1 + GOS
synbiotic group D, IVS-1 persisted in six subjects during the washout period, and the
number of IVS-1 was significantly higher than the number of Bb12 in group E (P =
0.0057).
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In addition to strain-specific quantification, the absolute numbers of bifidobacteria
were measured for all six groups at the three time points by genus-specific quantitative real
time PCR (Figure 4.3A). Even though both Bifidobacterium strains were significantly
enriched as determined by strain-specific qPCR, neither IVS-1 nor Bb12 supplementation
increased the total number of bifidobacteria. Only groups D (IVS-1 + GOS) and F (GOS)
showed a significant increase of bifidobacteria due to the treatments (P = 0.0203 and P =
0.0191, respectively).
The Bifidobacterium numbers at the baseline varied greatly within each group,
ranging from the detection limit (log10 4.67 cells g-1 feces) to log10 10.42 cells g-1 feces in
group F (GOS). Therefore, the change in cell number was calculated for each subject
(Figure 4.3B). The highest increases in Bifidobacterium numbers were for group F (GOS)
with 1.30 ± 1.7 log10, followed by group B (IVS-1 only) with 1.22 ± 1.4 log10. Interestingly,
the lactose group also had an increase in bifidobacteria (0.51 ± 0.9 log10). However, none
of these differences reached statistical significance.
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Fig. 4.2. A. Test of in vivo selected synergistic synbiotic application compared to a
commercial synbiotic. Quantification of absolute cell numbers of bifidobacteria in fecal
samples by qPCR using strain-specific primers for strains B. adolescentis IVS-1 and B.
lactis Bb12. Shown are probiotic and synbiotic treatment groups at baseline, treatment and
washout time points. Significance of P ≤ 0.05 is denoted by a single asterisk (*), P ≤ 0.01
as two asterisks (**), and P ≤ 0.001 by three asterisks (***). B. Direct comparison of
abundances of B. adolescentis IVS-1 and B. lactis Bb12 at each time point. Different letters
indicate significant differences between groups (P ≤ 0.05).
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Fig. 4.3. A. Quantification of absolute cell numbers of bifidobacteria in fecal samples by
genus-specific qPCR. B. Change in abundance of bifidobacteria for each subject due to
treatment consumption.
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4.4.3 Community-wide characterization of effects on gut microbiota confirms
ecological advantage of GOS and IVS-1 compared to Bb12 and GOS.
Community-wide changes that were introduced by the dietary treatments to the
resident gut microbiota were assessed by sequencing 16S rRNA tags. Interestingly, only
one phylum was significantly influenced by the dietary treatments as Actinobacteria was
significantly higher in subjects treated with IVS-1 + lactose (group B, P = 0.0181, Table
4.2, Figure 4.S1), and the genus Bifidobacterium in groups B (IVS-1 + lactose) and C
(Bb12 + lactose). Apart from this, only at the OTU level were significant changes
introduced to the gut microbiota. However, the abundance of these OTUs was extremely
low in most cases, and high variations in the sample populations were also observed.
Accordingly, the alpha and beta diversity of each group and between groups was not
significantly different (data not shown).
The ability of the test strains (alone and as synbiotics) to become established in the
GI tract was based on the abundance of operational taxonomic units (OTU) representing
the species B. adolescentis (OTU_1) and B. lactis subsp. animalis (OTU_167) (Table 4.3).
B. adolescentis is an autochthonous species in the human GI tract and was detected at low
average abundances in the GI tract of the subjects at baseline (2.27 ± 4.7 %). In contrast,
B. animalis subsp. lactis was detected in baseline samples for only seven subjects. In four
of these subjects the abundance of OTU_167 was below 0.01 %. The other three subjects
are identical to the ones identified in the qPCR analysis (Figure 4.2).
Based on the sequencing analysis, OTU_1 was significantly enriched by the
probiotic-alone and synbiotic treatments to 3.7 and 7.3 %, respectively (Table 4.2). In
groups D (IVS-1 + GOS), E (Bb12 + GOS), and F (GOS) OTU_1 B. adolescentis became
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the most abundant OTU, representing an average of 7.3 %, 7.2 %, and 6.7 % of the
microbiota, respectively, and the second most abundant in group B (3.4 %). This increase
was clearly based on the presence of IVS-1 and/or GOS in the treatments, as the abundance
of OTU_1 B. adolescentis was only 0.01 % in group A (Lactose) and 1.2 % in group C
(Bb12 + lactose). A comparison of the abundance of OTU_1 between group B (IVS-1 +
lactose), C (IVS-1 + GOS), and group F (GOS) showed no significant difference (P > 0.1).
There was a significant increase in the relative abundance of OTU_167 B. animalis
between baseline and treatment in group C (Bb12 + lactose) and E (Bb12 + GOS) (0.4 %
and 0.1 %, respectively).

4.4.4 Systematic analyses of members of the gut microbiota.
To identify potential interactions between the test strains and other members of the
gut microbiota, we performed correlation analyses at the treatment time point. As a cutoff,
the genus had to have an average abundance of at least 0.5 %, and the OTU an average
abundance of at least 1 %, with the exception of OTU_167 (B. animalis) which was
included even though its average abundance was below 1 %. No significant correlations
between the genus Bifidobacterium, or any Bifidobacterium OTUs, and other genera or
OTU could be identified once outliers were removed. However, several other significant
correlations between other members of the gut microbiota were observed (Figure 4.S2 and
4.S3).
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Table 4.3. Proportions of bacterial taxa significantly influenced by dietary treatments
Mean % bacterial abundance ± SD b
Treatments

Taxonomic Group

Group A
Lactose
control
Group B
IVS-1
Probiotic

OTUs a

P
value

Baseline

Treatment

Washout

0.01±0.0 AB

0.01±0.0 A

0.02±0.0 B

0.0139

9.16±5.5 A

15.44±6.2 B

14.39±5.9 AB

0.0181

7.85±7.8 A

14.66±7.2 B

13.43A±6.9 B

0.0378

OTU_2353 (Dorea sp.))

0.01±0.0 A

0.02±0.0 AB

0.02±0.0 B

0.0068

OTU_1 (B. adolescentis)

1.30±4.4 A

3.69±5.2 B

3.56±4.7 B

0.0010

9.53±5.3 A

10.18±8.3 B

9.96±6.1 AB

0.0378

OTU_167 (B. animalis subsp. lactis)
OTUs a

0.04±0.1 AB

0.04±0.1 A

0.00±0.0 B

0.0328

OTU_469 (Anaerotruncus sp.)

0.03±0.1 A

0.00±0.0 B

0.01±0.0 AB

0.0188

OTU_102: (Lachnospiracea incertae sedis
sp.)

0.35±0.5 A

0.01±0.2 B

0.24±0.6 AB

0.0444

OTU_1 (B. adolescentis)

2.48±4.5 A

7.34±7.2 B

4.75±5.1 B

0.0343

OTU_167 (B. animalis subsp. lactis)

0.00±0.0 A

0.12±0.2 B

0.01±0.0 A

0.0043

OTU_1800 (unclass. Lachnospiraceae sp.)
OTUs a

0.00±0.0 AB

0.01±0.0 A

0.00±0.0 B

0.0241

OTU_643 (Bacteroides sp.)

0.02±0.0 A

0.00±0.0 B

0.00±0.0 AB

0.0372

OTU_319 (Butyricimonas sp.)

0.00±0.0 AB

0.00±0.0 A

0.05±0.1 B

0.0382

OTU_2050 (Ruminococcus2 sp.)
Phylum
Actinobacteria
Genus
Bifidobacterium
OTUs a

Group C
Bb12
Probiotic

Genus
Bifidobacterium
OTUs a

Group D
IVS-1 GOS

Group E
Bb12 GOS

Group F
GOS

OTUs a

a

If the strain could not be assigned to a type strain (< 97 % homology), RDP Classifier was used to determine the most
likely genus (80 % cutoff). b Values with different uppercase letters are significantly different from each other.

The ratio of Prevotella to Bacteroides has been previously suggested to be strongly
associated with diet, especially diets rich in animal fat (Bacteroides) versus carbohydrates
(Prevotella) (55). Other studies have reported a significant change in the ratio between
Prevotella and Bacteroides due to dietary treatments (56), but an analysis of the Prevotella
and Bacteroides ratio in this study showed no significant difference within a treatment
group, or when groups were compared (Figure 4.S4). Furthermore, the abundance of
butyrate producing genera such as Faecalibacterium, Eubacterium, Roseburia,
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Lachnobacterium, and Ruminococcus was not significantly influenced by any of the
treatments, nor was their combined abundance changed by any of the treatments (data not
shown).

4.4.5 Systematic analyses of subjects that showed IVS-1 persistence after treatment
termination.
We observed that for nine subjects IVS-1 persisted during the four week washout
period. Three subjects were from group B and six were from group D (IVS-1 alone and
IVS-1 + GOS, respectively). The microbiota of these nine persisters was compared with
the microbiota of all the other subjects in groups B and D (referred to as non-persisters).
The aim of this analysis was to determine if the persister status could be predicted before
the treatment had begun (i.e., from the baseline samples), based on the composition of the
gut microbiota. In order to identify genera and OTUs that affected persistence of IVS-1 in
the GI tract of these two groups, a Random Forest classification was performed. This
analysis shows the importance that the relative abundances of different taxa have in
predicting persistence. Output of this analysis is a “value of mean decrease in accuracy”.
The higher the value of mean decrease in accuracy of the taxa, the stronger the prediction
of persistence of IVS-1. All genera and OTUs with a value of mean decrease in accuracy
of at least one are reported here (Figure 4.4). The random forest analysis identified Slackia
as the most important predictor of persistence. When the abundance of Slackia was
compared between persisters and non-persisters, Slackia abundance was higher in nonpersisters with a ratio of almost 200. However, despite the high ratio, the absolute
abundance of Slackia was only 0.23 % in non-persisters and almost absent in persisters.
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Other members of the Coriobacteriales order are also predictive for the ability of IVS-1 to
persist in the subjects, including Asaccharobacter, Collinsella, and Olsenella. Except for
Asaccharobacter, all of these Coriobacteriales were present at a higher abundance in nonpersisters than in persisters. Three members of the Clostridiales order, Ruminococcus,
Eubacterium and Mogibacterium, one member of the Bacteroides order, Prevotella, and
one member of the Erysipelotrichales order, Holdemania, also appeared to have the
greatest impact on IVS-1 persistence. At the OTU level, eight OTUs had a value of mean
decrease in accuracy of at least one; six belonged to the order Clostridiales, one to
Coriobacteriales, and one to Lactobacillales. The prediction value of the OTUs for
persistence appears to be strain dependent. For example, OTU_21 Blautia sp. and OTU_98
Blautia sp. were present in higher abundance in persisters then in non-persisters, while
OTU_103 Blautia sp. had a significantly higher abundance in non-persisters (P = 0.0353).
Three Lachnospiraceae OTUs were also identified. OTU_61 Lachnospiraceae incertea
sedis and OTU_2093 Lachnospiraceae incertea sedis share 96 % identity and are both in
higher abundance in persisters than in non-persisters (P = 0.0365 and P = 0.0805,
respectively). OTU_76, an unclassified Lachnospiraceae sp., on the other hand was
present in significantly higher numbers in non-persisters (P = 0.0177) and shared 91 % and
90 % identity with OTU_61 and OTU_2093, respectively. OTU_1 B. adolescentis was
only present in two of the persister subjects at the baseline and was not detected by the
Random Forest analysis (< -1.0).
Even though no Bifidobacterium species had a Random Forest importance value
above 1, three Bifidobacterium OTUs had values above zero and were further analyzed
(Figure 4.6A). Those three OTUs consisted of OTU_2055 B. pseudocatenulatum (99%
identity, e-value 6 · 10-120, 100% query cover), OTU_2202 B. pseudocatenulatum (98%
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identity, e-value 2 · 10-119, 100% query cover), and OTU_7 B. ruminantium/adolescentis
(100 % identity, e-value 4 · 10-126, 100% query cover in each case according to NCBI).
OTU_7 had a 144-fold higher relative abundance in non-persisters than in persisters on
average (P = 0.0454), even though it was not present in all non-persisters at the baseline.
OTU_7 is very closely related to IVS-1 (98 % identity) and possibly the same species
(Figure 4.6B). OTU_2055 B. pseudocatenulatum and OTU_2202 B. pseudocatenulatum,
were higher in persisters by a ratio of 24 and 5.5, respectively, but their abundance was not
significantly different between the groups.
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Fig. 4.4. Prediction analysis of IVS-1 persisters and non-persisters. Random Forest
variable importance plots and relative abundance of genera (A) and OTUs (B) with a
variable importance of at least 1 in mean decrease in accuracy. The ratio of the given taxa
between responders and non-responders is shown on the right. Taxa are color coded by
order.
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Fig. 4.5. A. Prediction analysis of IVS-1 persisters and non-persisters. Random Forest
variable importance plots and relative abundance of Bifidobacterium OTUs with a variable
importance of at least zero in mean decrease in accuracy. B. The ratio of the given
Bifidobacterium OTUs between responders and non-responders.

While different markers for alpha diversity such as Shannon index, Simpson index,
and the number of observed species was not significantly different among persisters and
non-persisters in the baseline sample (Figure 4.S5), the beta diversity of the samples tended
to separate (Figure 4.6). However, this trend was not significant (P = 0.2637)
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Fig. 4.6. NMDS plot of beta diversity analysis based on Bray-Curtis distance of baseline
samples between IVS-1 persisters and non-persisters.

4.4.6. Analysis of anthropometric markers and gastrointestinal symptoms
Anthropometric markers were analyzed at the baseline and after three weeks of
treatment, and the change (as percent) is reported in Table 4.4. There was no change
detected in anthropometrics between groups.
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Table 4.4. Percent change in anthropometrics in participants compared to the baseline1
Total
Sample
(n=94)
Anthropometrics
Body
weight,
0.4 (2.9)
kg
BMI,
0.4 (2.9)
kg/m2
Waist
circum0.0 (4.6)
ference,
inches

Group A
Lactose
(n=17)

Group B
IVS-1
(n=14)

Group C
Bb12
(n=14)

Group D
IVS-1 +
GOS
(n=16)

Group E
Bb12 +
GOS
(n=17)

Group
F
GOS
(n=16)

0.4 (5.0)

-0.1 (2.9)

0.6 (2.4)

-0.3 (3.4)

-0.1 (3.6)

1.3 (3.6)

0.4 (5.0)

-0.1 (2.9)

0.6 (2.4)

-0.3 (3.4)

-0.1 (3.6)

1.3 (3.6)

-1.3 (3.8)

0.0 (6.9)

0.2 (5.2)

0.0 (5.5)

1.8 (3.0)

0.0 (5.1)

1

Per-protocol sample based on those that were randomized to treatment and were considered compliant
to the treatment
2
All clinical characteristics are listed as median (IQR)

A structured 34-item questionnaire with a Likert scale from 0 (no symptoms) to 10
(very severe symptoms) was used to assess gastrointestinal symptoms at baseline and any
changes in these symptoms with supplementation. At baseline, subjects reported no
symptoms to 28 of 34 (82.4 %) GI symptoms included on the questionnaire; this number
of symptoms increased to 85.3 % (29 of 34 items) at the end of the treatment. The most
common symptoms at baseline were bloating, passing gas, hard stools, and watery stools,
with 60.6 %, 85.1 %, 46.8 %, and 43.6 % overall indicating presence of these symptoms,
respectively. The median symptom score for each of these four symptoms both before and
after treatment are listed in Table 4.5. Overall, low median scores indicated that most
subjects either had minimal GI symptoms or low severity of that symptom. No significant
differences existed between median symptom score for the six groups at baseline. At the
end of treatment, those in the GOS group had significantly more hard stools than the Bb12
+ GOS group (Kruskal-Wallis; P = 0.024). Passing gas increased from a median of 2.0 to
5.0 with lactose supplementation, but this was not significantly different (Mann-Whitney,
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P = 0.15). The severity of passing gas significantly reduced from 4.0 to 1.0 in the Bb12 +
GOS group (P = 0.040), and severity of hard stools increased from 1.0 to 3.5 in the GOS
group (Wilcoxon Signed Ranks Test, P = 0.030).

Table 4.5. Gastrointestinal symptoms by supplementation group1,2,3
Total
Sample
(n=92)

Group A
Lactose
(n=16)

Group B
IVS-1
(n=14)

Group C
Bb12
(n=14)

Group D
IVS-1 +
GOS
(n=15)

Group E
Bb12 +
GOS
(n=17)

Group F
GOS
(n=16)

Bloating

2.0 (4.8)

2.0 (4.8)

1.0 (3.3)

2.0 (4.0)

2.0 (5.0)

4.0 (6.0)

2.5 (7.8)

Passing Gas

3.0 (5.0)

2.5 (4.8)

2.5 (3.5)

2.5 (4.5)

3.0 (5.0)

4.0 (3.5) *

2.5 (5.8)

Hard Stools

1.0 (2.8)

0.5 (3.0)

1.0 (2.3)

0.0 (2.3)

0.0 (3.0)

1.0 (3.5)

1.0 (3.8) *

1.0 (4.8)

1.0 (3.8)

1.0 (3.5)

1.5 (3.5)

2.0 (5.0)

1.0 (4.5)

2.0 (5.8)

Bloating

1.0 (4.0)

0.0 (4.0)

1.5 (4.0)

1.0 (2.0)

1.0 (3.0)

2.0 (4.0)

2.5 (5.0)

Passing Gas

3.0 (5.0)

5.0 (4.8)

3.0 (2.0)

3.0 (6.3)

2.0 (3.0)

1.0 (5.0) *

3.0 (5.8)

Hard Stools

1.0 (3.0)

0.0 (3.0)

1.0 (1.3)

1.0 (3.3)

1.0 (3.0)

0.0 (1.0) A

3.5 (4.8) B *

Watery Stools

1.0 (3.0)

1.0 (2.0)

1.0 (3.3)

0.5 (1.5)

1.0 (4.0)

1.0 (2.5)

2.5 (4.8)

Baseline 2

Watery Stools
Treatment End

3,4

1Per-protocol

sample based on those that were randomized to treatment and were considered compliant to the
treatment
2Change in gastrointestinal symptoms are listed as median (IQR). Only the most common symptoms experienced
are listed
4Different

letters indicate a significant difference in distribution between groups within symptom; identical symbol
indicate differences in symptoms before and after treatment within a treatment group

4.5 Discussion
There is much interest in the health promoting capabilities of bifidobacteria in the
human GI tract. Synbiotics have advantages in promoting bifidobacteria as they could
result in improved establishment of a specific Bifidobacterium strains in the human gut
when compared to the probiotic alone, and increase bifidobacteria in individuals that do
not possess them or that do not respond to probiotics alone. However, if synbiotics are in
fact more successful than their parts has not adequately been studied in humans. Here we
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systematically assessed the ability of two Bifidobacterium strains, administered alone and
combined with GOS as synbiotics, to become established in the gastrointestinal tract of
obese adults. In addition, community sequencing was used to identify other changes
introduced to the gastrointestinal microbiota by the dietary treatments.
The first objective of this study was to test if the prebiotic carbohydrate GOS
included in the two synbiotic preparations supported the establishment of the test probiotic
strains in the human gut. Both strains were significantly enriched during the treatment
period compared to baseline and washout levels, whether consumed alone or as synbiotics
according to the qPCR analysis (Figure 4.2). The absolute numbers of IVS-1 were
significantly higher than those detected for Bb12, independently of the presence of GOS.
This suggests that the autochthonous strain IVS-1 has an ecological advantage over the
allochthonous commercial strain Bb12. This is an important finding as it emphasizes the
necessity to consider ecological requirements of the probiotic strains when synbiotic
combinations are formulated. Bb12 and IVS-1 are both capable of utilizing GOS in vitro
(1, 54), however enhanced Bb12 colonization of the human GI tract is not supported by
GOS as demonstrated here, and as also previously reported (48–50). There was a tendency
of IVS-1 being specifically enriched by GOS. However, this synergistic effect between
IVS-1 and GOS did not reach significance in this study cohort. Interestingly, the synbiotic
of IVS-1 and GOS led to significantly higher numbers of IVS-1 than the commercial
synbiotic of Bb12 and GOS. This indicates that IVS can be used to formulate a synergistic
synbiotic that can enhance population levels and the competitiveness of a putative probiotic
strain in the gastrointestinal tract compared to a commercial synbiotic. Indeed, this is only
the second report of a prebiotic specifically enriching for a putative probiotic strain in
humans (57).
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Secondly, we compared the ability of the two strains and their respective synbiotic
combinations to alter the composition of the gut microbiota in obese individuals. Our
analyses showed that the probiotic, prebiotic, and synbiotic treatments altered the gut
microbiota of the study subjects to a very limited extent (Table 4.3). Only in treatment
group B (IVS-1 + lactose) the phylum Actinobacteria was significantly higher in the
treatment sample than at the baseline, and the genus Bifidobacterium was significantly
higher in groups B (IVS-1 + lactose) and C (Bb12 + lactose) compared to the baseline
based on 16S rRNA sequencing. One limitation of this sequencing approach is that it
returns the relative abundance of taxa, instead of the absolute numbers present in the GI
tract. Therefore a qPCR approach was done, which is more quantitative. This analysis
showed that the absolute number of bifidobacteria was significantly increased by the IVS1 + GOS synbiotic (group D) and GOS alone (group F) (Figure 4.3). This increase in
numbers and abundance of bifidobacteria due to GOS feeding has been previously shown
(1, 36). Interestingly, however, the treatment of Bb12 and GOS did not significantly enrich
for bifidobacteria. This may be caused by a large variance in the subject cohort’s
microbiota, as there was no other member of the gut microbiota identified that was enriched
by this treatment and could have outcompeted the bifidobacteria for GOS. While both
strains, IVS-1 and Bb12, were significantly enriched by the probiotic dietary treatments in
group B (IVS-1 + lactose) and C (Bb12 + lactose) (Figure 4.2), but the absolute number of
bifidobacteria was not increased in these groups (Figure 4.3).
According to the 16S rRNA sequencing analysis, in all other cases only OTUs were
significantly influenced in their abundances by the treatments (Table 4.2). This overall
resilience of the gut microbiota to the treatments was characterized by a great variability
between the subjects. For example, the bifidogenic response to GOS treatment varied
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between an increase of almost 5 logs in one subject and a decrease of 0.6 logs in a different
individual. This responder and non-responder phenomenon was previously described for
GOS treatment in healthy adult subjects (40), and was also observed in this study, despite
the presence of the added probiotic strain. The stability of the gut microbiota was also
confirmed by the lack of change in the alpha and beta diversities, no change in the
abundance of butyrate producers, and a consistency of the Prevotella and Bacteroides ratio.
Few significant correlations were found between members of the gut microbiota, and none
between bifidobacteria and any other taxa.
Overall these analyses showed that a strain of a core species of the human gut
microbiota, B. adolescentis, can be established in almost all of the subjects by probiotic
and synbiotic consumption, and at significantly higher numbers than an allochthonous
strain. However, this establishment had little effect on the resident community in the GI
tract.
Strain-specific qPCR analysis at the four week washout time point showed that
IVS-1 did not only reach higher colonization levels compared to Bb12, but IVS-1 was also
significantly more persistent than Bb12 (Figure 4.2 B). This finding supports the concept
of in vivo selection to select for ecologically more competitive probiotic strains. The
autochthonous strain IVS-1 had a significant advantage to become established in the GI
tract and avoid niche exclusion from the resident microbiota compared to the allochthonous
strain Bb12.
Interestingly, IVS-1 persisted in twice as many subjects when consumed as a
synbiotic with GOS compared to IVS consumption alone.

It has to be taken into

consideration, however, that the number of subjects that showed persistence was very low,
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only three in group B (IVS-1 + lactose) and six in group D (IVS-1 + GOS), and the washout
sample was taken four weeks after the last consumption of the treatment. This study was
not designed to specifically test persistence and a strain detection at only four weeks after
the end of the treatment does not allow any conclusion about long-term persistence of IVS1. In this study the addition of GOS did not significantly support the persistence of IVS1, but because of the small sample size a final conclusion about the synergistic effect of
GOS and IVS-1 in regard to persistence cannot be drawn. A future study may consider to
extend the consumption of GOS after IVS-1 consumption has been terminated in order to
establish if GOS specifically supports IVS-1 colonization and competitive fitness.
In order to get insight into the ecological niche that IVS-1 may be occupying in the
GI tract of persisters, the composition of the gut microbiota was compared between
persisters and non-persisters in order to determine if a persistence of IVS-1 could be
predicted before the beginning of the treatment. By Random Forest analysis, mostly
members of the Coriobacteriaceae family were identified (Figure 4.4). Coriobacteriaceae
are frequently found in patients suffering from overweight (58) or inflammatory bowel
diseases, but there is no corresponding quantitative or functional data available yet (59).
Slackia was identified as the most important genus predictor of persistence (Figure 4.4).
The genus Slackia is part of the family Coriobacteriaceae and contains five species (60–
63). In vitro analyses suggest that none of these species are capable of utilizing GOS (62,
63).

Additionally, Slackia has been characterized as asaccharolytic (as well as

Eubacterium and Mogibacterium) (64). Therefore it is unlikely that Slackia would have
been competing with IVS-1 for GOS. This genus is known as a commensal of the
mammalian microbiota (59) and two of its members, S. isoflavoniconvertens and S.
equolifaciens. are known equol producers (63). Whether or not the Slackia detected here
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produces equol remains unknown. Overall Slackia is present at very low abundance in
non-persisters (0.2 %) but almost absent in persisters.
Other members of the Coriobacteriaceae family, Asaccharobacter, Collinsella,
and Olsenella, were also predictors of persistence. OTU_3 Collinsella aerofaciens and the
genus Collinsella were both present at approximately 3 % abundance in persisters.
Therefore the genus Collinsella mostly likely consists only of OTU_3 Collinsella
aerofaciens in this case. This species is considered to be a member of the core human gut
microbiome (65). Interestingly, the identification of Collinsella, C. aerofaciens, and
Coriobacteriaceae has been consistent in comparison to another study (Maldonado-Gomez
et al., unpublished). In that case, these taxa were predictive of long-term persistence for B.
longum in healthy human subjects. In this study no significant correlation between IVS-1
or bifidobacteria and any of these taxa could be identified that could explain this
phenomenon.

For now it remains speculative which effect the presence of

Coriobacteriaceae has on the persistence of IVS-1.
Three Blautia OTUs were identified by Random Forest. Two of the three Blautia
OTUs were in higher abundance in persisters than in non-persisters. Blautia has not been
reported to utilize GOS, but a strong positive correlation and potentially cross-feeding
between Blautia and Bifidobacterium was previously reported (1). On the other side,
OTU_23, a Streptococcus sp., was also identified to be predictive of IVS-1 persistence. It
has been previously shown that this species is capable of utilizing complex carbohydrates
like GOS (66), so this species could have been competing with IVS-1. However, this OTU
was in significantly higher abundance in persisters than in non-persisters (P = 0.0266).
Again, the number of persister subjects was very low for this analysis and, unfortunately,
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for now it cannot be explained how the taxa identified by Random Forest shape the GI
niche that can be occupied by IVS-1.
Interestingly, three Bifidobacterium OTUs were identified as predictors of IVS-1
colonization (Figure 4.5). While the mean decrease in accuracy values were quite low and
therefore these results have to be considered with caution, two OTUs that potentially
contributed to IVS-1 colonization were identified (both B. pseudocatenulatum), and one
that was possibly preventing it (OTU_7). While the identity of OTU_7 could not be clearly
established, OTU_7 was a very closely related strain to IVS-1 with 98 % identity.
Therefore, these two strains may have very similar ecological niche preferences and
requirements. Based on niche exclusion theory (67) it could be possible that OTU_7 was
occupying a niche in the GI tract that could have been occupied by IVS-1 as well, but not
by both strains at the same time. IVS-1 was not capable of outcompeting the closely related
resident strain in this case.

4.6 Conclusion
This study has provided novel insights into the complex interactions between the
gut microbiota and dietary regimens consisting of prebiotics, probiotics, and synbiotics.
The potential of synbiotic applications on human health has been previously established
(45). However, many synbiotic formulas lack synergistic activity in that the probiotic is
not enriched by the prebiotic. Thus, the probiotic strain is established in the GI tract not
more effectively had it been introduced by itself. While this lack of success may be due to
the arbitrary selection of the synbiotic components, we have previously shown that in vivo
selection can overcome the ecological limitations imposed on the probiotic strains in the
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GI tract (1). By specifically enriching a B. adolescentis strain, IVS-1, with its cognate
prebiotic substrate, we have previously validated this synergistic synbiotic concept in rats
(1). We have now demonstrated the potential of in vivo selected probiotics and synbiotics
in a human trial as well. IVS-1 was successfully established in the GI tract of human
subjects in significantly higher numbers than a commercial probiotic, B. animalis subsp.
lactis Bb12, and also when the two synbiotic combinations were compared. IVS-1, as a
strain of a core species of the human gut microbiota, was established in all but one subject,
and OTU_1 B. adolescentis became the dominant member of the gut microbiota. This
study has clearly established that in vivo selection can identify autochthonous probiotic
strains that are highly competitive in the GI environment when introduced as probiotics or
synbiotics. While there was a trend for GOS specifically and synergistically enriching for
IVS-1 in this study, this trend did not reach significance.
This study provided important proof of concept that a rational selection of synbiotic
combinations based on the ecological requirements of the probiotic strain can significantly
enhance the colonization, and persistence of probiotic strains.

196

4.7 References
1.

Krumbeck JA, Maldonado-Gomez MX, Martínez I, Frese SA, Burkey TE,
Rasineni K, Ramer-Tait AE, Harris EN, Hutkins RW, Walter J. 2015. In Vivo
Selection to identify bacterial strains with enhanced ecological performance in
synbiotic applications. Applied and Environmental Microbiology 81:2455–2465.

2.

Joyce SA, Gahan CGM. 2014. The gut microbiota and the metabolic health of the
host. Current Opinion in Gastroenterology 30:120–7.

3.

Cho I, Blaser MJ. 2012. The human microbiome: at the interface of health and
disease. Nature Reviews Genetics 13:260–270.

4.

Guarner F, Malagelada J. 2003. Gut flora in health and disease. Lancet 361:512–
519.

5.

Musso G, Gambino R, Cassader M. 2010. Gut microbiota as a regulator of energy
homeostasis and ectopic fat deposition: mechanisms and implications for metabolic
disorders. Current Opininion in Lipidology 21:76–83.

6.

Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson
GR, Delzenne NM. 2007. Selective increases of bifidobacteria in gut microflora
improve high-fat-diet-induced diabetes in mice through a mechanism associated
with endotoxaemia. Diabetologia 50:2374–2383.

7.

Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A,
Sakamoto C. 2009. A randomized controlled trial on the efficacy of synbiotic
versus probiotic or prebiotic treatment to improve the quality of life in patients with
ulcerative colitis. Nutrition 25:520–525.

197

8.

Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y,
Tanaka R, Otani T. 2011. Beneficial effects of probiotic Bifidobacterium and
galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled
study. Digestion 84:128–133.

9.

Cappello C, Tremolaterra F, Pascariello A, Ciacci C, Iovino P. 2013. A
randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable
bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life.
International Journal of Colorectal Disease 28:349–358.

10.

Bittner AC, Croffut RM, Stranahan MC, Yokelson TN. 2007. Prescript-Assist
TM probiotic-prebiotic treatment for irritable bowel syndrome: An open-label,
partially controlled, 1-year extension of a previously published controlled clinical
trial. Clinical Therapeutics 29:1153–1160.

11.

Dughera L, Elia C, Navino M, Cisaro F, Aimo G, Bertele A, Calabrese C, De
Felici I, Diligente G, Febbraro I, Franze A, Fries W, Martorano M, Scifo V,
Villardo L. 2007. Effects of symbiotic preparations on constipated irritable bowel
syndrome symptoms. Acta Biomedica de l’Ateneo Parmense 78:111–116.

12.

Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP,
Federico A, Chilovi F, Milandri GL, De Bona M, Cavenati S, Gullini S, Abbiati
R, Garbagna N, Cerutti R, Grossi E. 2008. Clinical trial on the efficacy of a new
symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a
multicenter, randomized study. Journal of clinical gastroenterology 42 Suppl
3:S218–223.

13.

Savaiano DA, Ritter AJ, Klaenhammer TR, James GM, Longcore AT,

198

Chandler JR, Walker WA, Foyt HL. 2013. Improving lactose digestion and
symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a
randomized, double-blind clinical trial. Nutrition journal 12:160–169.
14.

Pakdaman MN, Udani JK, Molina JP, Shahani M. 2015. The effects of the DDS1 strain of Lactobacillus on symptomatic relief for lactose intolerance - a
randomized, double-blind, placebo-controlled, crossover clinical trial. Nutrition
Journal 15:56–67.

15.

Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A. 2014.
Effects of synbiotic food consumption on metabolic status of diabetic patients: A
double-blind randomized cross-over controlled clinical trial. Clinical Nutrition
33:198–203.

16.

Fernandes R, Beserra BTS, Mocellin MC, Kuntz MGF, da Rosa JS, de Miranda
RCD, Schreiber CSO, Froede TS, Nunes EA, Trindade EBSM. 2016. Effects of
Prebiotic and Synbiotic Supplementation on Inflammatory Markers and
Anthropometric Indices After Roux-en-Y Gastric Bypass. A randomized, Tripleblind, Placebo-controlled Pilot Study. Journal of Clinical Gastroenterology 50:208–
217.

17.

Dehghan P, Pourghassem Gargari B, Asghari Jafar-abadi M, Aliasgharzadeh
A. 2014. Inulin controls inflammation and metabolic endotoxemia in women with
type 2 diabetes mellitus: a randomized-controlled clinical trial. Journal of Food
Sciences and Nutrition 65:117–123.

18.

Pourghassem Gargari B, Dehghan P, Aliasgharzadeh A, Asghari Jafar-Abadi
M. 2013. Effects of high performance inulin supplementation on glycemic control

199

and antioxidant status in women with type 2 diabetes. Diabetes Metab J 37:140–
148.
19.

Shoelson SE, Goldfine AB. 2009. Fanning the flames of obesity-induced
inflammation. Nature medicine 15:373–374.

20.

Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. 2014. Gut microbiota
controls adipose tissue expansion, gut barrier and glucose metabolism: Novel
insights into molecular targets and interventions using prebiotics. Beneficial
Microbes 5:3–17.

21.

Serino M, Luche E, Gres S, Baylac A, Berge M, Cenac C, Waget A, Klopp P,
Iacovoni J, Klopp C, Mariette J, Bouchez O, Lluch J, Ouarne F, Monsan P,
Valet P, Roques C, Amar J, Bouloumie A, Theodorou V, Burcelin R. 2011.
Metabolic adaptation to a high-fat diet is associated with a change in the gut
microbiota. Gut 61:543–553.

22.

Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin
R. 2008. Changes in Gut Microbiota Control Metabolic Diet –Induced Inflammation
in High-Fat Diet- Induced Obesity and Diabetes in Mice. Diabetes 57:1470–1481.

23.

Cani PD, Osto M, Geurts L, Everard A. 2012. Involvement of gut microbiota in
the development of low-grade inflammation and type 2 diabetes associated with
obesity. Gut microbes 3:279–288.

24.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM,
Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T,
Chamontin B, Ferrières J, Tanti J-F, Gibson GR, Casteilla L, Delzenne NM,

200

Alessi MC, Burcelin R. 2007. Metabolic endotoxemia initiates obesity and insulin
resistance. Diabetes 56:1761–1772.
25.

Neves AL, Coelho J, Couto L, Leite-Moreira A, Roncon-Albuquerque R. 2013.
Metabolic endotoxemia: A molecular link between obesity and cardiovascular risk.
Journal of Molecular Endocrinology 51:R51–R64.

26.

Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer J,
Looijer-van Langen M, Madsen KL. 2008. Secreted bioactive factors from
Bifidobacterium infantis enhance epithelial cell barrier function. American Journal
of Physiology- Gastrointestinal and Liver Physiology 295:G1025–1034.

27.

Wang Z, Xiao G, Yao Y, Guo S, Lu K, Sheng Z. 2006. The Role of Bifidobacteria
in Gut Barrier Function After Thermal Injury in Rats. Journal of Trauma-Injury
Infection & Critical Care 61:pp 650–657.

28.

Cani P, Delzenne N. 2009. The Role of the Gut Microbiota in Energy Metabolism
and Metabolic Disease. Current Pharmaceutical Design 15:1546–1558.

29.

Martínez I, Wallace G, Zhang C, Legge R, Benson AK, Carr TP, Moriyama
EN, Walter J. 2009. Diet-induced metabolic improvements in a hamster model of
hypercholesterolemia are strongly linked to alterations of the gut microbiota.
Applied and Environmental Microbiology 75:4175–4184.

30.

Chen J, Wang RR-L, Li X-F, Wang RR-L. 2012. Bifidobacterium adolescentis
supplementation ameliorates visceral fat accumulation and insulin sensitivity in an
experimental model of the metabolic syndrome. The British journal of nutrition
107:1429–1434.

201

31.

Reichold A, Brenner SA, Spruss A, Förster-Fromme K, Bergheim I, Bischoff
SC. 2014. Bifidobacterium adolescentis protects from the development of
nonalcoholic steatohepatitis in a mouse model. The Journal of nutritional
biochemistry 25:118–125.

32.

Chen JJ, Wang R, Li X, Wang R. 2011. Bifidobacterium longum supplementation
improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I
gene expression. Experimental biology and medicine (Maywood, NJ) 236:823–831.

33.

Plaza-Diaz J, Gomez-Llorente C, Abadia-Molina F, Saez-Lara MJ, CampanaMartin L, Munoz-Quezada S, Romero F, Gil A, Fontana L. 2014. Effects of
Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and
Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in Zucker rats. PLoS
ONE 9:e98401.

34.

Kondo S, Xiao J, Satoh T, Odamaki T, Takahashi S, Sugahara H, Yaeshima T,
Iwatsuki K, Kamei A, Abe K. 2010. Antiobesity Effects of Bifidobacterium breve
Strain B-3 Supplementation in a Mouse Model with High-Fat Diet-Induced Obesity.
Bioscience, Biotechnology and Biochemistry 74:1656–1661.

35.

Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A,
Rossman J, Rich G, Dirienzo D, Ogra PL. 2004. In Vivo Effects of Bifidobacteria
and Lactoferrin on Gut Endotoxin Concentration and Mucosal Immunity in Balb/c
Mice. Digestive Diseases and Sciences 49:579–589.

36.

Davis LMG, Martínez I, Walter J, Goin C, Hutkins RW. 2011. Barcoded
pyrosequencing reveals that consumption of galactooligosaccharides results in a
highly specific bifidogenic response in humans. PloS One 6:e25200.

202

37.

Milani C, Ferrario C, Turroni F, Duranti S, Mangifesta M, van Sinderen D,
Ventura M. 2016. The human gut microbiota and its interactive connections to diet.
Journal of Human Nutrition and Dietetics 1–8.

38.

Fanaro S, Marten B, Bagna R, Vigi V, Fabris C, Peña-Quintana L, Argüelles
F, Scholz-Ahrens KE, Sawatzki G, Zelenka R, Schrezenmeir J, De Vrese M,
Bertino E. 2009. Galacto-oligosaccharides are bifidogenic and safe at weaning: a
double-blind randomized multicenter study. Journal of Pediatric Gastroenterology
and Nutrition 48:82–88.

39.

Sierra C, Bernal M-J, Blasco J, Martinez R, Dalmau J, Ortuno I, Espin B,
Vasallo M-I, Gil D, Vidal M-L, Infante D, Leis R, Maldonado J, Moreno JM,
Romon E. 2015. Prebiotic effect during the first year of life in healthy infants fed
formula containing GOS as the only prebiotic: a multicentre, randomised, doubleblind and placebo-controlled trial. European journal of nutrition 54:89–99.

40.

Davis LMG, Martínez I, Walter J, Hutkins R. 2010. A dose dependent impact of
prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults.
International Journal of Food Microbiology 144:285–292.

41.

Walton GE, van den Heuvel EGHM, Kosters MHW, Rastall RA, Tuohy KM,
Gibson GR. 2012. A randomised crossover study investigating the effects of
galacto-oligosaccharides on the faecal microbiota in men and women over 50 years
of age. Br J Nutr 107:1466–1475.

42.

Vulevic J, Juric A, Tzortzis G, Gibson GR. 2013. A Mixture of trans Galactooligosaccharides Reduces Markers of Metabolic Syndrome and Modulates
the Fecal Microbiota and Immune Function of Overweight Adults 1 – 3. Journal of

203

Nutrition 324–331.
43.

Salonen A, Lahti L, Salojärvi J, Holtrop G, Korpela K, Duncan SH, Date P,
Farquharson F, Johnstone AM, Lobley GE, Louis P, Flint HJ, de Vos WM.
2014. Impact of diet and individual variation on intestinal microbiota composition
and fermentation products in obese men. The ISME journal 8:2218–2230.

44.

Martínez I, Kim J, Duffy PR, Schlegel VL, Walter J. 2010. Resistant starches
types 2 and 4 have differential effects on the composition of the fecal microbiota in
human subjects. PloS one 5:e15046.

45.

Kolida S, Gibson GR. 2011. Synbiotics in health and disease. Annual Review of
Food Science and Technology 2:373–393.

46.

Lawley TD, Walker AW. 2013. Intestinal colonization resistance. Immunology
138:1–11.

47.

Rattanaprasert M, Roos S, Hutkins RW, Walter J. 2014. Quantitative evaluation
of synbiotic strategies to improve persistence and metabolic activity of
Lactobacillus reuteri DSM 17938 in the human gastrointestinal tract. Journal of
Functional Foods 10:85–94.

48.

Alander M, Mättö J, Kneifel W, Johansson M, Koegle B, Crittenden R, MattilaSandholm T, Saarela M. 2001. Effect of galacto-oligosaccharide supplementation
on human faecal microflora and on survival and persistence of Bifidobacterium
lactis Bb-12 in the gastrointestinal tract. International Dair 11:817–825.

49.

Malinen E, Mättö J, Salmitie M, Alander M, Saarela M, Palva A. 2002. Analysis
of Bifidobacterium populations in human faecal samples from a consumption trial

204

with Bifidobacterium lactis Bb-12 and a galacto-oligosaccharide preparation.
Systematic and applied microbiology 25:249–258.
50.

Satokari RM, Vaughan EE, Akkermans AD, Saarela M, de Vos WM. 2001.
Polymerase Chain Reaction and Denaturing Gradient Gel Electrophoresis
Monitoring of Fecal Bifidobacterium Populations in a Prebiotic and Probiotic
Feeding Trial. Systematic and applied microbiology 231:227–231.

51.

Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, Klinder A,
O’Riordan M, O’Sullivan GC, Pool-Zobel B, Rechkemmer G, Roller M,
Rowland I, Salvadori M, Thijs H, Van Loo J, Watzl B, Collins JK. 2007. Dietary
synbiotics reduce cancer risk factors in polypectomized and colon cancer patients.
Am J Clin Nutr 85:488–496.

52.

Roller M, Clune Y, Collins K, Rechkemmer G, Watzl B. 2007. Consumption of
prebiotic inulin enriched with oligofructose in combination with the probiotics
Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected
immune parameters in polypectomised and colon cancer patients. The British
journal of nutrition 97:676–684.

53.

Taipale T, Pienihäkkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P,
Jokela J, Söderling E. 2010. Bifidobacterium animalis subsp. lactis BB-12 in
reducing the risk of infections in infancy. The British journal of nutrition 105:409–
416.

54.

Martinez RCR, Aynaou AE, Albrecht S, Schols HA, De Martinis ECP,
Zoetendal EG, Venema K, Saad SMI, Smidt H. 2011. In vitro evaluation of
gastrointestinal survival of Lactobacillus amylovorus DSM 16698 alone and

205

combined with galactooligosaccharides, milk and/or Bifidobacterium animalis
subsp. lactis Bb-12. International Journal of Food Microbiology 149:152–158.
55.

Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y, Keilbaugh SA, Bewtra M,
Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R,
Nessel L, Li H, Bushman FD, Lewis JD. 2011. Linking Long-Term Dietary
Patterns with Gut Microbial Enterotypes. Science 334:105–109.

56.

Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T,
Hallen A, Martens E, Bjoerck I, Baeckhed F. 2015. Dietary Fiber-Induced
Improvement in Glucose Metabolism Is Associated with Increased Abundance of
Prevotella. Cell Metabolism 22:971–982.

57.

Tanaka R, Takayama H, Morotomi M, Kuroshima T, Ueyama S, Matsumoto
K, Kuroda A, Masahiko M. 1983. Effects of Administration of TOS and
Bifidobacterium breve 4006 on the Human Fecal Flora. Bifidobacteria and
Microflora 2:17–24.

58.

Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D,
Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley
GE, Parkhill J, Flint HJ. 2011. Dominant and diet-responsive groups of bacteria
within the human colonic microbiota. The ISME journal 5:220–230.

59.

Clavel T, Lepage P, Charrier C. 2013. The Family Coriobacteriaceae, p. 201–
238. In Rosenberg, E, DeLong, EF, Lor, S, Stackebrandt, E, Thompson, F (eds.),
The Prokaryotes, 4th ed. Springer.

60.

Lawson PA, Greetham HL, Gibson GR, Giffard C, Falsen E, Collins MD. 2005.

206

Slackia faecicanis sp. nov., isolated from canine faeces. International Journal of
Systematic and Evolutionary Microbiology 55:1243–1246.
61.

Jin JS, Kitahara M, Sakamoto M, Hattori M, Benno Y. 2010. Slackia
equolifaciens sp. nov., a human intestinal bacterium capable of producing equol.
International Journal of Systematic and Evolutionary Microbiology 60:1721–1724.

62.

Kim KS, Rowlinson MC, Bennion R, Liu C, Talan D, Summanen P, Finegold
SM. 2010. Characterization of Slackia exigua isolated from human wound
infections, including abscesses of intestinal origin. Journal of Clinical Microbiology
48:1070–1075.

63.

Nagai F, Watanabe Y, Morotomi M. 2010. Slackia piriformis sp. nov. and
Collinsella tanakaei sp. nov., new members of the family Coriobacteriaceae,
isolated from human faeces. International Journal of Systematic and Evolutionary
Microbiology 60:2639–2646.

64.

Miyakawa H, Nakazawa F. 2010. Role of Asaccharolytic Anaerobic Gram－
positive Rods on Periodontitis. Journal of Oral Bioscience 52:240–244.

65.

Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E, MuñozTamayo R, Paslier DLE, Nalin R, Dore J, Leclerc M. 2009. Towards the human
intestinal microbiota phylogenetic core. Environmental Microbiology 11:2574–
2584.

66.

Cardelle-Cobas A, Corzo N, Olano A, Pelaez C, Requena T, Avila M. 2011.
Galactooligosaccharides derived from lactose and lactulose: Influence of structure
on Lactobacillus, Streptococcus and Bifidobacterium growth. International Journal

207

of Food Microbiology 149:81–87.
67.

Petrof EO, Khoruts A. 2014. From stool transplants to next-generation microbiota
therapeutics. Gastroenterology 146:1573–1582.

208

4.8 Supplements
Fig. 4.S1. Average
abundances of taxa
in fecal samples of
subjects

consum-

ing dietary treatments.
Bacterial quantities
are expressed as
percent

abundan-

ces of total bacteria
as determined by
16S rRNA sequencing. Significance
of P ≤ 0.05 is
denoted by a single
asterisk (*).

209

20

15
10
5
0
20

15

10

5

25

Group A Lactose

2
1
0

1
0

4
2

% abundance Roseburia

% abundance Dorea

2
0
4

1

0

4

r = -0.6505
P = 0.0047

2
1
0
10

20

30

% abundance Blautia

40

% abundance Faecalibacterium

Group F GOS

0

10

0

0
0

4

3

2

1

% abundance Oscillibacter

1.5

1.0

0.5

15
10

Group D IVS-1 + GOS
r = -0.6273
P = 0.0070

8
6
4
2
0
0

30

20

10

40

6
4

r = 0.9992
P = <0.0001

2
0
0

2

4

6

% abundance Parasutterella

5
0
30

% abundance Blautia

40

r = -0.5040
P = 0.0391

15
10
5
0
0

10

20

50

8

25
20

2.0

10

Group F GOS
r = -0.6297
P = 0.0067

20

0
0.0

Group E Bb12 + GOS

1

Group F GOS

10

2

% abundance Bacteroides

r = -0.7258
P = 0.0010

2

5

20

0

15

10

5

3

% abundance Ruminococcus

5

3

4

3

2

1

4

Group E Bb12 + GOS

2

5

6

% abundance Catenibacterium

0
3

2

20

15

r = 0.6575
P = 0.0041

% abundance Ethanoligenens

% abundance Ethanoligenes

10

5

4

3

% abundance Sporobacterium

0
0

2

Group B IVS-1 + Lactose
r = 0.9296
P = <0.0001

8

2.5

30

Group E Bb12 + GOS

4

2.0

r = -0.6168
P = 0.0084

40

0

3

6

1.5

1.0

50

% abundance Dorea

r = -0.6486
P = 0.0049

1

1

Group D IVS-1 + GOS

r = 0.6522
P = 0.0115

6

Group E Bb12 + GOS

0

2

0.5

1

0

% abundance Ethanoligenens

8

% abundance Roseburia

8

25

20

10

6

4

0

% abundance Ethanoligenens

r = -0.6977
P = 0.0080

0
0.0

% abundance Blautia

2

10

15

10

Group C Bb12 + Lactose
% abundance Coprococcus

% abundance Ruminococcus

3

2

5

2

40

30

3

3

0

20

10

r = -0.5237
P = 0.0257
4

Group B IVS-1 + Lactose

r = 0.7004
P = 0.0012

% abundance Bacteroides

Group C Bb12 + Lactose r = 0.7783
P <0.0010

0

0

6

% abundance Blautia

4

% abundance Dorea

4

0

% abundance Dialister

r = -0.5547
P = 0.0169

20

0

40

30

1

% abundance Blautia

% abundance Parabacteroides

% abundance Bacteroides

Group A Lactose
25

20

10

0

2

Group A Lactose
% abundance Anaerostipes

0

25

% abundance Collinsella

3

% abundance Streptococcus

15

10

5

% abundance Akkermansia

0

2

r = -0.5723
P = 0.0131

% abundance Anaerostipes

0

4

Group A Lactose
4

% abundance Parabacteroides

2

r = 0.7190
P = 0.0008

% abundance Burkolderiales

4

Group A Lactose
6

% abundance Parabacteroides

r = -0.5263
P = 0.0249

% abundance Bacteroides

% abundance Anaerostipes

Group A Lactose
6

30

% abundance Dorea

Fig. 4.S2. Correlation analysis of fecal genera present with at least 0.5% abundance in
subjects consuming dietary treatments. Bacterial quantities are expressed as percent
abundances of total bacteria as determined by 16S rRNA sequencing.

8

210

4
3
2
1
0
0

1

2

3

4

5

% abundance OTU_6 Dorea

r = 0.-6121
P = 0.0117

4
3
2
1
0
0

5

10

15

% abundance OTU_32 Anaerostipes

% abundance OTU_2555 Blautia

% abundance OTU_1843 Dorea

r = 0.6338
P = 0.0149

5

Group F GOS

Group E Bb12 + GOS

Group C Bb12 + Lactose

r = 0.6524
P = 0.0033

6

4

2

0
0

% abundance OTU_2 Lachnospiraceae incertea sedis

1

2

3

% abundance OTU_17 Blautia

Fig. 4.S3. Correlation analysis of fecal OTUs present with at least 1% abundance in
subjects consuming dietary treatments. Bacterial quantities are expressed as percent
abundances of total bacteria as determined by 16S rRNA sequencing.

Group D
Group E

0

Group F

15

Group C

10

Group B

BL
TR
WO
BL
TR
WO
BL
TR
WO
BL
TR
WO
BL
TR
WO
BL
TR
WO
5

Group A

Ratio Bacteroides/Prevotella

Fig. 4.S4. Ratio of Bacteroides and Prevetolla taxa present in fecal samples of subjects
consuming dietary treatments.

4

211

Alpha diversity
1.05

400

200

8

1.00

Shannon Index

Simpson Index

Observed Species

600

0.95
0.90
0.85

0
Persisters

Non-persister

7
6
5
4
3

Persisters

Non-persister

Persisters

Non-persister

Baseline

Baseline

Baseline

P = 0.8699

P = 0.8964

P = 0.8960

Fig. 4.S5. Alpha diversity comparison between persisters and non-persisters.

212

ITT analysis
Table 4.S1. Proportions of bacterial taxa significantly influenced by dietary treatments
based on intend to treat analysis.
Mean % bacterial abundance ± SD b
Baseline

Treatment

Washout

P
value

OTU_2047 (Blautia sp.)

0.01±0.0 A

0.01±0.0 B

0.02±0.0 AB

0.0270

OTU_2511 (Blautia sp.)

0.89±1.2 A

1.06±1.6 B

0.91±1.1 AB

0.0278

OTU_1 (B. adolescentis)

1.32±3.9 A

3.66±4.9 B

3.25±4.2 B

0.0130

OTU_2353 (Dorea sp.)

0.01±0.0 A

0.02±0.0 B

0.01±0.0 AB

0.0243

0.00±0.0 A

0.08±0.2 AB

0.04±0.1 B

0.0375

4.67± 4.1 A

11.70±6.6 B

9.02±8.7 AB

0.0260

Treatment
Taxonomic group
Group A
Lactose
control
Group B
IVS-1
Probiotic

OTUs a

OTUs

a

Group C
Bb12
Probiotic

OTUs

Group D
IVS-1 GOS

Family

a

OTU_2003 (unclass. Lachnospiraceae)

Bifidobacteriaceae
OTUs

a

OTU_1 (B. adolescentis)

2.31±4.4 A

6.92±7.0 B

4.43±5.0 AB

0.0106

OTU_469 (Anaerotruncus sp.)

0.03±0.1 A

0.00±0.0 B

0.01±0.0 AB

0.0391

0.24±0.3 A

0.07±0.2 B

0.20±0.5 AB

0.0214

Group E
Bb12 GOS

OTUs a

Group F
GOS

OTUs a

OTU_156 (Clostridium XI sp.)

OTU_643 (Bacteroides sp.)

0.02±0.0 A

0.00±0.0 B

0.00±0.0 AB

0.0372

OTU_319 (Butyricimonas sp.)

0.00±0.0 AB

0.00±0.0 A

0.05±0.1 B

0.0382

a

If the strain could not be assigned to a type strain (<97% homology), RDP Classifier was used to determine the most
likely genus, and the RDP Classifier value is shown (80% cutoff).
b

Values with different uppercase letters are significantly different from each other.
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Fig.
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samples

of

subjects

consuming dietary treatments
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analysis. Bacterial quantities
are expressed as percent
abundances of total bacteria
as determined by 16S rRNA
sequencing.
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Chapter 5

Conclusions and future direction.

5.1 Conclusions
The importance of gut microbiota on human health has been well demonstrated
over the past two decades. New analytical methods, as well as bioinformatics tools have
led to many new insights into this complex ecosystem. Food and diet have been shown to
strongly associate with health and disease, and it has become increasingly recognized that
human and animal health is profoundly affected by the specific types and proportions of
microorganisms that inhabit the intestinal tract. There is now much interest in formulating
dietary strategies to support a health associated gut microbiota. However, there is a
considerable knowledge gap on how diet shapes the bacterial populations, which bacteria
should be preferably enriched for to support host health, how to formulate dietary
treatments in order to be most effective, and which ecological requirements have to be met
in order to introduce new members into the gut microbiota.
One strategy to establish microbial members that confer health benefits to the host
in the gut microbiota is with the application of probiotics, prebiotics, and synbiotics. As
reviewed in Chapter 1, there is much clinical and commercial interest in the development
of novel synbiotics. While the health claims made for synbiotic applications are currently
outpacing the research, there is little known about the mechanisms by which probiotics and
synbiotics become established in the GI tract. The development of novel synbiotics based
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on ecological requirements of the probiotic strains to survive and colonize the GI tract may
enhance the beneficial health effects already observed for some of the synbiotic
applications. However, a better understanding of the gastrointestinal niche, with its very
specific biotic and abiotic factors, and the interaction of the resident microbiota is
fundamental in order to develop novel probiotics and synbiotics.
The studies presented here first address ecological colonization factors that enable
a truly symbiotic model organism, L. reuteri, to densely colonize its rodent host in Chapter
2, and secondly introduce and establish a novel method to select for putative probiotic
strains and synbiotic combinations in vivo in Chapters 3 and 4.
Chapter 2 provided a better understanding of the phenotypic adaptations of a
vertebrate gut symbiont, L. reuteri, that contribute to both specialization towards a
particular host and a highly successful lifestyle. The analysis of this probiotic model
organism provided new insights into the ecological requirements and challenges that
probiotic strains face in the GI environment, specifically in the stomach. This study’s
objective was to systematically determine which genes of L. reuteri 100-23 contribute to
tolerance towards host gastric acid secretion. There were three main findings of this study:
(i) the urease cluster was the predominant factor in mediating resistance to gastric acid
production; (ii) gene annotations and in vitro tests have limitations to predict the exact
ecological functions of colonization factors of bacterial gut symbionts; and (iii) novel
information was revealed on the mechanisms by which L. reuteri colonizes its gastric
niche. Ultimately, the basic molecular research described in this chapter broadens our
understanding of GI niches and the ecological challenges probiotic strains have to tolerate.
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Chapters 3 and 4 focus on the effect of probiotic, prebiotic, and synbiotic
applications on the microbial community in the GI tract. Relatively little is known about
the effects of synbiotic treatments on the gut microbiota. In order to address this knowledge
gap, a functional analysis of specific microbes to colonize the GI tract was done. In Chapter
3, we introduced in vivo selection (IVS) as a technique to select synergistic synbiotic
combinations. In this approach putative probiotic strains are enriched in subjects by
extended consumption of a prebiotic substrate, in this case GOS. A rat study was then
conducted to assess the impact of the selected synergistic synbiotic in comparison to
prebiotic and probiotic feeding alone. The main finding in this rat model of non-alcoholic
fatty liver disease (NAFLD) was that even though the synbiotic did not influence host
phenotypes, it was highly efficient at enhancing population levels of the probiotic strain,
and making it the most dominant operational taxonomic unit in the GI tract of the rats.
This was a novel finding that has not been reported in the probiotic literature. Our findings
indicated that B. adolescentis IVS-1 not only had a higher affinity for GOS in vivo than the
resident Bifidobacterium species but also utilized GOS to increase its competitiveness and
effectively outcompete a closely related resident species. This study showed that IVS-1
and GOS were acting as a truly synergistic synbiotic in rats.
To test the potential of IVS-1 as a probiotic and as a synbiotic application (i.e., IVS1 and GOS specifically) in human subjects, we conducted a clinical trial assessing the
impact of the probiotic, prebiotic, and synbiotic treatments on the microbial community in
the GI tract of human subjects suffering from obesity. As described in Chapter 4, we
compared the rationally selected synbiotic to a commercial synbiotic that applied an
allochthonous probiotic component (B. animalis subsp. lactis Bb12). This study aimed to
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answer two important ecological questions: (i) does the in vivo selected autochthonous
bacterial strain IVS-1 have an ecological advantage compared to the allochthonous
bacterial strain Bb12 in the GI tract of human subjects; and (ii) does the supplementation
of each strain with the prebiotic GOS support the colonization of the respective strain in
vivo. Even though both strains were bifidobacteria, there was a significant difference in
the colonization rate. IVS-1 colonized the GI tract in significantly higher numbers than
Bb12 and even became most dominant operational taxonomic unit in the subjects. This
suggested that the autochthonous strain IVS-1 had an ecological advantage over the
allochthonous commercial strain Bb12. This finding supported our hypothesis that IVS
can be used to select a bacterial strain that can substantially enhance population levels and
the competitiveness of a putative probiotic strain in the gastrointestinal tract compared to
a commercial probiotic. This was an important finding as it underlined the necessity to
consider ecological requirements of the probiotic strains when synbiotic combinations are
formulated. A clear synergistic effect between IVS-1 and GOS was previously established
in rats in Chapter 3. However, in the human study the synergistic effect between IVS-1
and GOS did not reach significance.
In summary, the findings in Chapters 3 and 4 demonstrated that the competitive fitness
of strain IVS-1 was increased by GOS, which supported the conclusion that in vivo
selection can be a valuable technique to screen for synbiotic combinations with high
synergism in vivo.
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5.2 Future direction
Our group is currently working on the metabolic data of the human trial described
in Chapter 4. This additional data will allow us to correlate health symptoms and
improvements with the gut microbiota of the study subjects. This analysis will give us
important insight into to the health impacts of the prebiotic, probiotic and synbiotic
treatment in comparison to a commercial synbiotic application.
The results presented in this thesis have clearly demonstrated that the application
of IVS is likely to enhance the ecological performance of probiotic strains or live
biotherapeutics within the habitats in which they are thought to function. The technology
could be readily applied in the design of microbiota-modulating therapies, including novel
and rational synbiotics.

